Hello I'm Raiyyan Tahsan
Brand Model and Executive

TC(1486).(02). Dermatology Department Case No 107:- Suspected Superficial Dermatophytosis with Possible Coexisting Allergic Rhinitis: Clinical Diagnosis, Prescription Analysis and Evidence-Based Management (1PR+0RE+0IMG)4433

Prescription attached:-

đŸŠē LIPU MED — COMPLETE CLINICAL CASE REVIEW

āϏāĻŽā§āĻĒā§‚āĻ°ā§āĻŖ āĻĻā§āĻŦāĻŋāĻ­āĻžāώāĻŋāĻ• āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āϕ⧇āϏ āĻ“ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āĻŦāĻŋāĻļā§āϞ⧇āώāĻŖ

🟧 TC(1486).(02). Dermatology Department Case No. 107

Suspected Superficial Dermatophytosis with Possible Coexisting Allergic Rhinitis: Clinical Diagnosis, Prescription Analysis and Evidence-Based Management

āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ¤ā§āĻŦāϕ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻŦāĻž āĻĻāĻžāĻĻ āĻāĻŦāĻ‚ āϏāĻšāĻžāĻŦāĻ¸ā§āĻĨāĻžāύāĻ•āĻžāϰ⧀ āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ: āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟, āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āĻŦāĻŋāĻļā§āϞ⧇āώāĻŖ āĻ“ āĻĒā§āϰāĻŽāĻžāĻŖāĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž

Case Category — āϕ⧇āϏ⧇āϰ āĻŦāĻŋāĻ­āĻžāĻ—: Dermatology — āϚāĻ°ā§āĻŽāϰ⧋āĻ—āĨ¤

Case Type — āϕ⧇āϏ⧇āϰ āϧāϰāύ: Retrospective Prescription-Based Clinical Assessment — āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āĻ“āĻĒāϰ āĻ­āĻŋāĻ¤ā§āϤāĻŋ āĻ•āϰ⧇ āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύāĨ¤

Case Materials — āϕ⧇āϏ⧇āϰ āωāĻĒāĻ•āϰāĻŖ: One Prescription, Zero Investigation Reports, Zero Clinical Photographs — āĻāĻ•āϟāĻŋ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ, āϕ⧋āύ⧋ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āϰāĻŋāĻĒā§‹āĻ°ā§āϟ āύ⧇āχ, āϰ⧋āϗ⧇āϰ āĻĒ⧃āĻĨāĻ• āĻ›āĻŦāĻŋ āύ⧇āχāĨ¤

Diagnostic Status — āϰ⧋āĻ—āύāĻŋāĻ°ā§āĻŖā§Ÿā§‡āϰ āĻ…āĻŦāĻ¸ā§āĻĨāĻž: Provisional, Not Confirmed — āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ, āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟āĨ¤

Overall Diagnostic Confidence — āϏāĻžāĻŽāĻ—ā§āϰāĻŋāĻ• āϰ⧋āĻ—āύāĻŋāĻ°ā§āĻŖā§Ÿā§‡āϰ āĻŦāĻŋāĻļā§āĻŦāĻžāϏāϝ⧋āĻ—ā§āϝāϤāĻž: 0.65/1.00āĨ¤

Clinical Evidence Statement — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻĒā§āϰāĻŽāĻžāĻŖ āϏāĻŽā§āĻĒāĻ°ā§āϕ⧇ āĻ˜ā§‹āώāĻŖāĻž

The independent diagnosis is inferred from the medicines and general instructions written on the prescription.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āϞ⧇āĻ–āĻž āĻ“āώ⧁āϧ āĻāĻŦāĻ‚ āϏāĻžāϧāĻžāϰāĻŖ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻž āĻŦāĻŋāĻļā§āϞ⧇āώāĻŖ āĻ•āϰ⧇ āĻ¸ā§āĻŦāĻžāϧ⧀āύāĻ­āĻžāĻŦ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤

No specific chief complaint, physical examination findings or diagnostic test result is documented.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€āϰ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻĒā§āϰāϧāĻžāύ āĻ…āĻ­āĻŋāϝ⧋āĻ—, āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ āĻŦāĻž āϰ⧋āĻ—āύāĻŋāĻ°ā§āĻŖā§Ÿā§‡āϰ āϕ⧋āύ⧋ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

Clinical Confidence — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻŦāĻŋāĻļā§āĻŦāĻžāϏāϝ⧋āĻ—ā§āϝāϤāĻž: 0.98 — āϤāĻĨā§āϝ⧇āϰ āϏ⧀āĻŽāĻžāĻŦāĻĻā§āϧāϤāĻž āĻļāύāĻžāĻ•ā§āϤ āĻ•āϰāĻžāϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇āĨ¤


🟧 01. ORIGINAL PRESCRIPTION INFORMATION

āĻŽā§‚āϞ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āϤāĻĨā§āϝ

Parameter — āĻŦāĻŋāώ⧟Original Information — āĻŽā§‚āϞ āϤāĻĨā§āϝ
Patient Name — āϰ⧋āĻ—ā§€āϰ āύāĻžāĻŽNasima Begum — āύāĻžāϏāĻŋāĻŽāĻž āĻŦ⧇āĻ—āĻŽ
Age — āĻŦ⧟āϏ35 years — ā§Šā§Ģ āĻŦāĻ›āϰ
Sex — āϞāĻŋāĻ™ā§āĻ—Female, inferred from patient identification — āϰ⧋āĻ—ā§€āϰ āĻĒāϰāĻŋāϚ⧟ āĻĨ⧇āϕ⧇ āύāĻžāϰ⧀ āĻŦāϞ⧇ āϧāĻžāϰāĻŖāĻž
Prescription Date — āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āϤāĻžāϰāĻŋāĻ–20 October 2026 — ⧍ā§Ļ āĻ…āĻ•ā§āĻŸā§‹āĻŦāϰ ⧍ā§Ļ⧍ā§Ŧ
Physician — āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ•Dr. Hassan Ahmed — āĻĄāĻž. āĻšāĻžāϏāĻžāύ āφāĻšāĻŽā§‡āĻĻ
Qualifications — āĻļāĻŋāĻ•ā§āώāĻžāĻ—āϤ āϝ⧋āĻ—ā§āϝāϤāĻžMBBS, BCS (Health), CCD (BIRDEM), DDV (BMU) — āĻŽā§āĻĻā§āϰāĻŋāϤ āϤāĻĨā§āϝ āĻ…āύ⧁āϝāĻžā§Ÿā§€
Training — āĻĒā§āϰāĻļāĻŋāĻ•ā§āώāĻŖFellowship Training in Dermatosurgery — āĻĄāĻžāĻ°ā§āĻŽāĻžāĻŸā§‹āϏāĻžāĻ°ā§āϜāĻžāϰāĻŋāϤ⧇ āĻĢ⧇āϞ⧋āĻļāĻŋāĻĒ āĻĒā§āϰāĻļāĻŋāĻ•ā§āώāĻŖ
Additional Training — āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āĻĒā§āϰāĻļāĻŋāĻ•ā§āώāĻŖAdvanced Training in Sexual Medicine — āϝ⧌āύ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻŦāĻŋāĻœā§āĻžāĻžāύ⧇ āωāĻ¨ā§āύāϤ āĻĒā§āϰāĻļāĻŋāĻ•ā§āώāĻŖ
Speciality — āĻŦāĻŋāĻļ⧇āώāĻœā§āĻž āĻ•ā§āώ⧇āĻ¤ā§āϰSkin, Allergy & Sexual Diseases — āϚāĻ°ā§āĻŽāϰ⧋āĻ—, āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻ“ āϝ⧌āύāϰ⧋āĻ—
Department — āĻŦāĻŋāĻ­āĻžāĻ—Skin & VD / Dermatology — āϚāĻ°ā§āĻŽ āĻ“ āϝ⧌āύāϰ⧋āĻ— āĻŦāĻŋāĻ­āĻžāĻ—
Physician Diagnosis — āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟Not documented — āϞ⧇āĻ–āĻž āύ⧇āχ
Investigation — āĻĒāϰ⧀āĻ•ā§āώāĻžNot documented — āϞ⧇āĻ–āĻž āύ⧇āχ
Follow-up — āĻĒ⧁āύāϰāĻžā§Ÿ āĻĻ⧇āĻ–āĻžāύ⧋āϰ āϏāĻŽā§ŸApproximately two months appears handwritten — āϏāĻŽā§āĻ­āĻŦāϤ āĻĻ⧁āχ āĻŽāĻžāϏ āĻĒāϰ⧇; āĻšāĻžāϤ⧇āϰ āϞ⧇āĻ–āĻž āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟

Information Extraction Confidence — āϤāĻĨā§āϝ āĻļāύāĻžāĻ•ā§āϤāĻ•āϰāϪ⧇āϰ āĻŦāĻŋāĻļā§āĻŦāĻžāϏāϝ⧋āĻ—ā§āϝāϤāĻž: 0.95āĨ¤

āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āύāĻŋāĻŦāĻ¨ā§āϧāύ āύāĻŽā§āĻŦāϰ āĻ“ āĻ…āĻ¸ā§āĻĒāĻˇā§āϟ āĻšāĻžāϤ⧇āϰ āϞ⧇āĻ–āĻž āϝāĻžāϚāĻžāχ āĻ›āĻžā§œāĻž āύāϤ⧁āύ āĻ•āϰ⧇ āωāĻ˛ā§āϞ⧇āĻ– āĻ•āϰāĻž āĻšā§ŸāύāĻŋāĨ¤


🟩 02. CHIEF COMPLAINTS (C/C)

āϰ⧋āĻ—ā§€āϰ āĻĒā§āϰāϧāĻžāύ āĻ…āĻ­āĻŋāϝ⧋āĻ—

Definition — āϏāĻ‚āĻœā§āĻžāĻž

Chief Complaints are the main symptoms or problems for which a patient seeks medical consultation.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€ āϝ⧇ āĻĒā§āϰāϧāĻžāύ āϏāĻŽāĻ¸ā§āϝāĻž āĻŦāĻž āωāĻĒāϏāĻ°ā§āϗ⧇āϰ āĻ•āĻžāϰāϪ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻ•āĻžāϛ⧇ āφāϏ⧇āύ, āϤāĻžāϕ⧇ Chief Complaints āĻŦāĻž āĻĒā§āϰāϧāĻžāύ āĻ…āĻ­āĻŋāϝ⧋āĻ— āĻŦāϞāĻž āĻšā§ŸāĨ¤

A. Doctor-Documented Chief Complaints — āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϞ⧇āĻ–āĻž āĻ…āĻ­āĻŋāϝ⧋āĻ—

Not documented — āωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχāĨ¤

The physician did not explicitly document the patient’s symptoms.

āĻŦāĻžāĻ‚āϞāĻž: āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āϰ⧋āĻ—ā§€āϰ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āωāĻĒāϏāĻ°ā§āĻ—āϗ⧁āϞ⧋ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āϞ⧇āϖ⧇āύāύāĻŋāĨ¤

Confidence: 0.99āĨ¤

B. Possible Chief Complaints — āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻĒā§āϰāϧāĻžāύ āĻ…āĻ­āĻŋāϝ⧋āĻ—

1. Possible Itching of Skin — āĻ¤ā§āĻŦāϕ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϚ⧁āϞāĻ•āĻžāύāĻŋāĨ¤

Itraconazole and luliconazole treatment suggests a possible fungal skin disorder that may cause itching.

āĻŦāĻžāĻ‚āϞāĻž: Itraconazole āĻ“ Luliconazole āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ•āĻžāϰāϪ⧇ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϚāĻ°ā§āĻŽāϰ⧋āϗ⧇āϰ āϏāĻ¨ā§āĻĻ⧇āĻš āĻšāĻšā§āϛ⧇āĨ¤ āĻ āϧāϰāύ⧇āϰ āϰ⧋āϗ⧇ āϚ⧁āϞāĻ•āĻžāύāĻŋ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.70āĨ¤

2. Possible Skin Rash — āĻ¤ā§āĻŦāϕ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻĢ⧁āϏāĻ•ā§ā§œāĻŋ āĻŦāĻž āĻĻāĻžāĻ—āĨ¤

Superficial dermatophytosis commonly produces erythematous or scaly skin lesions.

āĻŦāĻžāĻ‚āϞāĻž: āĻ¤ā§āĻŦāϕ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇ āϏāĻžāϧāĻžāϰāĻŖāϤ āϞāĻžāϞāĻšā§‡ āĻĻāĻžāĻ— āĻ…āĻĨāĻŦāĻž āĻ–ā§‹āϏāĻžāϝ⧁āĻ•ā§āϤ āĻ•ā§āώāϤ āĻĻ⧇āĻ–āĻž āϝ⧇āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.65āĨ¤

3. Possible Nasal Allergy — āύāĻžāϕ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāĨ¤

Fexofenadine and fluticasone nasal spray suggest treatment of possible allergic rhinitis.

āĻŦāĻžāĻ‚āϞāĻž: Fexofenadine āĻ“ Fluticasone Nasal Spray āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ•āĻžāϰāϪ⧇ āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϜāύāĻŋāϤ āϰ⧋āϗ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

Confidence: 0.75āĨ¤

4. Possible Recurrent Fungal Infection — āĻŦāĻžāϰāĻŦāĻžāϰ āĻšāĻ“ā§ŸāĻž āĻ›āĻ¤ā§āϰāĻžāĻ• āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻžāĨ¤

Combined oral and topical antifungal treatment may indicate extensive or difficult-to-treat infection, but recurrence is not documented.

āĻŦāĻžāĻ‚āϞāĻž: āĻŽā§āϖ⧇ āĻ–āĻžāĻ“ā§ŸāĻžāϰ āĻāĻŦāĻ‚ āĻ¤ā§āĻŦāϕ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āĻāĻ•āϏāĻ™ā§āϗ⧇ āĻĻ⧇āĻ“ā§ŸāĻžā§Ÿ āĻŦā§āϝāĻžāĻĒāĻ• āĻŦāĻž āϜāϟāĻŋāϞ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāĻž āϝāĻžā§ŸāĨ¤ āϤāĻŦ⧇ āĻŦāĻžāϰāĻŦāĻžāϰ āϰ⧋āĻ— āĻšāĻ“ā§ŸāĻžāϰ āχāϤāĻŋāĻšāĻžāϏ āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

Confidence: 0.40āĨ¤

Clinical Interpretation — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻŦā§āϝāĻžāĻ–ā§āϝāĻž

These findings are medication-based possibilities, not patient-reported complaints.

āĻŦāĻžāĻ‚āϞāĻž: āĻāϗ⧁āϞ⧋ āĻ“āώ⧁āϧ āĻĻ⧇āϖ⧇ āĻ•āϰāĻž āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϧāĻžāϰāĻŖāĻžāĨ¤ āϰ⧋āĻ—ā§€ āύāĻŋāĻœā§‡ āĻāχ āĻ…āĻ­āĻŋāϝ⧋āĻ—āϗ⧁āϞ⧋ āϜāĻžāύāĻŋā§Ÿā§‡āϛ⧇āĻ¨â€”āĻāĻŽāύ āϞāĻŋāĻ–āĻŋāϤ āϤāĻĨā§āϝ āύ⧇āχāĨ¤

Confidence: 0.98āĨ¤


🟧 03. CLINICAL HISTORY ASSESSMENT

āϰ⧋āĻ—ā§€āϰ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āĻ“ āĻŦāĻ°ā§āϤāĻŽāĻžāύ āχāϤāĻŋāĻšāĻžāϏ

History Parameters — āχāϤāĻŋāĻšāĻžāϏ⧇āϰ āĻŦāĻŋāώ⧟āϏāĻŽā§‚āĻš

Abbreviation — āϏāĻ‚āĻ•ā§āώāĻŋāĻĒā§āϤ āϰ⧂āĻĒEnglish Meaning — āχāĻ‚āϰ⧇āϜāĻŋ āĻ…āĻ°ā§āĻĨāĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨDoctor’s Documentation — āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϞ⧇āĻ–āĻž āϤāĻĨā§āϝ
C/CChief ComplaintsāĻĒā§āϰāϧāĻžāύ āĻ…āĻ­āĻŋāϝ⧋āĻ—Not documented — āύ⧇āχ
I/HIllness HistoryāĻŦāĻ°ā§āϤāĻŽāĻžāύ āĻ…āϏ⧁āĻ¸ā§āĻĨāϤāĻžāϰ āχāϤāĻŋāĻšāĻžāϏNot documented — āύ⧇āχ
HPIHistory of Present IllnessāĻŦāĻ°ā§āϤāĻŽāĻžāύ āϰ⧋āϗ⧇āϰ āĻŦāĻŋāĻ¸ā§āϤāĻžāϰāĻŋāϤ āχāϤāĻŋāĻšāĻžāϏNot documented — āύ⧇āχ
O/HObstetric History or Other History, depending on contextāĻĒā§āϰāϏ⧂āϤāĻŋ āχāϤāĻŋāĻšāĻžāϏ āĻŦāĻž āĻĒā§āϰāĻžāϏāĻ™ā§āĻ—āĻŋāĻ• āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āχāϤāĻŋāĻšāĻžāϏNot documented — āύ⧇āχ
D/HDrug HistoryāĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āĻ“āώ⧁āϧ āϏ⧇āĻŦāύ⧇āϰ āχāϤāĻŋāĻšāĻžāϏNot documented — āύ⧇āχ
M/HMedical HistoryāĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āϰ⧋āϗ⧇āϰ āχāϤāĻŋāĻšāĻžāϏNot documented — āύ⧇āχ
P/HPast HistoryāĻ…āϤ⧀āϤ āϰ⧋āϗ⧇āϰ āχāϤāĻŋāĻšāĻžāϏNot documented — āύ⧇āχ
F/HFamily HistoryāĻĒāĻžāϰāĻŋāĻŦāĻžāϰāĻŋāĻ• āϰ⧋āϗ⧇āϰ āχāϤāĻŋāĻšāĻžāϏNot documented — āύ⧇āχ
S/HSocial HistoryāϏāĻžāĻŽāĻžāϜāĻŋāĻ• āĻ“ āĻœā§€āĻŦāύāϝāĻžāĻĒāύ⧇āϰ āχāϤāĻŋāĻšāĻžāϏNot documented — āύ⧇āχ
Allergy H/OHistory of AllergyāĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āχāϤāĻŋāĻšāĻžāϏNot documented — āύ⧇āχ

Important History Required — āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āχāϤāĻŋāĻšāĻžāϏ āϝāĻž āύ⧇āĻ“ā§ŸāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύ

1. Duration of Illness — āϰ⧋āϗ⧇āϰ āĻ¸ā§āĻĨāĻžā§ŸāĻŋāĻ¤ā§āĻŦāĨ¤

How long have the skin lesions been present?

āĻŦāĻžāĻ‚āϞāĻž: āĻ¤ā§āĻŦāϕ⧇āϰ āϏāĻŽāĻ¸ā§āϝāĻžāϟāĻŋ āĻ•āϤāĻĻāĻŋāύ āϧāϰ⧇ āĻ°ā§Ÿā§‡āϛ⧇?

2. Site of Infection — āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āĻ¸ā§āĻĨāĻžāύāĨ¤

Which part of the body is affected?

āĻŦāĻžāĻ‚āϞāĻž: āĻļāϰ⧀āϰ⧇āϰ āϕ⧋āύ āĻ¸ā§āĻĨāĻžāύ⧇ āĻĻāĻžāĻ— āĻŦāĻž āĻ•ā§āώāϤ āĻ°ā§Ÿā§‡āϛ⧇?

3. Previous Antifungal Therapy — āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĨ¤

Has the patient previously used oral or topical antifungals?

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€ āφāϗ⧇ āϕ⧋āύ⧋ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āĻŸā§āϝāĻžāĻŦāϞ⧇āϟ āĻŦāĻž āĻ•ā§āϰāĻŋāĻŽ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰ⧇āϛ⧇āύ āĻ•āĻŋ?

4. Steroid Cream History — āĻ¸ā§āĻŸā§‡āĻ°ā§Ÿā§‡āĻĄāϝ⧁āĻ•ā§āϤ āĻ•ā§āϰāĻŋāĻŽ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āχāϤāĻŋāĻšāĻžāϏāĨ¤

Has the patient used steroid-containing combination creams?

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€ āφāϗ⧇ āĻ¸ā§āĻŸā§‡āĻ°ā§Ÿā§‡āĻĄāϝ⧁āĻ•ā§āϤ āĻŽāĻŋāĻļā§āϰ āĻ•ā§āϰāĻŋāĻŽ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰ⧇āϛ⧇āύ āĻ•āĻŋ?

5. Diabetes History — āĻĄāĻžā§ŸāĻžāĻŦ⧇āϟāĻŋāϏ⧇āϰ āχāϤāĻŋāĻšāĻžāϏāĨ¤

Does the patient have diabetes or symptoms suggesting uncontrolled blood glucose?

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€āϰ āĻĄāĻžā§ŸāĻžāĻŦ⧇āϟāĻŋāϏ āφāϛ⧇ āĻ•āĻŋ āĻ…āĻĨāĻŦāĻž āϰāĻ•ā§āϤ⧇ āĻļāĻ°ā§āĻ•āϰāĻž āĻŦ⧇āĻļāĻŋ āĻĨāĻžāĻ•āĻžāϰ āωāĻĒāϏāĻ°ā§āĻ— āĻ°ā§Ÿā§‡āϛ⧇ āĻ•āĻŋ?

6. Pregnancy History — āĻ—āĻ°ā§āĻ­āϧāĻžāϰāĻŖāϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āχāϤāĻŋāĻšāĻžāϏāĨ¤

Is the patient pregnant, breastfeeding or planning pregnancy?

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€ āĻŦāĻ°ā§āϤāĻŽāĻžāύ⧇ āĻ—āĻ°ā§āĻ­āĻŦāϤ⧀, āϏāĻ¨ā§āϤāĻžāύāϕ⧇ āĻŦ⧁āϕ⧇āϰ āĻĻ⧁āϧ āĻ–āĻžāĻ“ā§ŸāĻžāĻšā§āϛ⧇āύ āĻ…āĻĨāĻŦāĻž āĻ—āĻ°ā§āĻ­āϧāĻžāϰāϪ⧇āϰ āĻĒāϰāĻŋāĻ•āĻ˛ā§āĻĒāύāĻž āĻ•āϰāϛ⧇āύ āĻ•āĻŋ?

7. Hepatic and Cardiac History — āϞāĻŋāĻ­āĻžāϰ āĻ“ āĻšā§ƒāĻĻā§â€Œāϰ⧋āϗ⧇āϰ āχāϤāĻŋāĻšāĻžāϏāĨ¤

Is there any history of liver disease or heart failure?

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€āϰ āϞāĻŋāĻ­āĻžāϰ⧇āϰ āϰ⧋āĻ— āĻ…āĻĨāĻŦāĻž āĻšā§ƒāĻĻā§â€ŒāϝāĻ¨ā§āĻ¤ā§āϰ⧇āϰ āĻ•āĻžāĻ°ā§āϝāĻ•ā§āώāĻŽāϤāĻž āĻ•āĻŽā§‡ āϝāĻžāĻ“ā§ŸāĻžāϰ āχāϤāĻŋāĻšāĻžāϏ āφāϛ⧇ āĻ•āĻŋ?

8. Household Exposure — āĻĒāϰāĻŋāĻŦāĻžāϰ⧇āϰ āϏāĻ‚āĻ¸ā§āĻĒāĻ°ā§āĻļāϜāύāĻŋāϤ āχāϤāĻŋāĻšāĻžāϏāĨ¤

Do other household members have similar skin lesions?

āĻŦāĻžāĻ‚āϞāĻž: āĻĒāϰāĻŋāĻŦāĻžāϰ⧇āϰ āĻ…āĻ¨ā§āϝ āĻ•āĻžāϰāĻ“ āĻāĻ•āχ āϧāϰāύ⧇āϰ āĻ¤ā§āĻŦāϕ⧇āϰ āϏāĻŽāĻ¸ā§āϝāĻž āĻ°ā§Ÿā§‡āϛ⧇ āĻ•āĻŋ?

Assessment — āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ

No relevant history was explicitly recorded.

āĻŦāĻžāĻ‚āϞāĻž: āωāĻĒāϰ⧋āĻ•ā§āϤ āϕ⧋āύ⧋ āχāϤāĻŋāĻšāĻžāϏāχ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āĻŽā§‚āϞ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āĻ¸ā§āĻĒāĻˇā§āϟāĻ­āĻžāĻŦ⧇ āϞ⧇āϖ⧇āύāύāĻŋāĨ¤

Confidence: 0.98āĨ¤


🟩 04. PHYSICAL EXAMINATION (O/E)

āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ

Definition — āϏāĻ‚āĻœā§āĻžāĻž

On Examination refers to clinical findings obtained during physical examination.

āĻŦāĻžāĻ‚āϞāĻž: āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āϰ⧋āĻ—ā§€āϕ⧇ āϏāϰāĻžāϏāϰāĻŋ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰ⧇ āϝ⧇ āϞāĻ•ā§āώāĻŖ āĻŦāĻž āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ āĻļāύāĻžāĻ•ā§āϤ āĻ•āϰ⧇āύ, āϏ⧇āϗ⧁āϞ⧋āϕ⧇ On Examination āĻŦāĻž O/E āĻŦāϞāĻž āĻšā§ŸāĨ¤

Doctor’s Original O/E — āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻŽā§‚āϞ āĻĒāĻ°ā§āϝāĻŦ⧇āĻ•ā§āώāĻŖ

Not documented — āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

Expected Findings in Dermatophytosis — āĻĻāĻžāĻĻ āĻĨāĻžāĻ•āϞ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϞāĻ•ā§āώāĻŖ

1. Annular Plaque — āĻŦ⧃āĻ¤ā§āϤāĻžāĻ•āĻžāϰ āĻ•ā§āώāϤāĨ¤

A ring-shaped skin lesion may occur in tinea corporis.

āĻŦāĻžāĻ‚āϞāĻž: āĻļāϰ⧀āϰ⧇āϰ āĻĻāĻžāĻĻ⧇āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻ¤ā§āĻŦāϕ⧇ āĻ—ā§‹āϞāĻžāĻ•āĻžāϰ āĻ•ā§āώāϤ āĻĻ⧇āĻ–āĻž āϝ⧇āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

2. Peripheral Scaling — āĻ•ā§āώāϤ⧇āϰ āĻĒā§āϰāĻžāĻ¨ā§āϤ⧇ āĻ–ā§‹āϏāĻž āĻ“āĻ āĻžāĨ¤

Scaling may be prominent at the active border of a dermatophyte lesion.

āĻŦāĻžāĻ‚āϞāĻž: āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āĻ•ā§āώāϤ⧇āϰ āϏāĻ•ā§āϰāĻŋ⧟ āĻĒā§āϰāĻžāĻ¨ā§āϤ⧇ āĻ–ā§‹āϏāĻž āĻ“āĻ āĻž āĻĻ⧇āĻ–āĻž āϝ⧇āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

3. Central Clearing — āĻ•ā§āώāϤ⧇āϰ āĻŽāĻžāĻāĻ–āĻžāύ āϤ⧁āϞāύāĻžāĻŽā§‚āϞāĻ• āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āĻĨāĻžāĻ•āĻžāĨ¤

Some lesions demonstrate relative clearing in the centre.

āĻŦāĻžāĻ‚āϞāĻž: āĻ•āĻŋāϛ⧁ āĻĻāĻžāĻĻ⧇āϰ āĻ•ā§āώāϤ⧇āϰ āĻŽāĻžāĻā§‡āϰ āĻ…āĻ‚āĻļ āϤ⧁āϞāύāĻžāĻŽā§‚āϞāĻ• āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āĻĻ⧇āĻ–āĻž āϝāĻžā§ŸāĨ¤

4. Excoriation — āϚ⧁āϞāĻ•āĻžāύ⧋āϰ āφāρāϚ⧜āĨ¤

Scratching may produce secondary skin injury.

āĻŦāĻžāĻ‚āϞāĻž: āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āϚ⧁āϞāĻ•āĻžāύ⧋āϰ āĻ•āĻžāϰāϪ⧇ āĻ¤ā§āĻŦāϕ⧇ āφāρāϚ⧜ āĻŦāĻž āĻ•ā§āώāϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Expected Nasal Findings — āύāĻžāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰāϞ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϞāĻ•ā§āώāĻŖ

1. Pale or Swollen Turbinates — āύāĻžāϕ⧇āϰ āϭ⧇āϤāϰ⧇āϰ āϟāĻžāϰāĻŦāĻŋāύ⧇āϟ āĻĢā§āϝāĻžāĻ•āĻžāĻļ⧇ āĻŦāĻž āĻĢā§‹āϞāĻžāĨ¤

These findings may occur in allergic rhinitis.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϤ⧇ āύāĻžāϕ⧇āϰ āϭ⧇āϤāϰ⧇āϰ āϟāĻžāϰāĻŦāĻŋāύ⧇āϟ āĻĢā§āϝāĻžāĻ•āĻžāĻļ⧇ āĻŦāĻž āĻĢ⧁āϞ⧇ āϝ⧇āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

2. Watery Nasal Discharge — āύāĻžāĻ• āĻĻāĻŋā§Ÿā§‡ āĻĒāĻžāύāĻŋāϰ āĻŽāϤ⧋ āĻ¸ā§āϰāĻžāĻŦāĨ¤

Watery rhinorrhoea is a common allergic symptom.

āĻŦāĻžāĻ‚āϞāĻž: āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāĻ• āϰāĻžāχāύāĻžāχāϟāĻŋāϏ⧇ āύāĻžāĻ• āĻĻāĻŋā§Ÿā§‡ āĻĒāĻžāϤāϞāĻž āĻĒāĻžāύāĻŋāϰ āĻŽāϤ⧋ āĻ¸ā§āϰāĻžāĻŦ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Clinical Limitation — āϏ⧀āĻŽāĻžāĻŦāĻĻā§āϧāϤāĻž

These are textbook descriptions, not actual findings observed in Nasima Begum.

āĻŦāĻžāĻ‚āϞāĻž: āĻāϗ⧁āϞ⧋ āĻĒāĻžāĻ ā§āϝāĻĒ⧁āĻ¸ā§āϤāϕ⧇ āĻŦāĻ°ā§āĻŖāĻŋāϤ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϞāĻ•ā§āώāĻŖāĨ¤ āύāĻžāϏāĻŋāĻŽāĻž āĻŦ⧇āĻ—āĻŽā§‡āϰ āĻļāϰ⧀āϰ⧇ āĻāχ āϞāĻ•ā§āώāĻŖāϗ⧁āϞ⧋ āĻĒāĻžāĻ“ā§ŸāĻž āϗ⧇āĻ›ā§‡â€”āĻāĻŽāύ āĻĒā§āϰāĻŽāĻžāĻŖ āύ⧇āχāĨ¤

Confidence: 0.98 for general clinical descriptions; patient-specific findings remain unknownāĨ¤


🟧 05. OTHER CLINICAL EXAMINATION PARAMETERS

āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻŦāĻŋāώ⧟

Parameter — āĻŦāĻŋāώ⧟English Meaning — āχāĻ‚āϰ⧇āϜāĻŋ āĻ…āĻ°ā§āĻĨāĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨStatus — āĻ…āĻŦāĻ¸ā§āĻĨāĻž
O/S/EOther/Systemic ExaminationāĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ…āĻ™ā§āĻ—-āĻĒā§āϰāĻ¤ā§āϝāĻ™ā§āϗ⧇āϰ āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻžNot documented — āύ⧇āχ
O/G/EObstetric and Gynaecological ExaminationāĻĒā§āϰāϏ⧂āϤāĻŋ āĻ“ āĻ¸ā§āĻ¤ā§āϰ⧀āϰ⧋āĻ—āϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻĒāϰ⧀āĻ•ā§āώāĻžNot documented — āύ⧇āχ
G/EGeneral ExaminationāϏāĻžāϧāĻžāϰāĻŖ āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻžNot documented — āύ⧇āχ
VitalsVital SignsāϰāĻ•ā§āϤāϚāĻžāĻĒ, āύāĻžā§œāĻŋāϰ āĻ—āϤāĻŋ, āϤāĻžāĻĒāĻŽāĻžāĻ¤ā§āϰāĻž āχāĻ¤ā§āϝāĻžāĻĻāĻŋNot documented — āύ⧇āχ
Skin ExaminationDermatological ExaminationāĻ¤ā§āĻŦāϕ⧇āϰ āĻ•ā§āώāϤ āĻĒāϰ⧀āĻ•ā§āώāĻžNot documented — āύ⧇āχ
ENT ExaminationEar, Nose and Throat ExaminationāĻ•āĻžāύ, āύāĻžāĻ• āĻ“ āĻ—āϞāĻžāϰ āĻĒāϰ⧀āĻ•ā§āώāĻžNot documented — āύ⧇āχ
Systemic ExaminationExamination of Organ SystemsāĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ āĻ…āĻ™ā§āϗ⧇āϰ āĻ•āĻžāĻ°ā§āϝāĻ•ā§āϰāĻŽ āĻĒāϰ⧀āĻ•ā§āώāĻžNot documented — āύ⧇āχ

Confidence: 0.98āĨ¤

Important Observation — āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻĒāĻ°ā§āϝāĻŦ⧇āĻ•ā§āώāĻŖ

No systemic examination findings or vital signs are written.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āϕ⧋āύ⧋ āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ āĻŦāĻž Vital Signs āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤


🟩 06. DEFINITION OF THE SUSPECTED DISEASES

āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϰ⧋āĻ—āϗ⧁āϞ⧋āϰ āϏāĻ‚āĻœā§āĻžāĻž

Disease 1: Superficial Dermatophytosis — āĻ¤ā§āĻŦāϕ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ

Definition — āϏāĻ‚āĻœā§āĻžāĻž

Dermatophytosis is a fungal infection affecting keratinized tissues, including the skin, hair and nails.

āĻŦāĻžāĻ‚āϞāĻž: Dermatophytosis āĻšāϞ⧋ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ, āϝāĻž āĻ¤ā§āĻŦāĻ•, āϚ⧁āϞ āĻāĻŦāĻ‚ āύāϖ⧇āϰ āϕ⧇āϰāĻžāϟāĻŋāύāϝ⧁āĻ•ā§āϤ āĻ…āĻ‚āĻļ⧇ āφāĻ•ā§āϰāĻŽāĻŖ āĻ•āϰ⧇āĨ¤

Common Types — āϏāĻžāϧāĻžāϰāĻŖ āϧāϰāύ

Tinea Corporis — āĻļāϰ⧀āϰ⧇āϰ āĻĻāĻžāĻĻāĨ¤

Fungal infection involving the glabrous skin of the body.

āĻŦāĻžāĻ‚āϞāĻž: āĻļāϰ⧀āϰ⧇āϰ āϞ⧋āĻŽāĻŦāĻŋāĻšā§€āύ āĻŦāĻž āϤ⧁āϞāύāĻžāĻŽā§‚āϞāĻ• āĻŽāϏ⧃āĻŖ āĻ¤ā§āĻŦāϕ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĨ¤

Tinea Cruris — āϕ⧁āρāϚāĻ•āĻŋāϰ āĻĻāĻžāĻĻāĨ¤

Dermatophyte infection involving the groin region.

āĻŦāĻžāĻ‚āϞāĻž: āϕ⧁āρāϚāĻ•āĻŋ āĻ“ āφāĻļāĻĒāĻžāĻļ⧇āϰ āĻ¤ā§āĻŦāϕ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĨ¤

Tinea Pedis — āĻĒāĻžā§Ÿā§‡āϰ āĻĻāĻžāĻĻāĨ¤

Dermatophyte infection involving the feet.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒāĻžā§Ÿā§‡āϰ āĻ¤ā§āĻŦāϕ⧇ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĨ¤

Tinea Manuum — āĻšāĻžāϤ⧇āϰ āĻĻāĻžāĻĻāĨ¤

Dermatophyte infection involving the hands.

āĻŦāĻžāĻ‚āϞāĻž: āĻšāĻžāϤ⧇āϰ āĻ¤ā§āĻŦāϕ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĨ¤

Tinea Unguium — āύāϖ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ• āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĨ¤

Dermatophyte infection involving the nails.

āĻŦāĻžāĻ‚āϞāĻž: āύāϖ⧇ dermatophyte āĻ›āĻ¤ā§āϰāĻžāϕ⧇āϰ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĨ¤

Patient-Specific Interpretation — āϰ⧋āĻ—ā§€āĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻŦā§āϝāĻžāĻ–ā§āϝāĻž

The affected anatomical site is not documented; therefore, the specific type of tinea cannot be determined.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€āϰ āĻļāϰ⧀āϰ⧇āϰ āϕ⧋āύ āϜāĻžā§ŸāĻ—āĻžā§Ÿ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻšā§Ÿā§‡āϛ⧇ āϤāĻž āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤ āϤāĻžāχ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟāĻ­āĻžāĻŦ⧇ Tinea Corporis, Tinea Cruris āĻŦāĻž āĻ…āĻ¨ā§āϝ āϕ⧋āύ⧋ āϧāϰāύ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϏāĻŽā§āĻ­āĻŦ āύ⧟āĨ¤

Confidence: 0.95 for definition; 0.70 for suspected diseaseāĨ¤

Disease 2: Allergic Rhinitis — āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ

Definition — āϏāĻ‚āĻœā§āĻžāĻž

Allergic rhinitis is an IgE-mediated inflammatory disorder of the nasal mucosa caused by exposure to allergens.

āĻŦāĻžāĻ‚āϞāĻž: āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāĻ• āϰāĻžāχāύāĻžāχāϟāĻŋāϏ āĻšāϞ⧋ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āĻœā§‡āύ⧇āϰ āϏāĻ‚āĻ¸ā§āĻĒāĻ°ā§āĻļ⧇ IgE-mediated āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻžāϰ āĻŽāĻžāĻ§ā§āϝāĻŽā§‡ āύāĻžāϕ⧇āϰ āϭ⧇āϤāϰ⧇āϰ āĻļā§āϞ⧈āĻˇā§āĻŽāĻŋāĻ• āφāĻŦāϰāϪ⧇ āĻĒā§āϰāĻĻāĻžāĻš āϏ⧃āĻˇā§āϟāĻŋ āĻšāĻ“ā§ŸāĻžāĨ¤

Common Symptoms — āϏāĻžāϧāĻžāϰāĻŖ āωāĻĒāϏāĻ°ā§āĻ—

Sneezing — āĻšāĻžāρāϚāĻŋāĨ¤

Rhinorrhoea — āύāĻžāĻ• āĻĻāĻŋā§Ÿā§‡ āĻĒāĻžāύāĻŋ āĻĒ⧜āĻžāĨ¤

Nasal Itching — āύāĻžāĻ• āϚ⧁āϞāĻ•āĻžāύ⧋āĨ¤

Nasal Congestion — āύāĻžāĻ• āĻŦāĻ¨ā§āϧ āĻĨāĻžāĻ•āĻžāĨ¤

Watery Eyes — āĻšā§‹āĻ– āĻĻāĻŋā§Ÿā§‡ āĻĒāĻžāύāĻŋ āĻĒ⧜āĻžāĨ¤

Patient-Specific Interpretation — āϰ⧋āĻ—ā§€āĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻŦā§āϝāĻžāĻ–ā§āϝāĻž

The prescription includes fexofenadine and intranasal fluticasone, but the patient’s nasal symptoms are undocumented.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ Fexofenadine āĻāĻŦāĻ‚ āύāĻžāϕ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ Fluticasone āĻ°ā§Ÿā§‡āϛ⧇āĨ¤ āϤāĻŦ⧇ āϰ⧋āĻ—ā§€āϰ āύāĻžāϕ⧇āϰ āĻĒā§āϰāĻ•ā§ƒāϤ āωāĻĒāϏāĻ°ā§āĻ—āϗ⧁āϞ⧋ āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

Confidence: 0.75āĨ¤


🟧 07. ETIOLOGY AND PATHOPHYSIOLOGY

āϰ⧋āϗ⧇āϰ āĻ•āĻžāϰāĻŖ āĻ“ āϰ⧋āĻ— āϏ⧃āĻˇā§āϟāĻŋāϰ āĻĒā§āϰāĻ•ā§āϰāĻŋ⧟āĻž

A. Etiology of Dermatophytosis — āĻĻāĻžāĻĻ⧇āϰ āĻ•āĻžāϰāĻŖ

Common dermatophyte organisms include:

āĻŦāĻžāĻ‚āϞāĻž: āĻĻāĻžāĻĻ āϏ⧃āĻˇā§āϟāĻŋāĻ•āĻžāϰ⧀ āϏāĻžāϧāĻžāϰāĻŖ āĻ›āĻ¤ā§āϰāĻžāĻ•āϗ⧁āϞ⧋ āĻšāĻ˛ā§‹â€”

  1. Trichophyton rubrum — āĻĻāĻžāĻĻ āϏ⧃āĻˇā§āϟāĻŋāĻ•āĻžāϰ⧀ āĻāĻ•āϟāĻŋ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻ›āĻ¤ā§āϰāĻžāĻ•āĨ¤
  2. Trichophyton mentagrophytes complex — āĻĻāĻžāĻĻ āϏ⧃āĻˇā§āϟāĻŋāĻ•āĻžāϰ⧀ āĻ›āĻ¤ā§āϰāĻžāϕ⧇āϰ āĻāĻ•āϟāĻŋ āĻ—ā§‹āĻˇā§āĻ ā§€āĨ¤
  3. Trichophyton indotineae — āĻĻāĻ•ā§āώāĻŋāĻŖ āĻāĻļāĻŋ⧟āĻžā§Ÿ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ, āĻ•āĻ–āύ⧋ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ-āĻĒā§āϰāϤāĻŋāϰ⧋āϧ⧀ āĻ›āĻ¤ā§āϰāĻžāĻ•āĨ¤
  4. Epidermophyton floccosum — āĻ¤ā§āĻŦāϕ⧇ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āĻāĻ•āϟāĻŋ āĻ•āĻžāϰāĻŖāĨ¤
  5. Microsporum species — āĻ¤ā§āĻŦāĻ• āĻ“ āϚ⧁āϞ⧇āϰ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āϘāϟāĻžāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Pathophysiology — āϰ⧋āĻ— āϏ⧃āĻˇā§āϟāĻŋāϰ āĻĒā§āϰāĻ•ā§āϰāĻŋ⧟āĻž

Dermatophytes colonize keratin-containing tissues and use keratin as a nutrient source.

āĻŦāĻžāĻ‚āϞāĻž: Dermatophyte āĻ›āĻ¤ā§āϰāĻžāĻ• āĻ¤ā§āĻŦāϕ⧇āϰ āϕ⧇āϰāĻžāϟāĻŋāύāϝ⧁āĻ•ā§āϤ āĻ…āĻ‚āĻļ⧇ āĻŦ⧃āĻĻā§āϧāĻŋ āĻĒāĻžā§Ÿ āĻāĻŦāĻ‚ āϕ⧇āϰāĻžāϟāĻŋāύāϕ⧇ āĻĒ⧁āĻˇā§āϟāĻŋāϰ āĻ‰ā§ŽāϏ āĻšāĻŋāϏ⧇āĻŦ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰ⧇āĨ¤

Fungal invasion and the host inflammatory response may produce redness, scaling and itching.

āĻŦāĻžāĻ‚āϞāĻž: āĻ›āĻ¤ā§āϰāĻžāϕ⧇āϰ āφāĻ•ā§āϰāĻŽāĻŖ āĻāĻŦāĻ‚ āĻļāϰ⧀āϰ⧇āϰ āĻĒā§āϰāϤāĻŋāϰ⧋āϧāĻŦā§āϝāĻŦāĻ¸ā§āĻĨāĻžāϰ āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻžā§Ÿ āϞāĻžāϞāĻšā§‡ āĻĻāĻžāĻ—, āĻ–ā§‹āϏāĻž āĻ“āĻ āĻž āĻ“ āϚ⧁āϞāĻ•āĻžāύāĻŋ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

B. Etiology of Allergic Rhinitis — āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āĻ•āĻžāϰāĻŖ

Common allergens include house dust mites, pollen, animal dander and mould spores.

āĻŦāĻžāĻ‚āϞāĻž: āϧ⧁āϞāĻžāϰ āĻŽāĻžāχāϟ, āĻĢ⧁āϞ⧇āϰ āϰ⧇āϪ⧁, āĻĒā§āϰāĻžāĻŖā§€āϰ āĻļāϰ⧀āϰ āĻĨ⧇āϕ⧇ āĻāϰ⧇ āĻĒ⧜āĻž āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āĻœā§‡āύ āĻāĻŦāĻ‚ āĻ›āĻ¤ā§āϰāĻžāϕ⧇āϰ āĻ¸ā§āĻĒā§‹āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āϏ⧃āĻˇā§āϟāĻŋ āĻ•āϰāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Pathophysiology — āϰ⧋āĻ— āϏ⧃āĻˇā§āϟāĻŋāϰ āĻĒā§āϰāĻ•ā§āϰāĻŋ⧟āĻž

Allergen exposure activates IgE-sensitized mast cells and stimulates the release of histamine and other inflammatory mediators.

āĻŦāĻžāĻ‚āϞāĻž: āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āĻœā§‡āύ⧇āϰ āϏāĻ‚āĻ¸ā§āĻĒāĻ°ā§āĻļ⧇ IgE-āϏāĻ‚āĻŦ⧇āĻĻāύāĻļā§€āϞ Mast Cell āϏāĻ•ā§āϰāĻŋ⧟ āĻšā§Ÿā§‡ Histamine āĻ“ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻĒā§āϰāĻĻāĻžāĻšāϏ⧃āĻˇā§āϟāĻŋāĻ•āĻžāϰ⧀ āĻĒāĻĻāĻžāĻ°ā§āĻĨ āύāĻŋāσāϏāϰāĻŖ āĻ•āϰ⧇āĨ¤

These mediators cause sneezing, itching, watery discharge and nasal congestion.

āĻŦāĻžāĻ‚āϞāĻž: āĻāϏāĻŦ āϰāĻžāϏāĻžā§ŸāύāĻŋāĻ• āĻĒāĻĻāĻžāĻ°ā§āĻĨ⧇āϰ āĻĒā§āϰāĻ­āĻžāĻŦ⧇ āĻšāĻžāρāϚāĻŋ, āϚ⧁āϞāĻ•āĻžāύāĻŋ, āύāĻžāĻ• āĻĻāĻŋā§Ÿā§‡ āĻĒāĻžāύāĻŋ āĻĒ⧜āĻž āĻāĻŦāĻ‚ āύāĻžāĻ• āĻŦāĻ¨ā§āϧ āĻĨāĻžāĻ•āĻžāϰ āϏāĻŽāĻ¸ā§āϝāĻž āĻĻ⧇āĻ–āĻž āĻĻā§‡ā§ŸāĨ¤

Scientific Confidence — āĻŦ⧈āĻœā§āĻžāĻžāύāĻŋāĻ• āĻŦāĻŋāĻļā§āĻŦāĻžāϏāϝ⧋āĻ—ā§āϝāϤāĻž: 0.98āĨ¤


🟩 08. INVESTIGATIONS

āϰ⧋āĻ—āύāĻŋāĻ°ā§āĻŖā§Ÿā§‡āϰ āĻĒāϰ⧀āĻ•ā§āώāĻž

Physician-Documented Investigations — āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϞ⧇āĻ–āĻž āĻĒāϰ⧀āĻ•ā§āώāĻž

None documented — āϕ⧋āύ⧋ āĻĒāϰ⧀āĻ•ā§āώāĻž āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

Suggested Investigations — āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻĒā§āϰāĻ¸ā§āϤāĻžāĻŦāĻŋāϤ āĻĒāϰ⧀āĻ•ā§āώāĻž

Investigation — āĻĒāϰ⧀āĻ•ā§āώāĻžPurpose — āωāĻĻā§āĻĻ⧇āĻļā§āϝInterpretation — āĻŦā§āϝāĻžāĻ–ā§āϝāĻžConfidence
Skin Scraping for KOH — āĻ¤ā§āĻŦāϕ⧇āϰ āĻ–ā§‹āϏāĻžāϰ KOH āĻĒāϰ⧀āĻ•ā§āώāĻžDetect fungal elements — āĻ›āĻ¤ā§āϰāĻžāĻ• āĻļāύāĻžāĻ•ā§āϤ āĻ•āϰāĻžHyphae support fungal infection — āĻšāĻžāχāĻĢāĻž āĻĒāĻžāĻ“ā§ŸāĻž āϗ⧇āϞ⧇ āĻ›āĻ¤ā§āϰāĻžāϕ⧇āϰ āĻĒāĻ•ā§āώ⧇ āĻĒā§āϰāĻŽāĻžāĻŖ0.95
Fungal Culture — āĻ›āĻ¤ā§āϰāĻžāϕ⧇āϰ āĻ•āĻžāϞāϚāĻžāϰIdentify fungal growth — āĻ›āĻ¤ā§āϰāĻžāϕ⧇āϰ āĻŦ⧃āĻĻā§āϧāĻŋ āĻļāύāĻžāĻ•ā§āϤ āĻ•āϰāĻžUseful in persistent infection — āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžā§Ÿā§€ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇ āĻ•āĻžāĻ°ā§āϝāĻ•āϰ0.92
Fungal Species Identification — āĻ›āĻ¤ā§āϰāĻžāϕ⧇āϰ āĻĒā§āϰāϜāĻžāϤāĻŋ āĻļāύāĻžāĻ•ā§āϤāĻ•āϰāĻŖIdentify unusual/resistant organisms — āĻ…āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āĻŦāĻž āĻĒā§āϰāϤāĻŋāϰ⧋āϧ⧀ āĻ›āĻ¤ā§āϰāĻžāĻ• āĻļāύāĻžāĻ•ā§āϤConsider in selected resistant cases — āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻĒā§āϰāϤāĻŋāϰ⧋āϧ⧀ āϰ⧋āϗ⧇ āĻŦāĻŋāĻŦ⧇āĻšā§āϝ0.90
Liver Function Tests — āϞāĻŋāĻ­āĻžāϰ⧇āϰ āĻ•āĻžāĻ°ā§āϝāĻ•ā§āώāĻŽāϤāĻž āĻĒāϰ⧀āĻ•ā§āώāĻžAssess systemic antifungal safety — āĻŽā§āϖ⧇ āĻ–āĻžāĻ“ā§ŸāĻžāϰ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ⧇āϰ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻžInterpret according to clinical risk — āϰ⧋āĻ—ā§€āϰ āĻā§āρāĻ•āĻŋ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻŦā§āϝāĻžāĻ–ā§āϝāĻž0.95
Blood Glucose/HbA1c — āϰāĻ•ā§āϤ⧇ āĻļāĻ°ā§āĻ•āϰāĻž āĻĒāϰ⧀āĻ•ā§āώāĻžAssess diabetes when indicated — āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻĄāĻžā§ŸāĻžāĻŦ⧇āϟāĻŋāϏ āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύNot routinely required for every case — āϏāĻŦāĻžāϰ āϜāĻ¨ā§āϝ āĻŦāĻžāĻ§ā§āϝāϤāĻžāĻŽā§‚āϞāĻ• āύ⧟0.90
Pregnancy Assessment — āĻ—āĻ°ā§āĻ­āϧāĻžāϰāĻŖ āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύAssess medicine-related reproductive risk — āĻ“āώ⧁āϧ⧇āϰ āĻĒā§āϰāϜāύāύāϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻā§āρāĻ•āĻŋ āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύRelevant before systemic antifungal therapy — āĻŽā§āϖ⧇ āĻ–āĻžāĻ“ā§ŸāĻžāϰ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ⧇āϰ āφāϗ⧇ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ0.95
Bacterial Culture — āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϰ āĻ•āĻžāϞāϚāĻžāϰAssess suspected bacterial infection — āϏāĻ¨ā§āĻĻ⧇āĻšāϜāύāĻ• āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻž āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻļāύāĻžāĻ•ā§āϤOnly when clinically indicated — āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϞ⧇āχ āĻ•āϰāĻž āωāϚāĻŋāϤ0.85

Clinical Interpretation — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻŦā§āϝāĻžāĻ–ā§āϝāĻž

KOH microscopy is particularly useful when the appearance of a lesion is atypical or the diagnosis is uncertain.

āĻŦāĻžāĻ‚āϞāĻž: āĻ¤ā§āĻŦāϕ⧇āϰ āĻ•ā§āώāϤ āĻ…āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āĻĻ⧇āĻ–āĻžāϞ⧇ āĻ…āĻĨāĻŦāĻž āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟ āĻ…āύāĻŋāĻļā§āϚāĻŋāϤ āĻšāϞ⧇ KOH āĻĒāϰ⧀āĻ•ā§āώāĻž āĻŦāĻŋāĻļ⧇āώāĻ­āĻžāĻŦ⧇ āωāĻĒāĻ•āĻžāϰ⧀āĨ¤

Routine fungal culture or extensive blood investigations are not required for every uncomplicated localized tinea infection.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻžāϧāĻžāϰāĻŖ āϏ⧀āĻŽāĻŋāϤ āĻĻāĻžāĻĻ⧇āϰ āĻĒā§āϰāϤāĻŋāϟāĻŋ āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āĻ•āĻžāϞāϚāĻžāϰ āĻ…āĻĨāĻŦāĻž āĻ…āύ⧇āĻ• āϰāĻ•ā§āϤāĻĒāϰ⧀āĻ•ā§āώāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšā§Ÿ āύāĻžāĨ¤

Confidence: 0.95āĨ¤


🟧 09. DIFFERENTIAL DIAGNOSIS

āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟

Diagnosis — āϰ⧋āĻ—āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨSupporting Evidence — āϏāĻŽāĻ°ā§āĻĨāύāĻ•āĻžāϰ⧀ āϤāĻĨā§āϝConfidence
Superficial DermatophytosisāĻĻāĻžāĻĻ āĻŦāĻž āĻ¤ā§āĻŦāϕ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ• āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖOral and topical antifungals — āĻŽā§āϖ⧇ āĻ“ āĻŦāĻžāĻšā§āϝāĻŋāĻ• āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ0.70
Allergic RhinitisāύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋFexofenadine and nasal fluticasone — āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āĻ“āώ⧁āϧ0.75
Pityriasis Versicolorāϛ⧁āϞāĻŋItraconazole may be used — Itraconazole āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇0.35
Cutaneous CandidiasisāĻ¤ā§āĻŦāϕ⧇āϰ āĻ•ā§āϝāĻžāύāĻĄāĻŋāĻĄāĻž āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖSome antifungals have activity — āĻ•āĻŋāϛ⧁ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āĻ•āĻžāĻ°ā§āϝāĻ•āϰ0.30
Eczematous DermatitisāĻāĻ•āϜāĻŋāĻŽāĻžāϜāύāĻŋāϤ āĻ¤ā§āĻŦāϕ⧇āϰ āĻĒā§āϰāĻĻāĻžāĻšCan resemble tinea — āĻĻāĻžāĻĻ⧇āϰ āĻŽāϤ⧋ āĻĻ⧇āĻ–āϤ⧇ āĻšāϤ⧇ āĻĒāĻžāϰ⧇0.25
Secondary Bacterial Skin InfectionāĻ¤ā§āĻŦāϕ⧇āϰ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻž āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖPossible antibiotic entry — āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻŦāĻžā§Ÿā§‹āϟāĻŋāĻ•0.25

Final Differential Interpretation — āĻšā§‚ā§œāĻžāĻ¨ā§āϤ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āϰ⧋āĻ— āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ

Dermatophytosis is the leading medication-supported possibility. Allergic rhinitis is a separate possible coexisting condition.

āĻŦāĻžāĻ‚āϞāĻž: āĻ“āώ⧁āϧ⧇āϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻĻāĻžāĻĻ āϏāĻŦāĻšā§‡ā§Ÿā§‡ āĻŦ⧇āĻļāĻŋ āϏāĻ¨ā§āĻĻ⧇āĻš āĻšāĻšā§āϛ⧇āĨ¤ āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻāĻ•āϟāĻŋ āĻĒ⧃āĻĨāĻ• āϏāĻšāĻžāĻŦāĻ¸ā§āĻĨāĻžāύāĻ•āĻžāϰ⧀ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϰ⧋āĻ—āĨ¤

Confidence: 0.70āĨ¤


🟩 10. ORIGINAL PRESCRIPTION DRUG IDENTIFICATION

āĻŽā§‚āϞ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āĻ“āώ⧁āϧ āĻļāύāĻžāĻ•ā§āϤāĻ•āϰāĻŖ

No.Drug — āĻ“āώ⧁āϧGeneric — āĻœā§‡āύ⧇āϰāĻŋāĻ•Intended Purpose — āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āωāĻĻā§āĻĻ⧇āĻļā§āϝReading Confidence
1Itracon SUBA 65 mgItraconazole — āχāĻŸā§āϰāĻžāϕ⧋āύāĻžāϜāϞSystemic Antifungal — āĻŽā§āϖ⧇ āĻ–āĻžāĻ“ā§ŸāĻžāϰ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ0.99
2Tinacure Cream 30 gLuliconazole 1% — āϞ⧁āϞāĻŋāϕ⧋āύāĻžāϜāϞTopical Antifungal — āĻ¤ā§āĻŦāϕ⧇āϰ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ0.98
3Zimax 500 mgAzithromycin — āĻāϜāĻŋāĻĨā§āϰ⧋āĻŽāĻžāχāϏāĻŋāύAntibiotic — āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻŦāĻžā§Ÿā§‹āϟāĻŋāĻ•0.95
4Fastel 180 mgFexofenadine — āĻĢ⧇āĻ•ā§āϏ⧋āĻĢ⧇āύāĻžāĻĄāĻŋāύAntihistamine — āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āĻ“āώ⧁āϧ0.99
5ABC BarProbable antifungal cleansing bar — āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āϏāĻžāĻŦāĻžāύSupportive skin care — āĻ¤ā§āĻŦāϕ⧇āϰ āϏāĻšāĻžā§ŸāĻ• āϝāĻ¤ā§āύ0.90
6Snofas Nasal SprayFluticasone Furoate — āĻĢā§āϞ⧁āϟāĻŋāĻ•āĻžāϏāύ āĻĢāĻŋāωāĻ°ā§‹ā§Ÿā§‡āϟIntranasal Corticosteroid — āύāĻžāϕ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ•āĻ°ā§āϟāĻŋāϕ⧋āĻ¸ā§āĻŸā§‡āĻ°ā§Ÿā§‡āĻĄ0.98

Prescription Legibility Warning — āĻšāĻžāϤ⧇āϰ āϞ⧇āĻ–āĻž āϏāĻŽā§āĻĒāĻ°ā§āϕ⧇ āϏāϤāĻ°ā§āĻ•āϤāĻž

Itracon SUBA-āĻāϰ āύāĻŋāĻšā§‡ āĻāĻ•āĻžāϧāĻŋāĻ• āĻĄā§‹āϜ āĻ“ āϏāĻŽā§ŸāϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻ°ā§Ÿā§‡āϛ⧇, āϤāĻŦ⧇ āϏ⧇āϗ⧁āϞ⧋ āύāĻŋāĻ°ā§āĻ­āϰāϝ⧋āĻ—ā§āϝāĻ­āĻžāĻŦ⧇ āϏāĻŽā§āĻĒā§‚āĻ°ā§āĻŖ āĻĒ⧜āĻž āϝāĻžāĻšā§āϛ⧇ āύāĻžāĨ¤

Zimax-āĻāϰ āĻĒāĻžāĻļ⧇ āĻŦ⧜ āĻāĻ•āϟāĻŋ āĻ•āĻžāϟāĻž āĻŦāĻž āϚāĻŋāĻšā§āύ āĻ°ā§Ÿā§‡āϛ⧇āĨ¤ āĻāϰ āĻ…āĻ°ā§āĻĨ āĻ“āώ⧁āϧāϟāĻŋ āĻŦāĻžāϤāĻŋāϞ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇ āĻ•āĻŋ āύāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟āĨ¤

āĻŦāĻžāĻ‚āϞāĻž āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ: āĻŽā§‚āϞ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϏāĻ™ā§āϗ⧇ āϝāĻžāϚāĻžāχ āĻ›āĻžā§œāĻž āĻāχ āĻĻ⧁āχ āĻ“āώ⧁āϧ⧇āϰ āĻĄā§‹āϜ āĻŦāĻž āĻŦā§āϝāĻŦāĻšāĻžāϰ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

Confidence: 0.98āĨ¤


🟧 11. COMPLETE MEDEx MEDICINE REVIEW

MedEx āĻ…āύ⧁āϏāĻžāϰ⧇ āĻĒā§āϰāϤāĻŋāϟāĻŋ āĻ“āώ⧁āϧ⧇āϰ āĻĒā§‚āĻ°ā§āĻŖ ā§§ā§­-āĻĒā§āϝāĻžāϰāĻžāĻŽāĻŋāϟāĻžāϰ āĻŦāĻŋāĻļā§āϞ⧇āώāĻŖ

💊 MEDICINE 01 — ITRACON SUBA 65 MG

1. Generic Name — āĻœā§‡āύ⧇āϰāĻŋāĻ• āύāĻžāĻŽ

Itraconazole — āχāĻŸā§āϰāĻžāϕ⧋āύāĻžāϜāϞāĨ¤

Confidence: 0.99āĨ¤

2. Brand Name — āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āύāĻžāĻŽ

Itracon SUBA 65 mg — Navana Pharmaceuticals Ltd.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻ­āĻžāύāĻž āĻĢāĻžāĻ°ā§āĻŽāĻžāϏāĻŋāωāϟāĻŋāĻ•ā§āϝāĻžāϞāϏ⧇āϰ āχāĻŸā§āϰāĻžāĻ•āύ āϏ⧁āĻŦāĻž ā§Ŧā§Ģ āĻŽāĻŋāĻ—ā§āϰāĻž āĻ•ā§āϝāĻžāĻĒāϏ⧁āϞāĨ¤

Confidence: 0.99āĨ¤

3. MedEx Alternate Brands — āĻŽā§‡āĻĄāĻāĻ•ā§āϏ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

SUBA-i 65 mg, Subacon 65 mg, SuperItra 65 mg, Itracare SB 65 mg.

āĻŦāĻžāĻ‚āϞāĻž: āĻāĻ•āχ āĻœā§‡āύ⧇āϰāĻŋāϕ⧇āϰ SUBA-āϜāĻžāĻ¤ā§€ā§Ÿ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄāĨ¤

Confidence: 0.98āĨ¤

4. MedEx Therapeutic Class — āĻŽā§‡āĻĄāĻāĻ•ā§āϏ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻ—āϤ āĻļā§āϰ⧇āĻŖāĻŋ

Drugs for subcutaneous and mycoses.

āĻŦāĻžāĻ‚āϞāĻž: āĻ¤ā§āĻŦāϕ⧇āϰ āĻ—āĻ­ā§€āϰāϤāϰ āĻ“ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžā§Ÿ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻ“āώ⧁āϧ⧇āϰ āĻļā§āϰ⧇āĻŖāĻŋāĨ¤

Confidence: 0.99āĨ¤

5. Pharmacological Class — āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Triazole Antifungal — āĻŸā§āϰāĻžā§ŸāĻžāĻœā§‹āϞ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞāĨ¤

āĻŦāĻžāĻ‚āϞāĻž: Azole āĻļā§āϰ⧇āĻŖāĻŋāϰ āĻ›āĻ¤ā§āϰāĻžāĻ•āĻŦāĻŋāϰ⧋āϧ⧀ āĻ“āώ⧁āϧāĨ¤

Confidence: 0.99āĨ¤

6. Use/Purpose — āĻ“āώ⧁āϧ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ

English: Treatment of susceptible superficial and selected systemic fungal infections.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻ‚āĻŦ⧇āĻĻāύāĻļā§€āϞ āωāĻĒāϰāĻŋāĻ­āĻžāϗ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ• āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻāĻŦāĻ‚ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ—āĻ­ā§€āϰ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϰ⧋āϗ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĨ¤

Confidence: 0.99āĨ¤

7. Why Prescribed to This Patient — āĻāχ āϰ⧋āĻ—ā§€āϕ⧇ āϕ⧇āύ āĻĻ⧇āĻ“ā§ŸāĻž āĻšāϤ⧇ āĻĒāĻžāϰ⧇

English: Most likely intended for suspected dermatophytosis.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€āϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻĻāĻžāĻĻ āĻŦāĻž āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āĻ¤ā§āĻŦāϕ⧇āϰ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āϜāĻ¨ā§āϝ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.75āĨ¤

8. Side Effects — āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

English: Nausea, abdominal discomfort, headache, liver enzyme elevation, hepatitis, oedema and occasionally serious drug reactions.

āĻŦāĻžāĻ‚āϞāĻž: āĻŦāĻŽāĻŋāĻ­āĻžāĻŦ, āĻĒ⧇āĻŸā§‡āϰ āĻ…āĻ¸ā§āĻŦāĻ¸ā§āϤāĻŋ, āĻŽāĻžāĻĨāĻžāĻŦā§āϝāĻĨāĻž, āϞāĻŋāĻ­āĻžāϰ⧇āϰ āĻāύāϜāĻžāχāĻŽ āĻŦ⧃āĻĻā§āϧāĻŋ, āĻšā§‡āĻĒāĻžāϟāĻžāχāϟāĻŋāϏ, āĻļāϰ⧀āϰ āĻĢ⧁āϞ⧇ āϝāĻžāĻ“ā§ŸāĻž āĻāĻŦāĻ‚ āĻ•āĻ–āύ⧋ āϗ⧁āϰ⧁āϤāϰ āĻ“āώ⧁āϧ-āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻžāĨ¤

Confidence: 0.98āĨ¤

9. Direct MedEx Link — āϏāϰāĻžāϏāϰāĻŋ āĻŽā§‡āĻĄāĻāĻ•ā§āϏ āϞāĻŋāĻ‚āĻ•

Itracon SUBA 65 mg — MedEx

āĻŦāĻžāĻ‚āϞāĻž: āĻāχ āϞāĻŋāĻ‚āϕ⧇ āĻ“āώ⧁āϧ⧇āϰ āĻŽā§‚āϞ MedEx āϤāĻĨā§āϝ, āĻĄā§‹āϜ, āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž āĻāĻŦāĻ‚ āĻŽā§‚āĻ˛ā§āϝ āĻĻ⧇āĻ–āĻž āϝāĻžāĻŦ⧇āĨ¤

10. Unit Price, Strip Price and Other Composition — āĻāĻ•āĻ• āĻŽā§‚āĻ˛ā§āϝ, āĻ¸ā§āĻŸā§āϰāĻŋāĻĒ āĻŽā§‚āĻ˛ā§āϝ āĻ“ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ—āĻ āύ

Unit Price — āĻĒā§āϰāϤāĻŋ āĻ•ā§āϝāĻžāĻĒāϏ⧁āϞ: ā§ŗ20āĨ¤

Strip Price — ā§§ā§Ļ āĻ•ā§āϝāĻžāĻĒāϏ⧁āϞ: ā§ŗ200āĨ¤

Pack Price — ā§Šā§Ļ āĻ•ā§āϝāĻžāĻĒāϏ⧁āϞ: ā§ŗ600āĨ¤

Other Forms — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ—āĻ āύ: 100 mg capsule, 200 mg tablet, 50 mg/5 mL oral solution — ā§§ā§Ļā§Ļ āĻŽāĻŋāĻ—ā§āϰāĻž āĻ•ā§āϝāĻžāĻĒāϏ⧁āϞ, ⧍ā§Ļā§Ļ āĻŽāĻŋāĻ—ā§āϰāĻž āĻŸā§āϝāĻžāĻŦāϞ⧇āϟ āĻāĻŦāĻ‚ āĻ–āĻžāĻ“ā§ŸāĻžāϰ āϏāϞāĻŋāωāĻļāύāĨ¤

Confidence: 0.99āĨ¤

11. Mechanism of Action — āĻ“āώ⧁āϧ⧇āϰ āĻ•āĻžāĻ°ā§āϝāĻĒā§āϰāĻ•ā§āϰāĻŋ⧟āĻž

English: Inhibits fungal CYP-dependent lanosterol 14-alpha-demethylase, reducing ergosterol synthesis and impairing fungal cell membrane function.

āĻŦāĻžāĻ‚āϞāĻž: āĻ›āĻ¤ā§āϰāĻžāϕ⧇āϰ Ergosterol āϤ⧈āϰāĻŋāϰ āĻĒā§āϰāĻ•ā§āϰāĻŋ⧟āĻž āĻŦāĻžāϧāĻžāĻ—ā§āϰāĻ¸ā§āϤ āĻ•āϰ⧇ āϕ⧋āώāĻāĻŋāĻ˛ā§āϞāĻŋāϰ āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āĻ•āĻžāĻ°ā§āϝāĻ•ā§āϰāĻŽ āύāĻˇā§āϟ āĻ•āϰ⧇āĨ¤

Confidence: 0.99āĨ¤

12. Drug Indications — āϝ⧇āϏāĻŦ āϰ⧋āϗ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻšā§Ÿ

Tinea corporis — āĻļāϰ⧀āϰ⧇āϰ āĻĻāĻžāĻĻāĨ¤

Tinea cruris — āϕ⧁āρāϚāĻ•āĻŋāϰ āĻĻāĻžāĻĻāĨ¤

Tinea pedis — āĻĒāĻžā§Ÿā§‡āϰ āĻĻāĻžāĻĻāĨ¤

Pityriasis versicolor — āϛ⧁āϞāĻŋāĨ¤

Onychomycosis — āύāϖ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ• āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĨ¤

Selected systemic mycoses — āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ—āĻ­ā§€āϰ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĨ¤

Confidence: 0.98āĨ¤

13. Drug Interactions and Contraindications — āĻ“āώ⧁āϧ⧇āϰ āĻĒāĻžāϰāĻ¸ā§āĻĒāϰāĻŋāĻ• āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āĻŦā§āϝāĻŦāĻšāĻžāϰ āύāĻŋāώ⧇āϧ

English: Itraconazole strongly inhibits CYP3A4 and can interact with simvastatin, selected sedatives, antiarrhythmics and other medicines.

āĻŦāĻžāĻ‚āϞāĻž: Itraconazole CYP3A4 āĻāύāϜāĻžāχāĻŽā§‡āϰ āĻ•āĻžāĻ°ā§āϝāĻ•ā§āϰāĻŽ āĻ•āĻŽāĻžā§ŸāĨ¤ āĻĢāϞ⧇ Simvastatin, āĻ•āĻŋāϛ⧁ āϘ⧁āĻŽā§‡āϰ āĻ“āώ⧁āϧ, āĻšā§ƒāĻĻā§â€ŒāĻ¸ā§āĻĒāĻ¨ā§āĻĻāύ⧇āϰ āĻ“āώ⧁āϧ āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ“āώ⧁āϧ⧇āϰ āϏāĻ™ā§āϗ⧇ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

English: Avoid use in relevant contraindicated conditions, including pregnancy and certain cardiac conditions, according to product labeling.

āĻŦāĻžāĻ‚āϞāĻž: āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻāĻŦāĻ‚ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻšā§ƒāĻĻā§â€Œāϰ⧋āϗ⧇āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻ“āώ⧁āϧ⧇āϰ āĻ…āύ⧁āĻŽā§‹āĻĻāĻŋāϤ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻž āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻā§œāĻžāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.98āĨ¤

14. Precautions and Warnings — āϏāϤāĻ°ā§āĻ•āϤāĻž

English: Review liver disease, heart failure, pregnancy status and concurrent medication before use.

āĻŦāĻžāĻ‚āϞāĻž: āĻ“āώ⧁āϧ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āφāϗ⧇ āϞāĻŋāĻ­āĻžāϰ⧇āϰ āϰ⧋āĻ—, āĻšā§ƒāĻĻā§â€ŒāϝāĻ¨ā§āĻ¤ā§āϰ⧇āϰ āϏāĻŽāĻ¸ā§āϝāĻž, āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ“āώ⧁āϧ⧇āϰ āχāϤāĻŋāĻšāĻžāϏ āϝāĻžāϚāĻžāχ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.98āĨ¤

15. Dosage and Administration — āĻŽāĻžāĻ¤ā§āϰāĻž āĻ“ āϏ⧇āĻŦāύāĻŦāĻŋāϧāĻŋ

MedEx Reference Dose — āĻŽā§‡āĻĄāĻāĻ•ā§āϏ⧇āϰ āωāĻĻāĻžāĻšāϰāĻŖ āĻĄā§‹āϜ:

For tinea corporis/cruris, the SUBA formulation monograph lists 65 mg once daily for 15 days or 65 mg twice daily for 7 days.

āĻŦāĻžāĻ‚āϞāĻž: āĻļāϰ⧀āϰ āĻŦāĻž āϕ⧁āρāϚāĻ•āĻŋāϰ āĻĻāĻžāĻĻ⧇āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ MedEx SUBA formulation-āĻāϰ āϜāĻ¨ā§āϝ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻĒāϰāĻŋāĻ¸ā§āĻĨāĻŋāϤāĻŋāϤ⧇ āĻĻ⧈āύāĻŋāĻ• ā§Ŧā§Ģ āĻŽāĻŋāĻ—ā§āϰāĻž ā§§ā§Ģ āĻĻāĻŋāύ āĻ…āĻĨāĻŦāĻž āĻĻ⧈āύāĻŋāĻ• āĻĻ⧁āχāĻŦāĻžāϰ ā§Ŧā§Ģ āĻŽāĻŋāĻ—ā§āϰāĻž ā§­ āĻĻāĻŋāύ⧇āϰ āĻĄā§‹āϜ āωāĻ˛ā§āϞ⧇āĻ– āĻ•āϰ⧇āϛ⧇āĨ¤

Important — āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ: This is reference information, not a confirmed dose for Nasima Begum.

āĻŦāĻžāĻ‚āϞāĻž: āĻāϟāĻŋ āϏāĻžāϧāĻžāϰāĻŖ āϤāĻĨā§āϝāĨ¤ āύāĻžāϏāĻŋāĻŽāĻž āĻŦ⧇āĻ—āĻŽā§‡āϰ āϜāĻ¨ā§āϝ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āύāĻŋāĻ°ā§āϧāĻžāϰāĻŋāϤ āĻĄā§‹āϜ āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟āĨ¤

SUBA and conventional itraconazole formulations must not be substituted milligram-for-milligram without clinical verification.

āĻŦāĻžāĻ‚āϞāĻž: SUBA āĻ“ āϏāĻžāϧāĻžāϰāĻŖ Itraconazole formulation āĻāĻ•āχ āĻŽāĻŋāϞāĻŋāĻ—ā§āϰāĻžāĻŽ āϧāϰ⧇ āϏāϰāĻžāϏāϰāĻŋ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ āĻ•āϰāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

Confidence: 0.99 for monograph information; prescription-dose certainty: lowāĨ¤

16. Pregnancy and Lactation — āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύ

English: Systemic itraconazole is generally avoided or contraindicated in pregnancy, depending on the indication and product labeling. Breastfeeding requires specialist assessment.

āĻŦāĻžāĻ‚āϞāĻž: āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻžā§Ÿ āĻŽā§āϖ⧇ āĻ–āĻžāĻ“ā§ŸāĻžāϰ Itraconazole āϏāĻžāϧāĻžāϰāĻŖāϤ āĻā§œāĻŋā§Ÿā§‡ āϚāϞāϤ⧇ āĻšā§Ÿ āĻ…āĻĨāĻŦāĻž āύāĻŋāώāĻŋāĻĻā§āϧ āĻĨāĻžāϕ⧇āĨ¤ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύāĻ•āĻžāϞ⧇ āĻŦāĻŋāĻļ⧇āώāĻœā§āĻžā§‡āϰ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

Confidence: 0.98āĨ¤

17. Other Compositions / Combinations — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ—āĻ āύ āĻŦāĻž āϏāĻ‚āĻŽāĻŋāĻļā§āϰāĻŖ

English: Conventional capsules, tablets, oral solutions and SUBA formulations are available. No fixed combination is confirmed from this prescription.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻžāϧāĻžāϰāĻŖ āĻ•ā§āϝāĻžāĻĒāϏ⧁āϞ, āĻŸā§āϝāĻžāĻŦāϞ⧇āϟ, āĻ–āĻžāĻ“ā§ŸāĻžāϰ āϏāϞāĻŋāωāĻļāύ āĻāĻŦāĻ‚ SUBA formulation āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāĨ¤ āĻāχ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āϕ⧋āύ⧋ fixed-dose combination āĻļāύāĻžāĻ•ā§āϤ āĻšā§ŸāύāĻŋāĨ¤

Confidence: 0.98āĨ¤

Clinical Verdict — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ

English: Potentially appropriate for selected fungal infections, but exact indication, dose, duration and safety require confirmation.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇ āĻ“āώ⧁āϧāϟāĻŋ āωāĻĒāϝ⧋āĻ—ā§€ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ āϤāĻŦ⧇ āϰ⧋āĻ—, āĻĄā§‹āϜ, āϏāĻŽā§ŸāĻ•āĻžāϞ āĻāĻŦāĻ‚ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

Overall Confidence: 0.85āĨ¤


💊 MEDICINE 02 — TINACURE 1% CREAM

1. Generic Name — āĻœā§‡āύ⧇āϰāĻŋāĻ• āύāĻžāĻŽ

Luliconazole 1% — āϞ⧁āϞāĻŋāϕ⧋āύāĻžāϜāϞ ā§§%āĨ¤

Confidence: 0.99āĨ¤

2. Brand Name — āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āύāĻžāĻŽ

Tinacure Cream — Healthcare Pharmaceuticals Ltd.

āĻŦāĻžāĻ‚āϞāĻž: āĻšā§‡āϞāĻĨāĻ•ā§‡ā§ŸāĻžāϰ āĻĢāĻžāĻ°ā§āĻŽāĻžāϏāĻŋāωāϟāĻŋāĻ•ā§āϝāĻžāϞāϏ⧇āϰ āϟāĻŋāύāĻžāĻ•āĻŋāωāϰ āĻ•ā§āϰāĻŋāĻŽāĨ¤

Confidence: 0.99āĨ¤

3. MedEx Alternate Brands — āĻŽā§‡āĻĄāĻāĻ•ā§āϏ⧇āϰ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Lulicure, Lulider, Lulikill, Lulima, Lulitin, Lulitop.

āĻŦāĻžāĻ‚āϞāĻž: āĻāĻ•āχ āĻœā§‡āύ⧇āϰāĻŋāϕ⧇āϰ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻ•ā§āϰāĻŋāĻŽāĨ¤

Confidence: 0.98āĨ¤

4. MedEx Therapeutic Class — āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻ—āϤ āĻļā§āϰ⧇āĻŖāĻŋ

Miscellaneous topical agents — āĻ¤ā§āĻŦāϕ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻ—āϤ āĻ“āώ⧁āϧāĨ¤

Confidence: 0.99āĨ¤

5. Pharmacological Class — āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Topical Azole Antifungal — āĻ¤ā§āĻŦāϕ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻ…ā§āϝāĻžāĻœā§‹āϞ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞāĨ¤

Confidence: 0.99āĨ¤

6. Use/Purpose — āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ

English: Treatment of selected superficial dermatophyte infections.

āĻŦāĻžāĻ‚āϞāĻž: āĻ¤ā§āĻŦāϕ⧇āϰ āωāĻĒāϰāĻŋāĻ­āĻžāϗ⧇āϰ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĨ¤

Confidence: 0.99āĨ¤

7. Why Prescribed to This Patient — āϕ⧇āύ āĻĻ⧇āĻ“ā§ŸāĻž āĻšāϤ⧇ āĻĒāĻžāϰ⧇

English: Probably intended to treat suspected fungal lesions on the skin.

āĻŦāĻžāĻ‚āϞāĻž: āĻ¤ā§āĻŦāϕ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻĻāĻžāĻĻ āĻŦāĻž āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āĻ•ā§āώāϤ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āϜāĻ¨ā§āϝ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.85āĨ¤

8. Side Effects — āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

English: Local burning, irritation, erythema and contact dermatitis.

āĻŦāĻžāĻ‚āϞāĻž: āĻ•ā§āϰāĻŋāĻŽ āϞāĻžāĻ—āĻžāύ⧋āϰ āĻ¸ā§āĻĨāĻžāύ⧇ āĻœā§āĻŦāĻžāϞāĻž, āĻ¤ā§āĻŦāĻ• āϞāĻžāϞ āĻšāĻ“ā§ŸāĻž āĻ“ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϜāύāĻŋāϤ āĻĒā§āϰāĻĻāĻžāĻšāĨ¤

Confidence: 0.98āĨ¤

9. Direct MedEx Link — āĻŽā§‡āĻĄāĻāĻ•ā§āϏ āϞāĻŋāĻ‚āĻ•

Tinacure 1% Cream — MedEx

10. Unit Price, Strip Price and Composition — āĻŽā§‚āĻ˛ā§āϝ āĻ“ āĻ—āĻ āύ

30 g Tube Price — ā§Šā§Ļ āĻ—ā§āϰāĻžāĻŽ āϟāĻŋāωāĻŦ: ā§ŗ280āĨ¤

Strip Price — āĻ¸ā§āĻŸā§āϰāĻŋāĻĒ āĻŽā§‚āĻ˛ā§āϝ: Not applicable — āĻĒā§āϰāϝ⧋āĻœā§āϝ āύ⧟āĨ¤

Composition — āĻ—āĻ āύ: Luliconazole 1% — āϞ⧁āϞāĻŋāϕ⧋āύāĻžāϜāϞ ā§§%āĨ¤

Confidence: 0.99āĨ¤

11. Mechanism — āĻ•āĻžāĻ°ā§āϝāĻĒā§āϰāĻ•ā§āϰāĻŋ⧟āĻž

English: Inhibits fungal lanosterol demethylase and disrupts ergosterol synthesis.

āĻŦāĻžāĻ‚āϞāĻž: āĻ›āĻ¤ā§āϰāĻžāϕ⧇āϰ āϕ⧋āώāĻāĻŋāĻ˛ā§āϞāĻŋ āϤ⧈āϰāĻŋāϰ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āωāĻĒāĻžāĻĻāĻžāύ Ergosterol āĻ‰ā§ŽāĻĒāĻžāĻĻāύ āĻŦāĻžāϧāĻžāĻ—ā§āϰāĻ¸ā§āϤ āĻ•āϰ⧇āĨ¤

Confidence: 0.99āĨ¤

12. Indications — āĻŦā§āϝāĻŦāĻšāĻžāϰāϝ⧋āĻ—ā§āϝ āϰ⧋āĻ—

Tinea corporis — āĻļāϰ⧀āϰ⧇āϰ āĻĻāĻžāĻĻāĨ¤

Tinea cruris — āϕ⧁āρāϚāĻ•āĻŋāϰ āĻĻāĻžāĻĻāĨ¤

Interdigital tinea pedis — āĻĒāĻžā§Ÿā§‡āϰ āφāϙ⧁āϞ⧇āϰ āĻĢāĻžāρāϕ⧇āϰ āĻĻāĻžāĻĻāĨ¤

Confidence: 0.99āĨ¤

13. Interactions and Contraindications — āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āύāĻŋāώ⧇āϧāĻžāĻœā§āĻžāĻž

English: Contraindicated in patients with known hypersensitivity to luliconazole.

āĻŦāĻžāĻ‚āϞāĻž: Luliconazole-āĻ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻĨāĻžāĻ•āϞ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

English: Clinically significant systemic interactions are less likely because systemic exposure is limited.

āĻŦāĻžāĻ‚āϞāĻž: āĻ¤ā§āĻŦāϕ⧇āϰ āĻŽāĻžāĻ§ā§āϝāĻŽā§‡ āĻļāϰ⧀āϰ⧇ āĻļā§‹āώāĻŖ āĻ•āĻŽ āĻšāĻ“ā§ŸāĻžā§Ÿ āϗ⧁āϰ⧁āϤāϰ systemic interaction-āĻāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āϤ⧁āϞāύāĻžāĻŽā§‚āϞāĻ• āĻ•āĻŽāĨ¤

Confidence: 0.95āĨ¤

14. Precautions — āϏāϤāĻ°ā§āĻ•āϤāĻž

English: For external use only; avoid eyes, mouth and mucosal surfaces.

āĻŦāĻžāĻ‚āϞāĻž: āĻļ⧁āϧ⧁ āĻ¤ā§āĻŦāϕ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āϜāĻ¨ā§āϝāĨ¤ āĻšā§‹āĻ–, āĻŽā§āĻ– āĻ“ āĻļā§āϞ⧈āĻˇā§āĻŽāĻŋāĻ• āĻāĻŋāĻ˛ā§āϞāĻŋāϤ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

Confidence: 0.99āĨ¤

15. Dosage and Administration — āĻŽāĻžāĻ¤ā§āϰāĻž āĻ“ āĻŦā§āϝāĻŦāĻšāĻžāϰāĻŦāĻŋāϧāĻŋ

English: MedEx lists once-daily application for one week in tinea corporis/cruris and two weeks in interdigital tinea pedis.

āĻŦāĻžāĻ‚āϞāĻž: MedEx āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻļāϰ⧀āϰ āĻŦāĻž āϕ⧁āρāϚāĻ•āĻŋāϰ āĻĻāĻžāĻĻ⧇ āϏāĻžāϧāĻžāϰāĻŖāϤ āĻĻāĻŋāύ⧇ āĻāĻ•āĻŦāĻžāϰ āĻāĻ• āϏāĻĒā§āϤāĻžāĻš āĻāĻŦāĻ‚ āĻĒāĻžā§Ÿā§‡āϰ āφāϙ⧁āϞ⧇āϰ āĻĢāĻžāρāϕ⧇āϰ āĻĻāĻžāĻĻ⧇ āĻĻāĻŋāύ⧇ āĻāĻ•āĻŦāĻžāϰ āĻĻ⧁āχ āϏāĻĒā§āϤāĻžāĻš āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

Important — āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ: Patient-specific instructions must be verified from the treating physician.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āύāĻŋāĻ°ā§āϧāĻžāϰāĻŋāϤ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻŦā§āϝāĻŦāĻšāĻžāϰāĻŦāĻŋāϧāĻŋ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻ•āĻžāĻ› āĻĨ⧇āϕ⧇ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.99āĨ¤

16. Pregnancy and Lactation — āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύ

English: Use after benefit–risk assessment; avoid application where an infant could ingest the medicine.

āĻŦāĻžāĻ‚āϞāĻž: āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύāĻ•āĻžāϞ⧇ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§ŸāϤāĻž āĻ“ āĻā§āρāĻ•āĻŋ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤ āĻļāĻŋāĻļ⧁āϰ āĻŽā§āϖ⧇ āϞāĻžāĻ—āĻžāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āĻ°ā§Ÿā§‡āϛ⧇ āĻāĻŽāύ āĻ¸ā§āĻĨāĻžāύ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻā§œāĻžāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.95āĨ¤

17. Other Compositions / Combinations — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ—āĻ āύ

English: Other luliconazole 1% brands and lotion formulations exist; no specific fixed-dose combination is identified here.

āĻŦāĻžāĻ‚āϞāĻž: Luliconazole 1%-āĻāϰ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ•ā§āϰāĻŋāĻŽ āĻ“ āϞ⧋āĻļāύ āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāĨ¤ āĻāĻ–āĻžāύ⧇ āϕ⧋āύ⧋ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻŽāĻŋāĻļā§āϰ-āĻ“āώ⧁āϧ āĻļāύāĻžāĻ•ā§āϤ āĻ•āϰāĻž āĻšā§ŸāύāĻŋāĨ¤

Confidence: 0.98āĨ¤

Clinical Verdict — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ

English: A reasonable topical antifungal option if a compatible dermatophyte infection is confirmed.

āĻŦāĻžāĻ‚āϞāĻž: āωāĻĒāϝ⧁āĻ•ā§āϤ āϧāϰāύ⧇āϰ āĻĻāĻžāĻĻ āύāĻŋāĻļā§āϚāĻŋāϤ āĻšāϞ⧇ āĻāϟāĻŋ āĻ•āĻžāĻ°ā§āϝāĻ•āϰ āĻŦāĻžāĻšā§āϝāĻŋāĻ• āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Overall Confidence: 0.90āĨ¤


💊 MEDICINE 03 — ZIMAX 500 MG

1. Generic Name — āĻœā§‡āύ⧇āϰāĻŋāĻ• āύāĻžāĻŽ

Azithromycin Dihydrate — āĻāϜāĻŋāĻĨā§āϰ⧋āĻŽāĻžāχāϏāĻŋāύ āĻĄāĻžāχāĻšāĻžāχāĻĄā§āϰ⧇āϟāĨ¤

Confidence: 0.99āĨ¤

2. Brand Name — āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āύāĻžāĻŽ

Zimax 500 mg — Square Pharmaceuticals PLC.

āĻŦāĻžāĻ‚āϞāĻž: āĻ¸ā§āĻ•ā§ŸāĻžāϰ āĻĢāĻžāĻ°ā§āĻŽāĻžāϏāĻŋāωāϟāĻŋāĻ•ā§āϝāĻžāϞāϏ⧇āϰ āϜāĻŋāĻŽā§āϝāĻžāĻ•ā§āϏ ā§Ģā§Ļā§Ļ āĻŽāĻŋāĻ—ā§āϰāĻž āĻŸā§āϝāĻžāĻŦāϞ⧇āϟāĨ¤

Confidence: 0.99āĨ¤

3. MedEx Alternate Brands — āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Other azithromycin brands include Zithrin and various locally marketed azithromycin products.

āĻŦāĻžāĻ‚āϞāĻž: Zithrin āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āϕ⧋āĻŽā§āĻĒāĻžāύāĻŋāϰ Azithromycin āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāĨ¤

Confidence: 0.95āĨ¤

4. MedEx Therapeutic Class — āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻ—āϤ āĻļā§āϰ⧇āĻŖāĻŋ

Macrolides — āĻŽā§āϝāĻžāĻ•ā§āϰ⧋āϞāĻžāχāĻĄ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻŦāĻžā§Ÿā§‹āϟāĻŋāĻ•āĨ¤

Confidence: 0.99āĨ¤

5. Pharmacological Class — āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Azalide Antibiotic — āφāϜāĻžāϞāĻžāχāĻĄ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻŦāĻžā§Ÿā§‹āϟāĻŋāĻ•āĨ¤

Confidence: 0.99āĨ¤

6. Use/Purpose — āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ

English: Treatment of susceptible bacterial infections.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻ‚āĻŦ⧇āĻĻāύāĻļā§€āϞ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĨ¤

Confidence: 0.99āĨ¤

7. Why Prescribed to This Patient — āϕ⧇āύ āĻĻ⧇āĻ“ā§ŸāĻž āĻšāϤ⧇ āĻĒāĻžāϰ⧇

English: A bacterial infection may have been considered, but the indication is undocumented and the entry may have been crossed out.

āĻŦāĻžāĻ‚āϞāĻž: āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āĻšā§ŸāϤ⧋ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰ⧇āĻ›āĻŋāϞ⧇āύāĨ¤ āϤāĻŦ⧇ āĻ•āĻžāϰāĻŖ āϞ⧇āĻ–āĻž āύ⧇āχ āĻāĻŦāĻ‚ āĻ“āώ⧁āϧāϟāĻŋ āϕ⧇āĻŸā§‡ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.25āĨ¤

8. Side Effects — āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

English: Nausea, diarrhoea, abdominal pain, liver injury and possible QT-interval prolongation.

āĻŦāĻžāĻ‚āϞāĻž: āĻŦāĻŽāĻŋāĻ­āĻžāĻŦ, āĻĄāĻžā§ŸāϰāĻŋ⧟āĻž, āĻĒ⧇āϟāĻŦā§āϝāĻĨāĻž, āϞāĻŋāĻ­āĻžāϰ⧇āϰ āϏāĻŽāĻ¸ā§āϝāĻž āĻāĻŦāĻ‚ āĻ•āĻŋāϛ⧁ āϰ⧋āĻ—ā§€āϰ āĻšā§ƒāĻĻā§â€ŒāĻ¸ā§āĻĒāĻ¨ā§āĻĻāύ⧇āϰ āĻŦ⧈āĻĻā§āϝ⧁āϤāĻŋāĻ• āĻ›āĻ¨ā§āĻĻ⧇ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύāĨ¤

Confidence: 0.98āĨ¤

9. Direct MedEx Link — āĻŽā§‡āĻĄāĻāĻ•ā§āϏ āϞāĻŋāĻ‚āĻ•

Zimax 500 mg — MedEx

10. Unit Price, Strip Price and Composition — āĻŽā§‚āĻ˛ā§āϝ āĻ“ āĻ—āĻ āύ

Unit Price — āĻĒā§āϰāϤāĻŋ āĻŸā§āϝāĻžāĻŦāϞ⧇āϟ: ā§ŗ40āĨ¤

Strip Price — āĻ›ā§ŸāϟāĻŋ āĻŸā§āϝāĻžāĻŦāϞ⧇āϟ: ā§ŗ240āĨ¤

Other Forms — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ—āĻ āύ: 250 mg capsule, 200 mg/5 mL suspension, 500 mg IV preparation — ⧍ā§Ģā§Ļ āĻŽāĻŋāĻ—ā§āϰāĻž āĻ•ā§āϝāĻžāĻĒāϏ⧁āϞ, āϏāĻžāϏāĻĒ⧇āύāĻļāύ āĻ“ āχāύāĻœā§‡āĻ•āĻļāύāĨ¤

Confidence: 0.99āĨ¤

11. Mechanism — āĻ•āĻžāĻ°ā§āϝāĻĒā§āϰāĻ•ā§āϰāĻŋ⧟āĻž

English: Binds to the bacterial 50S ribosomal subunit and inhibits protein synthesis.

āĻŦāĻžāĻ‚āϞāĻž: āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϰ 50S Ribosome-āĻāϰ āϏāĻ™ā§āϗ⧇ āϝ⧁āĻ•ā§āϤ āĻšā§Ÿā§‡ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āĻĒā§āϰ⧋āϟāĻŋāύ āϤ⧈āϰāĻŋ āĻŦāĻžāϧāĻžāĻ—ā§āϰāĻ¸ā§āϤ āĻ•āϰ⧇āĨ¤

Confidence: 0.99āĨ¤

12. Indications — āĻŦā§āϝāĻŦāĻšāĻžāϰāϝ⧋āĻ—ā§āϝ āϰ⧋āĻ—

Selected respiratory bacterial infections — āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻļā§āĻŦāĻžāϏāϤāĻ¨ā§āĻ¤ā§āϰ⧇āϰ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻž āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĨ¤

Selected skin and soft-tissue infections — āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ¤ā§āĻŦāĻ• āĻ“ āϕ⧋āĻŽāϞ āĻ•āϞāĻžāϰ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻž āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĨ¤

Selected sexually transmitted bacterial infections — āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϝ⧌āύāĻŦāĻžāĻšāĻŋāϤ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻž āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĨ¤

Confidence: 0.98āĨ¤

13. Interactions and Contraindications — āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āύāĻŋāώ⧇āϧāĻžāĻœā§āĻžāĻž

English: Caution is needed with QT-prolonging medicines, certain antiarrhythmics, warfarin and digoxin.

āĻŦāĻžāĻ‚āϞāĻž: āĻšā§ƒāĻĻā§â€ŒāĻ¸ā§āĻĒāĻ¨ā§āĻĻāύ⧇āϰ āĻ›āĻ¨ā§āĻĻ⧇ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύāĻ•āĻžāϰ⧀ āĻ“āώ⧁āϧ, āĻ•āĻŋāϛ⧁ āĻšā§ƒāĻĻā§â€Œāϰ⧋āϗ⧇āϰ āĻ“āώ⧁āϧ, Warfarin āĻāĻŦāĻ‚ Digoxin-āĻāϰ āϏāĻ™ā§āϗ⧇ āϏāϤāĻ°ā§āĻ•āϤāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

Confidence: 0.95āĨ¤

14. Precautions — āϏāϤāĻ°ā§āĻ•āϤāĻž

English: Assess bacterial indication, macrolide allergy, liver function and cardiac risk.

āĻŦāĻžāĻ‚āϞāĻž: āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻž āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āĻ•āĻžāϰāĻŖ, Macrolide āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ, āϞāĻŋāĻ­āĻžāϰ⧇āϰ āĻ…āĻŦāĻ¸ā§āĻĨāĻž āĻāĻŦāĻ‚ āĻšā§ƒāĻĻā§â€Œāϰ⧋āϗ⧇āϰ āĻā§āρāĻ•āĻŋ āϝāĻžāϚāĻžāχ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.98āĨ¤

15. Dosage and Administration — āĻŽāĻžāĻ¤ā§āϰāĻž āĻ“ āϏ⧇āĻŦāύāĻŦāĻŋāϧāĻŋ

English: Adult dosing depends on the bacterial infection and clinical indication. A 500 mg once-daily three-day regimen is used for some indications.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—āϭ⧇āĻĻ⧇ āĻĄā§‹āϜ āĻ­āĻŋāĻ¨ā§āύ āĻšā§ŸāĨ¤ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ•āĻŋāϛ⧁ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϜāύāĻŋāϤ āϰ⧋āϗ⧇ ā§Ģā§Ļā§Ļ āĻŽāĻŋāĻ—ā§āϰāĻž āĻĻāĻŋāύ⧇ āĻāĻ•āĻŦāĻžāϰ āϤāĻŋāύ āĻĻāĻŋāύ⧇āϰ āĻĄā§‹āϜ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āĻšā§ŸāĨ¤

Important — āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ: This is not a recommended regimen for the current patient because the indication and prescription status are uncertain.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āĻāϟāĻŋ āϕ⧋āύ⧋ āύāϤ⧁āύ āĻĄā§‹āϜ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻž āύ⧟āĨ¤ āĻāχ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻ“āώ⧁āϧāϟāĻŋāϰ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§ŸāϤāĻž āĻāĻŦāĻ‚ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āĻĨ⧇āϕ⧇ āĻŦāĻžāϤāĻŋāϞ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇ āĻ•āĻŋ āύāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟āĨ¤

Confidence: 0.98 for general dosing informationāĨ¤

16. Pregnancy and Lactation — āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύ

English: May be used when appropriately indicated after clinical assessment.

āĻŦāĻžāĻ‚āϞāĻž: āωāĻĒāϝ⧁āĻ•ā§āϤ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻ—āϤ āĻ•āĻžāϰāĻŖ āĻĨāĻžāĻ•āϞ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ⧇āϰ āĻ­āĻŋāĻ¤ā§āϤāĻŋāϤ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āϝ⧇āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.95āĨ¤

17. Other Compositions / Combinations — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ—āĻ āύ

English: Capsules, tablets, oral suspension and intravenous formulations are available.

āĻŦāĻžāĻ‚āϞāĻž: āĻ•ā§āϝāĻžāĻĒāϏ⧁āϞ, āĻŸā§āϝāĻžāĻŦāϞ⧇āϟ, āĻ–āĻžāĻ“ā§ŸāĻžāϰ āϏāĻžāϏāĻĒ⧇āύāĻļāύ āĻāĻŦāĻ‚ āχāύāĻœā§‡āĻ•āĻļāύ āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāĨ¤

Confidence: 0.99āĨ¤

Clinical Verdict — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ

English: Azithromycin has no direct antifungal activity against dermatophytes. Its use requires a separate bacterial indication.

āĻŦāĻžāĻ‚āϞāĻž: Azithromycin āĻĻāĻžāĻĻ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāϕ⧇āϰ āĻŦāĻŋāϰ⧁āĻĻā§āϧ⧇ āĻ•āĻžāϜ āĻ•āϰ⧇ āύāĻžāĨ¤ āĻāϟāĻŋ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāϤ⧇ āĻšāϞ⧇ āĻĒ⧃āĻĨāĻ• āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϝ⧁āĻ•ā§āϤāĻŋāϏāĻ‚āĻ—āϤ āĻ•āĻžāϰāĻŖ āĻĨāĻžāĻ•āϤ⧇ āĻšāĻŦ⧇āĨ¤

Overall Confidence: 0.98 for pharmacology; 0.25 for this patient’s indicationāĨ¤


💊 MEDICINE 04 — FASTEL 180 MG

1. Generic Name — āĻœā§‡āύ⧇āϰāĻŋāĻ• āύāĻžāĻŽ

Fexofenadine Hydrochloride — āĻĢ⧇āĻ•ā§āϏ⧋āĻĢ⧇āύāĻžāĻĄāĻŋāύ āĻšāĻžāχāĻĄā§āϰ⧋āĻ•ā§āϞ⧋āϰāĻžāχāĻĄāĨ¤

Confidence: 0.99āĨ¤

2. Brand Name — āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āύāĻžāĻŽ

Fastel 180 mg — Radiant Pharmaceuticals Ltd.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧇āĻĄāĻŋā§Ÿā§‡āĻ¨ā§āϟ āĻĢāĻžāĻ°ā§āĻŽāĻžāϏāĻŋāωāϟāĻŋāĻ•ā§āϝāĻžāϞāϏ⧇āϰ āĻĢāĻžāĻ¸ā§āĻŸā§‡āϞ ā§§ā§Žā§Ļ āĻŽāĻŋāĻ—ā§āϰāĻž āĻŸā§āϝāĻžāĻŦāϞ⧇āϟāĨ¤

Confidence: 0.99āĨ¤

3. MedEx Alternate Brands — āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Fenadin and other fexofenadine brands.

āĻŦāĻžāĻ‚āϞāĻž: Fenadin āĻāĻŦāĻ‚ āĻāĻ•āχ āĻœā§‡āύ⧇āϰāĻŋāϕ⧇āϰ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄāĨ¤

Confidence: 0.95āĨ¤

4. MedEx Therapeutic Class — āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻ—āϤ āĻļā§āϰ⧇āĻŖāĻŋ

Anti-histamine — āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻšāĻŋāĻ¸ā§āϟāĻžāĻŽāĻŋāύāĨ¤

Confidence: 0.99āĨ¤

5. Pharmacological Class — āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Second-Generation H1 Antihistamine — āĻĻā§āĻŦāĻŋāĻ¤ā§€ā§Ÿ āĻĒā§āϰāϜāĻ¨ā§āĻŽā§‡āϰ H1 āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻšāĻŋāĻ¸ā§āϟāĻžāĻŽāĻŋāύāĨ¤

Confidence: 0.99āĨ¤

6. Use/Purpose — āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ

English: Relief of allergic rhinitis symptoms and urticaria.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻāĻŦāĻ‚ āĻ¤ā§āĻŦāϕ⧇ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϜāύāĻŋāϤ āϚāĻžāĻ•āĻž āĻ“āĻ āĻžāϰ āωāĻĒāϏāĻ°ā§āĻ— āĻ•āĻŽāĻžāύ⧋āĨ¤

Confidence: 0.99āĨ¤

7. Why Prescribed to This Patient — āϕ⧇āύ āĻĻ⧇āĻ“ā§ŸāĻž āĻšāϤ⧇ āĻĒāĻžāϰ⧇

English: Possibly for allergic rhinitis or associated itching.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻ…āĻĨāĻŦāĻž āĻ¤ā§āĻŦāϕ⧇āϰ āϚ⧁āϞāĻ•āĻžāύāĻŋ āĻ•āĻŽāĻžāύ⧋āϰ āϜāĻ¨ā§āϝ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.80āĨ¤

8. Side Effects — āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

English: Headache, dizziness, nausea and occasional drowsiness.

āĻŦāĻžāĻ‚āϞāĻž: āĻŽāĻžāĻĨāĻžāĻŦā§āϝāĻĨāĻž, āĻŽāĻžāĻĨāĻž āĻ˜ā§‹āϰāĻž, āĻŦāĻŽāĻŋāĻ­āĻžāĻŦ āĻāĻŦāĻ‚ āĻ•āĻ–āύ⧋ āĻāĻŋāĻŽā§āύāĻŋāĨ¤

Confidence: 0.98āĨ¤

9. Direct MedEx Link — āĻŽā§‡āĻĄāĻāĻ•ā§āϏ āϞāĻŋāĻ‚āĻ•

Fastel 180 mg — MedEx

10. Unit Price, Strip Price and Composition — āĻŽā§‚āĻ˛ā§āϝ āĻ“ āĻ—āĻ āύ

Unit Price — āĻĒā§āϰāϤāĻŋ āĻŸā§āϝāĻžāĻŦāϞ⧇āϟ: ā§ŗ13āĨ¤

Strip Price — āĻĻāĻļāϟāĻŋ āĻŸā§āϝāĻžāĻŦāϞ⧇āϟ: ā§ŗ130āĨ¤

Other Forms — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ—āĻ āύ: 120 mg tablet and oral suspension — ⧧⧍ā§Ļ āĻŽāĻŋāĻ—ā§āϰāĻž āĻŸā§āϝāĻžāĻŦāϞ⧇āϟ āĻ“ āϏāĻžāϏāĻĒ⧇āύāĻļāύāĨ¤

Confidence: 0.99āĨ¤

11. Mechanism — āĻ•āĻžāĻ°ā§āϝāĻĒā§āϰāĻ•ā§āϰāĻŋ⧟āĻž

English: Acts as a selective peripheral H1-receptor inverse agonist, reducing histamine-mediated allergic symptoms.

āĻŦāĻžāĻ‚āϞāĻž: Histamine-āĻāϰ H1 receptor-āĻāϰ āĻ•āĻžāĻ°ā§āϝāĻ•ā§āϰāĻŽ āĻ•āĻŽāĻŋā§Ÿā§‡ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āωāĻĒāϏāĻ°ā§āĻ— āύāĻŋ⧟āĻ¨ā§āĻ¤ā§āϰāĻŖ āĻ•āϰ⧇āĨ¤

Confidence: 0.99āĨ¤

12. Indications — āĻŦā§āϝāĻŦāĻšāĻžāϰāϝ⧋āĻ—ā§āϝ āϰ⧋āĻ—

Allergic Rhinitis — āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāĨ¤

Chronic Urticaria — āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžā§Ÿā§€ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϜāύāĻŋāϤ āϚāĻžāĻ•āĻž āĻ“āĻ āĻžāĨ¤

Allergic Pruritus — āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϜāύāĻŋāϤ āϚ⧁āϞāĻ•āĻžāύāĻŋāĨ¤

Confidence: 0.98āĨ¤

13. Interactions and Contraindications — āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āύāĻŋāώ⧇āϧāĻžāĻœā§āĻžāĻž

English: Aluminium/magnesium antacids and certain fruit juices can reduce absorption. Avoid in known hypersensitivity.

āĻŦāĻžāĻ‚āϞāĻž: Aluminium/Magnesium-āϝ⧁āĻ•ā§āϤ Antacid āĻāĻŦāĻ‚ āĻ•āĻŋāϛ⧁ āĻĢāϞ⧇āϰ āϰāϏ āĻ“āώ⧁āϧ⧇āϰ āĻļā§‹āώāĻŖ āĻ•āĻŽāĻžāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ āĻ“āώ⧁āϧāϟāĻŋāϤ⧇ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻĨāĻžāĻ•āϞ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

Confidence: 0.98āĨ¤

14. Precautions — āϏāϤāĻ°ā§āĻ•āϤāĻž

English: Consider renal impairment, previous allergy and other medicines.

āĻŦāĻžāĻ‚āϞāĻž: āĻ•āĻŋāĻĄāύāĻŋāϰ āĻ•āĻžāĻ°ā§āϝāĻ•ā§āώāĻŽāϤāĻž, āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ“āώ⧁āϧ⧇āϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.95āĨ¤

15. Dosage and Administration — āĻŽāĻžāĻ¤ā§āϰāĻž āĻ“ āϏ⧇āĻŦāύāĻŦāĻŋāϧāĻŋ

English: For appropriate adult indications, 180 mg once daily is a commonly listed regimen.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϰ⧋āϗ⧇ āĻĒā§āϰāĻžāĻĒā§āϤāĻŦ⧟āĻ¸ā§āĻ•āĻĻ⧇āϰ āϜāĻ¨ā§āϝ ā§§ā§Žā§Ļ āĻŽāĻŋāĻ—ā§āϰāĻž āĻĻāĻŋāύ⧇ āĻāĻ•āĻŦāĻžāϰ āĻāĻ•āϟāĻŋ āĻĒā§āϰāϚāϞāĻŋāϤ āĻĄā§‹āϜāĨ¤

Important — āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ: The patient-specific handwritten direction must be confirmed.

āĻŦāĻžāĻ‚āϞāĻž: āĻāχ āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āϞ⧇āĻ–āĻž āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.98āĨ¤

16. Pregnancy and Lactation — āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύ

English: Use after individualized assessment of safety and clinical necessity.

āĻŦāĻžāĻ‚āϞāĻž: āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύāĻ•āĻžāϞ⧇ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§ŸāϤāĻž āĻ“ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.95āĨ¤

17. Other Compositions / Combinations — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ—āĻ āύ

English: Fexofenadine is available in different tablet strengths and oral suspension formulations.

āĻŦāĻžāĻ‚āϞāĻž: Fexofenadine āĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ āĻŽāĻžāĻ¤ā§āϰāĻžāϰ āĻŸā§āϝāĻžāĻŦāϞ⧇āϟ āĻāĻŦāĻ‚ āĻ–āĻžāĻ“ā§ŸāĻžāϰ āϏāĻžāϏāĻĒ⧇āύāĻļāύ āĻšāĻŋāϏ⧇āĻŦ⧇ āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāĨ¤

Confidence: 0.98āĨ¤

Clinical Verdict — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ

English: Suitable for selected allergic symptoms but does not eradicate fungal infections.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āωāĻĒāϏāĻ°ā§āĻ— āĻ•āĻŽāĻžāϤ⧇ āĻ•āĻžāĻ°ā§āϝāĻ•āϰ, āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻĻāĻžāĻĻ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ• āĻ§ā§āĻŦāĻ‚āϏ āĻ•āϰ⧇ āύāĻžāĨ¤

Overall Confidence: 0.95āĨ¤


💊 MEDICINE 05 — ABC ANTI-FUNGAL BAR

1. Generic Name — āĻœā§‡āύ⧇āϰāĻŋāĻ• āύāĻžāĻŽ

Reported Ingredients — āĻĒā§āϰāĻ•āĻžāĻļāĻŋāϤ āωāĻĒāĻžāĻĻāĻžāύ: Ketoconazole + Zinc Pyrithione + Glycerine.

āĻŦāĻžāĻ‚āϞāĻž: āϕ⧇āĻŸā§‹āϕ⧋āύāĻžāϜāϞ, āϜāĻŋāĻ™ā§āĻ• āĻĒāĻžāχāϰāĻŋāĻĨāĻŋāĻ“āύ āĻ“ āĻ—ā§āϞāĻŋāϏāĻžāϰāĻŋāύāĨ¤

Important — āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ: Exact formulation and concentrations must be checked against the product label.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āϰāĻ•ā§ƒāϤ āωāĻĒāĻžāĻĻāĻžāύ āĻāĻŦāĻ‚ āĻĒā§āϰāϤāĻŋāϟāĻŋ āωāĻĒāĻžāĻĻāĻžāύ⧇āϰ āĻŽāĻžāĻ¤ā§āϰāĻž āĻĒāĻŖā§āϝ⧇āϰ āĻŽā§‹ā§œāĻ• āĻĨ⧇āϕ⧇ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.75āĨ¤

2. Brand Name — āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āύāĻžāĻŽ

ABC Anti-Fungal Bar — S-PA Trading International.

āĻŦāĻžāĻ‚āϞāĻž: āĻāϏ-āĻĒāĻŋāĻ āĻŸā§āϰ⧇āĻĄāĻŋāĻ‚ āχāĻ¨ā§āϟāĻžāϰāĻ¨ā§āϝāĻžāĻļāύāĻžāϞ⧇āϰ āĻāĻŦāĻŋāϏāĻŋ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āĻŦāĻžāϰāĨ¤

Confidence: 0.90āĨ¤

3. Alternate Brands — āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Fungikill Soap and other antifungal cleansing bars.

āĻŦāĻžāĻ‚āϞāĻž: Fungikill Soap āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āϏāĻžāĻŦāĻžāύāĨ¤

Confidence: 0.85āĨ¤

4. MedEx Therapeutic Class — āĻŽā§‡āĻĄāĻāĻ•ā§āϏ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻ—āϤ āĻļā§āϰ⧇āĻŖāĻŋ

Not independently verified on MedEx — āĻŽā§‡āĻĄāĻāĻ•ā§āϏ⧇ āĻāχ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻĒāĻŖā§āϝ⧇āϰ āĻļā§āϰ⧇āĻŖāĻŋ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžā§ŸāύāĻŋāĨ¤

āĻŦāĻžāĻ‚āϞāĻž: āĻĒāĻŖā§āϝāϟāĻŋāϰ āϜāĻ¨ā§āϝ āĻ…āύ⧁āĻŽāĻžāύ āĻ•āϰ⧇ āϕ⧋āύ⧋ MedEx Therapeutic Class āĻĻ⧇āĻ“ā§ŸāĻž āĻšāĻšā§āϛ⧇ āύāĻžāĨ¤

Confidence: 0.99 for verification limitationāĨ¤

5. Pharmacological Class — āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Topical Antifungal Cleansing Product — āĻ¤ā§āĻŦāϕ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āĻĒāϰāĻŋāĻˇā§āĻ•āĻžāϰāĻ•āĨ¤

Confidence: 0.90āĨ¤

6. Use/Purpose — āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ

English: Supportive cleansing in selected fungal skin conditions.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āĻ¤ā§āĻŦāϕ⧇āϰ āϏāĻŽāĻ¸ā§āϝāĻžā§Ÿ āĻĒāϰāĻŋāĻˇā§āĻ•āĻžāϰ-āĻĒāϰāĻŋāĻšā§āĻ›āĻ¨ā§āύāϤāĻžāϰ āϏāĻšāĻžā§ŸāĻ• āωāĻĒāĻžā§ŸāĨ¤

Confidence: 0.90āĨ¤

7. Why Prescribed to This Patient — āϕ⧇āύ āĻĻ⧇āĻ“ā§ŸāĻž āĻšāϤ⧇ āĻĒāĻžāϰ⧇

English: Likely intended as supportive skin care during antifungal treatment.

āĻŦāĻžāĻ‚āϞāĻž: āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ āĻ¤ā§āĻŦāĻ• āĻĒāϰāĻŋāĻˇā§āĻ•āĻžāϰ āϰāĻžāĻ–āĻžāϰ āϏāĻšāĻžā§ŸāĻ• āĻĒāĻŖā§āϝ āĻšāĻŋāϏ⧇āĻŦ⧇ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.75āĨ¤

8. Side Effects — āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

English: Dryness, burning, irritation and contact dermatitis.

āĻŦāĻžāĻ‚āϞāĻž: āĻ¤ā§āĻŦāĻ• āĻļ⧁āĻˇā§āĻ• āĻšā§Ÿā§‡ āϝāĻžāĻ“ā§ŸāĻž, āĻœā§āĻŦāĻžāϞāĻž, āĻ…āĻ¸ā§āĻŦāĻ¸ā§āϤāĻŋ āĻ“ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϜāύāĻŋāϤ āĻĒā§āϰāĻĻāĻžāĻšāĨ¤

Confidence: 0.90āĨ¤

9. Direct MedEx Link — āĻŽā§‡āĻĄāĻāĻ•ā§āϏ āϞāĻŋāĻ‚āĻ•

Verified MedEx Product Page — āϝāĻžāϚāĻžāχāĻ•ā§ƒāϤ āĻŽā§‡āĻĄāĻāĻ•ā§āϏ āĻĒ⧃āĻˇā§āĻ āĻž: Not found — āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāύāĻŋāĨ¤

Verified Retail Reference — āϝāĻžāϚāĻžāχāĻ•ā§ƒāϤ āĻŦāĻŋāĻ•ā§āϰ⧟āϤāĻĨā§āϝ:

ABC Anti-Fungal Bar 75 g — Arogga

āĻŦāĻžāĻ‚āϞāĻž: āĻāχ āĻĒāĻŖā§āϝ⧇āϰ āϏāϰāĻžāϏāϰāĻŋ MedEx āĻĒ⧃āĻˇā§āĻ āĻž āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžā§ŸāύāĻŋāĨ¤ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒāĻ­āĻžāĻŦ⧇ āĻŦāĻžāĻ‚āϞāĻžāĻĻ⧇āĻļāĻŋ āĻ…āύāϞāĻžāχāύ āĻĢāĻžāĻ°ā§āĻŽā§‡āϏāĻŋāϰ āĻĒāĻŖā§āϝ⧇āϰ āϤāĻĨā§āϝ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤

10. Unit Price, Strip Price and Composition — āĻŽā§‚āĻ˛ā§āϝ āĻ“ āĻ—āĻ āύ

75 g Bar — ā§­ā§Ģ āĻ—ā§āϰāĻžāĻŽ āϏāĻžāĻŦāĻžāύ: Approximately ā§ŗ585 — āφāύ⧁āĻŽāĻžāύāĻŋāĻ• ā§Ģā§Žā§Ģ āϟāĻžāĻ•āĻžāĨ¤

Strip Price — āĻ¸ā§āĻŸā§āϰāĻŋāĻĒ āĻŽā§‚āĻ˛ā§āϝ: Not applicable — āĻĒā§āϰāϝ⧋āĻœā§āϝ āύ⧟āĨ¤

Confidence: 0.95 for checked retail listingāĨ¤

11. Mechanism — āĻ•āĻžāĻ°ā§āϝāĻĒā§āϰāĻ•ā§āϰāĻŋ⧟āĻž

English: Ketoconazole inhibits fungal ergosterol synthesis; zinc pyrithione has antimicrobial activity, while glycerine helps retain moisture.

āĻŦāĻžāĻ‚āϞāĻž: Ketoconazole āĻ›āĻ¤ā§āϰāĻžāϕ⧇āϰ āϕ⧋āώāĻāĻŋāĻ˛ā§āϞāĻŋ āϤ⧈āϰāĻŋāϤ⧇ āĻŦāĻžāϧāĻž āĻĻā§‡ā§Ÿ, Zinc Pyrithione-āĻāϰ āĻœā§€āĻŦāĻžāϪ⧁āĻŦāĻŋāϰ⧋āϧ⧀ āĻ•āĻžāĻ°ā§āϝāĻ•ā§āϰāĻŽ āĻ°ā§Ÿā§‡āϛ⧇ āĻāĻŦāĻ‚ Glycerine āĻ¤ā§āĻŦāϕ⧇āϰ āφāĻ°ā§āĻĻā§āϰāϤāĻž āϧāϰ⧇ āϰāĻžāĻ–āϤ⧇ āϏāĻžāĻšāĻžāĻ¯ā§āϝ āĻ•āϰ⧇āĨ¤

Confidence: 0.95 for ingredient pharmacologyāĨ¤

12. Indications — āĻŦā§āϝāĻŦāĻšāĻžāϰāϝ⧋āĻ—ā§āϝ āĻ…āĻŦāĻ¸ā§āĻĨāĻž

English: Adjunctive cleansing for selected superficial fungal skin disorders.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āĻ¤ā§āĻŦāϕ⧇āϰ āϏāĻŽāĻ¸ā§āϝāĻžā§Ÿ āϏāĻšāĻžā§ŸāĻ• āĻĒāϰāĻŋāĻˇā§āĻ•āĻžāϰāĻ• āĻšāĻŋāϏ⧇āĻŦ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āϝ⧇āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.85āĨ¤

13. Interactions and Contraindications — āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āύāĻŋāώ⧇āϧāĻžāĻœā§āĻžāĻž

English: Avoid use in individuals with known hypersensitivity to the ingredients.

āĻŦāĻžāĻ‚āϞāĻž: āϕ⧋āύ⧋ āωāĻĒāĻžāĻĻāĻžāύ⧇ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻĨāĻžāĻ•āϞ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āωāϚāĻŋāϤ āύ⧟āĨ¤

Confidence: 0.95āĨ¤

14. Precautions — āϏāϤāĻ°ā§āĻ•āϤāĻž

English: Avoid eyes, mucosal surfaces and irritated or damaged skin unless the product instructions permit use.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒāĻŖā§āϝ⧇āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻžā§Ÿ āĻ…āύ⧁āĻŽāϤāĻŋ āύāĻž āĻĨāĻžāĻ•āϞ⧇ āĻšā§‹āĻ–, āĻļā§āϞ⧈āĻˇā§āĻŽāĻŋāĻ• āĻāĻŋāĻ˛ā§āϞāĻŋ āĻāĻŦāĻ‚ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āĻ•ā§āώāϤāĻŋāĻ—ā§āϰāĻ¸ā§āϤ āĻ¤ā§āĻŦāϕ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻā§œāĻžāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.95āĨ¤

15. Dosage and Administration — āĻŦā§āϝāĻŦāĻšāĻžāϰāĻŦāĻŋāϧāĻŋ

English: Follow the manufacturer’s verified instructions and the treating physician’s advice.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āϰāĻ¸ā§āϤ⧁āϤāĻ•āĻžāϰāϕ⧇āϰ āϝāĻžāϚāĻžāχāĻ•ā§ƒāϤ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻž āĻāĻŦāĻ‚ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.95āĨ¤

16. Pregnancy and Lactation — āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύ

English: Product-specific safety information is limited; seek clinical guidance.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻĒāĻŖā§āϝāϟāĻŋāϰ āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύāϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āϤāĻĨā§āϝ āϏ⧀āĻŽāĻŋāϤāĨ¤ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļ āύāĻŋāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.80āĨ¤

17. Other Compositions / Combinations — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ—āĻ āύ

English: Other marketed antifungal soaps may contain ketoconazole with zinc pyrithione or other cleansing ingredients.

āĻŦāĻžāĻ‚āϞāĻž: āĻŦāĻžāϜāĻžāϰ⧇āϰ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āϏāĻžāĻŦāĻžāύ⧇ Ketoconazole-āĻāϰ āϏāĻ™ā§āϗ⧇ Zinc Pyrithione āĻŦāĻž āĻ…āĻ¨ā§āϝ āĻĒāϰāĻŋāĻˇā§āĻ•āĻžāϰāĻ• āωāĻĒāĻžāĻĻāĻžāύ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.85āĨ¤

Clinical Verdict — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ

English: This product may support hygiene but should not replace established antifungal therapy.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻžāĻŦāĻžāύāϟāĻŋ āĻ¤ā§āĻŦāĻ• āĻĒāϰāĻŋāĻˇā§āĻ•āĻžāϰ āϰāĻžāĻ–āϤ⧇ āϏāĻšāĻžā§ŸāĻ• āĻšāϤ⧇ āĻĒāĻžāϰ⧇, āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻĒā§āϰāĻŽāĻžāĻŖāĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻŽā§‚āϞ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āύ⧟āĨ¤

Overall Confidence: 0.85āĨ¤


💊 MEDICINE 06 — SNOFAS NASAL SPRAY

1. Generic Name — āĻœā§‡āύ⧇āϰāĻŋāĻ• āύāĻžāĻŽ

Fluticasone Furoate — āĻĢā§āϞ⧁āϟāĻŋāĻ•āĻžāϏāύ āĻĢāĻŋāωāĻ°ā§‹ā§Ÿā§‡āϟāĨ¤

Confidence: 0.99āĨ¤

2. Brand Name — āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āύāĻžāĻŽ

Snofas Nasal Spray — Opsonin Pharma Ltd.

āĻŦāĻžāĻ‚āϞāĻž: āĻ…āĻĒāϏ⧋āύāĻŋāύ āĻĢāĻžāĻ°ā§āĻŽāĻžāϰ āĻ¸ā§āύ⧋āĻĢāĻžāϏ āĻ¨ā§āϝāĻžāϜāĻžāϞ āĻ¸ā§āĻĒā§āϰ⧇āĨ¤

Confidence: 0.99āĨ¤

3. MedEx Alternate Brands — āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Avamist, Avaspray, Rhinomist, Fixonase.

āĻŦāĻžāĻ‚āϞāĻž: āĻāĻ•āχ āĻœā§‡āύ⧇āϰāĻŋāϕ⧇āϰ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ¨ā§āϝāĻžāϜāĻžāϞ āĻ¸ā§āĻĒā§āϰ⧇ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄāĨ¤

Confidence: 0.98āĨ¤

4. MedEx Therapeutic Class — āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻ—āϤ āĻļā§āϰ⧇āĻŖāĻŋ

Nasal Steroid Preparations — āύāĻžāϕ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ¸ā§āĻŸā§‡āĻ°ā§Ÿā§‡āĻĄāϜāĻžāĻ¤ā§€ā§Ÿ āĻ“āώ⧁āϧāĨ¤

Confidence: 0.99āĨ¤

5. Pharmacological Class — āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Intranasal Corticosteroid — āύāĻžāϕ⧇āϰ āϭ⧇āϤāϰ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻ•āĻ°ā§āϟāĻŋāϕ⧋āĻ¸ā§āĻŸā§‡āĻ°ā§Ÿā§‡āĻĄāĨ¤

Confidence: 0.99āĨ¤

6. Use/Purpose — āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ

English: Control of inflammation associated with allergic rhinitis.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϜāύāĻŋāϤ āĻĒā§āϰāĻĻāĻžāĻš āύāĻŋ⧟āĻ¨ā§āĻ¤ā§āϰāĻŖ āĻ•āϰāĻžāĨ¤

Confidence: 0.99āĨ¤

7. Why Prescribed to This Patient — āϕ⧇āύ āĻĻ⧇āĻ“ā§ŸāĻž āĻšāϤ⧇ āĻĒāĻžāϰ⧇

English: Probably intended for allergic rhinitis symptoms.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€āϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āωāĻĒāϏāĻ°ā§āĻ— āĻ•āĻŽāĻžāύ⧋āϰ āϜāĻ¨ā§āϝ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.85āĨ¤

8. Side Effects — āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

English: Nasal irritation, dryness, epistaxis, headache and rarely clinically important corticosteroid-related effects.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻžāϕ⧇āϰ āϭ⧇āϤāϰ⧇ āĻœā§āĻŦāĻžāϞāĻž, āĻļ⧁āĻˇā§āĻ•āϤāĻž, āύāĻžāĻ• āĻĻāĻŋā§Ÿā§‡ āϰāĻ•ā§āϤ āĻĒ⧜āĻž, āĻŽāĻžāĻĨāĻžāĻŦā§āϝāĻĨāĻž āĻāĻŦāĻ‚ āĻŦāĻŋāϰāϞ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻ•āĻ°ā§āϟāĻŋāϕ⧋āĻ¸ā§āĻŸā§‡āĻ°ā§Ÿā§‡āĻĄāϜāύāĻŋāϤ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āϏāĻŽāĻ¸ā§āϝāĻžāĨ¤

Confidence: 0.98āĨ¤

9. Direct MedEx Link — āĻŽā§‡āĻĄāĻāĻ•ā§āϏ āϞāĻŋāĻ‚āĻ•

Snofas Nasal Spray — MedEx

10. Unit Price, Strip Price and Composition — āĻŽā§‚āĻ˛ā§āϝ āĻ“ āĻ—āĻ āύ

Strength — āĻŽāĻžāĻ¤ā§āϰāĻž: 27.5 mcg/spray — āĻĒā§āϰāϤāĻŋ āĻ¸ā§āĻĒā§āϰ⧇ ⧍⧭.ā§Ģ āĻŽāĻžāχāĻ•ā§āϰ⧋āĻ—ā§āϰāĻžāĻŽāĨ¤

Pack — āĻĒā§āϝāĻžāĻ•: 120 metered sprays — ⧧⧍ā§ĻāϟāĻŋ āύāĻŋāĻ°ā§āϧāĻžāϰāĻŋāϤ āĻ¸ā§āĻĒā§āϰ⧇āĨ¤

Pack Price — āĻĒā§āϝāĻžāϕ⧇āϰ āĻŽā§‚āĻ˛ā§āϝ: ā§ŗ275āĨ¤

Strip Price — āĻ¸ā§āĻŸā§āϰāĻŋāĻĒ āĻŽā§‚āĻ˛ā§āϝ: Not applicable — āĻĒā§āϰāϝ⧋āĻœā§āϝ āύ⧟āĨ¤

Confidence: 0.99āĨ¤

11. Mechanism — āĻ•āĻžāĻ°ā§āϝāĻĒā§āϰāĻ•ā§āϰāĻŋ⧟āĻž

English: Activates glucocorticoid receptors and suppresses inflammatory mediator activity in the nasal mucosa.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻžāϕ⧇āϰ āϭ⧇āϤāϰ⧇āϰ Glucocorticoid Receptor-āĻāϰ āĻŽāĻžāĻ§ā§āϝāĻŽā§‡ āĻĒā§āϰāĻĻāĻžāĻšāϏ⧃āĻˇā§āϟāĻŋāĻ•āĻžāϰ⧀ āĻĒāĻĻāĻžāĻ°ā§āĻĨ⧇āϰ āĻ•āĻžāĻ°ā§āϝāĻ•ā§āϰāĻŽ āĻ•āĻŽāĻŋā§Ÿā§‡ āĻĻā§‡ā§ŸāĨ¤

Confidence: 0.99āĨ¤

12. Indications — āĻŦā§āϝāĻŦāĻšāĻžāϰāϝ⧋āĻ—ā§āϝ āϰ⧋āĻ—

Seasonal Allergic Rhinitis — āĻŽā§ŒāϏ⧁āĻŽāĻŋ āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāĨ¤

Perennial Allergic Rhinitis — āϏāĻžāϰāĻž āĻŦāĻ›āϰāĻŦā§āϝāĻžāĻĒā§€ āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāĨ¤

Confidence: 0.99āĨ¤

13. Interactions and Contraindications — āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āύāĻŋāώ⧇āϧāĻžāĻœā§āĻžāĻž

English: Strong CYP3A4 inhibitors may increase systemic exposure to fluticasone. Itraconazole is a relevant potential interacting medicine.

āĻŦāĻžāĻ‚āϞāĻž: āĻļāĻ•ā§āϤāĻŋāĻļāĻžāϞ⧀ CYP3A4 inhibitor āĻ“āώ⧁āϧ⧇āϰ āĻ•āĻžāϰāϪ⧇ Fluticasone-āĻāϰ āĻļāϰ⧀āϰ⧇ āĻļā§‹āώāĻŖ āĻŦā§‡ā§œā§‡ āϝ⧇āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ Itraconazole-āĻāϰ āϏāĻ™ā§āϗ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

Confidence: 0.95āĨ¤

14. Precautions — āϏāϤāĻ°ā§āĻ•āϤāĻž

English: Use cautiously in recurrent nosebleeds, untreated nasal infection, glaucoma or previous nasal surgery.

āĻŦāĻžāĻ‚āϞāĻž: āĻŦāĻžāϰāĻŦāĻžāϰ āύāĻžāĻ• āĻĻāĻŋā§Ÿā§‡ āϰāĻ•ā§āϤ āĻĒ⧜āĻž, āύāĻžāϕ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻšā§€āύ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ, Glaucoma āĻŦāĻž āύāĻžāϕ⧇āϰ āĻ…āĻ¸ā§āĻ¤ā§āϰ⧋āĻĒāϚāĻžāϰ⧇āϰ āχāϤāĻŋāĻšāĻžāϏ āĻĨāĻžāĻ•āϞ⧇ āϏāϤāĻ°ā§āĻ•āϤāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

Confidence: 0.95āĨ¤

15. Dosage and Administration — āĻŽāĻžāĻ¤ā§āϰāĻž āĻ“ āĻŦā§āϝāĻŦāĻšāĻžāϰāĻŦāĻŋāϧāĻŋ

English: A commonly listed adult starting regimen is two sprays in each nostril once daily, with adjustment according to response and product instructions.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āϰāĻžāĻĒā§āϤāĻŦ⧟āĻ¸ā§āĻ•āĻĻ⧇āϰ āϜāĻ¨ā§āϝ āĻ…āύ⧇āĻ• āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻĒā§āϰāϤāĻŋāϟāĻŋ āύāĻžāϕ⧇ āĻĻ⧁āχ āĻ¸ā§āĻĒā§āϰ⧇ āĻĻāĻŋāύ⧇ āĻāĻ•āĻŦāĻžāϰ āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ• āĻĄā§‹āϜ āĻšāĻŋāϏ⧇āĻŦ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āĻšā§ŸāĨ¤ āĻĒāϰāĻŦāĻ°ā§āϤ⧀ āĻĄā§‹āϜ āϰ⧋āĻ—ā§€āϰ āωāĻ¨ā§āύāϤāĻŋ āĻāĻŦāĻ‚ āĻĒāĻŖā§āϝ⧇āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻž āĻ…āύ⧁āϝāĻžā§Ÿā§€ āύāĻŋāĻ°ā§āϧāĻžāϰāĻŋāϤ āĻšā§ŸāĨ¤

Important — āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ: The original handwritten dose is not sufficiently clear to confirm this regimen for the patient.

āĻŦāĻžāĻ‚āϞāĻž: āĻŽā§‚āϞ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āĻšāĻžāϤ⧇āϰ āϞ⧇āĻ–āĻž āϝāĻĨ⧇āĻˇā§āϟ āĻ¸ā§āĻĒāĻˇā§āϟ āύ⧟āĨ¤ āϤāĻžāχ āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āĻāχ āĻĄā§‹āϜāχ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡āϛ⧇ āĻŦāϞ⧇ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

Confidence: 0.98 for general drug informationāĨ¤

16. Pregnancy and Lactation — āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύ

English: Use after individualized assessment of clinical benefit and potential risk.

āĻŦāĻžāĻ‚āϞāĻž: āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύāĻ•āĻžāϞ⧇ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§ŸāϤāĻž āĻāĻŦāĻ‚ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻā§āρāĻ•āĻŋ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.95āĨ¤

17. Other Compositions / Combinations — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ—āĻ āύ

English: Other fluticasone furoate nasal preparations and inhaled products exist, but different formulations are not automatically interchangeable.

āĻŦāĻžāĻ‚āϞāĻž: Fluticasone Furoate-āĻāϰ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ¨ā§āϝāĻžāϜāĻžāϞ āĻ¸ā§āĻĒā§āϰ⧇ āĻ“ āĻļā§āĻŦāĻžāϏ⧇āϰ āĻŽāĻžāĻ§ā§āϝāĻŽā§‡ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ—āĻ āύ āĻ°ā§Ÿā§‡āϛ⧇āĨ¤ āϤāĻŦ⧇ āϏāĻŦ formulation āϏāϰāĻžāϏāϰāĻŋ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύāϝ⧋āĻ—ā§āϝ āύ⧟āĨ¤

Confidence: 0.98āĨ¤

Clinical Verdict — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ

English: Evidence-based treatment for allergic rhinitis when clinically indicated, but potential interaction with itraconazole warrants review.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āύāĻŋāĻļā§āϚāĻŋāϤ āĻšāϞ⧇ āĻāϟāĻŋ āĻĒā§āϰāĻŽāĻžāĻŖāĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĨ¤ āϤāĻŦ⧇ Itraconazole-āĻāϰ āϏāĻ™ā§āϗ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ interaction āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰāĻž āωāϚāĻŋāϤāĨ¤

Overall Confidence: 0.95āĨ¤


🟧 12. BANGLADESH MEDICINE COMPARISON — TABLE 1

āĻŦāĻžāĻ‚āϞāĻžāĻĻ⧇āĻļ⧇ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϚāĻ°ā§āĻŽāϰ⧋āϗ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻ“āώ⧁āϧ

No.Generic Medicine — āĻœā§‡āύ⧇āϰāĻŋāĻ•Therapeutic Class — āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻ—āϤ āĻļā§āϰ⧇āĻŖāĻŋPurpose — āωāĻĻā§āĻĻ⧇āĻļā§āϝ
1Luliconazole — āϞ⧁āϞāĻŋāϕ⧋āύāĻžāϜāϞMiscellaneous Topical Agents — āĻ¤ā§āĻŦāϕ⧇āϰ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ“āώ⧁āϧLocalized Dermatophytosis — āϏ⧀āĻŽāĻŋāϤ āĻĻāĻžāĻĻ
2Clotrimazole — āĻ•ā§āϞ⧋āĻŸā§āϰāĻŋāĻŽāĻžāϜāϞTopical Antifungal — āĻŦāĻžāĻšā§āϝāĻŋāĻ• āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞSuperficial Fungal Infection — āĻ¤ā§āĻŦāϕ⧇āϰ āωāĻĒāϰāĻŋāĻ­āĻžāϗ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ• āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ
3Terbinafine Topical — āϟāĻžāϰāĻŦāĻŋāύāĻžāĻĢāĻŋāύ āĻ•ā§āϰāĻŋāĻŽTopical Antifungal Preparations — āĻŦāĻžāĻšā§āϝāĻŋāĻ• āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞDermatophyte Infection — āĻĻāĻžāĻĻ
4Ketoconazole Topical — āϕ⧇āĻŸā§‹āϕ⧋āύāĻžāϜāϞ āĻ•ā§āϰāĻŋāĻŽDrugs for Subcutaneous and Mycoses — āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϰ⧋āϗ⧇āϰ āĻ“āώ⧁āϧSelected Fungal Skin Conditions — āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ›āĻ¤ā§āϰāĻžāĻ• āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ
5Itraconazole Oral — āχāĻŸā§āϰāĻžāϕ⧋āύāĻžāϜāϞSystemic Triazole Antifungal — āĻŽā§āϖ⧇ āĻ–āĻžāĻ“ā§ŸāĻžāϰ āĻŸā§āϰāĻžā§ŸāĻžāĻœā§‹āϞ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞSelected Extensive or Refractory Fungal Infections — āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻŦā§āϝāĻžāĻĒāĻ• āĻŦāĻž āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻĒā§āϰāϤāĻŋāϰ⧋āϧ⧀ āĻ›āĻ¤ā§āϰāĻžāĻ• āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ
6Terbinafine Oral — āϟāĻžāϰāĻŦāĻŋāύāĻžāĻĢāĻŋāύSystemic Allylamine Antifungal — āĻŽā§āϖ⧇ āĻ–āĻžāĻ“ā§ŸāĻžāϰ āĻ…ā§āϝāĻžāϞāĻžāχāϞāĻ…ā§āϝāĻžāĻŽāĻŋāύ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞSelected Dermatophyte and Nail Infections — āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻĻāĻžāĻĻ āĻ“ āύāϖ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ• āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ

Clinical Confidence — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻŦāĻŋāĻļā§āĻŦāĻžāϏāϝ⧋āĻ—ā§āϝāϤāĻž: 0.95āĨ¤

Important — āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ: This table lists possible therapeutic options; these medicines are not intended to be prescribed together automatically.

āĻŦāĻžāĻ‚āϞāĻž: āĻŸā§‡āĻŦāĻŋāϞāϟāĻŋāϤ⧇ āĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻĻ⧇āĻ–āĻžāύ⧋ āĻšā§Ÿā§‡āϛ⧇āĨ¤ āϏāĻŦ āĻ“āώ⧁āϧ āĻāĻ•āϏāĻ™ā§āϗ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻžāϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻž āύ⧟āĨ¤


🟩 13. BANGLADESH MEDICINE COMPARISON — TABLE 2

āĻŦāĻžāĻ‚āϞāĻžāĻĻ⧇āĻļ⧇ āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻ“ āϚ⧁āϞāĻ•āĻžāύāĻŋāϤ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻ“āώ⧁āϧ

No.Generic — āĻœā§‡āύ⧇āϰāĻŋāĻ•Pharmacological Class — āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋPurpose — āωāĻĻā§āĻĻ⧇āĻļā§āϝ
1Fexofenadine — āĻĢ⧇āĻ•ā§āϏ⧋āĻĢ⧇āύāĻžāĻĄāĻŋāύSecond-Generation Antihistamine — āĻĻā§āĻŦāĻŋāĻ¤ā§€ā§Ÿ āĻĒā§āϰāϜāĻ¨ā§āĻŽā§‡āϰ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻšāĻŋāĻ¸ā§āϟāĻžāĻŽāĻŋāύAllergic Rhinitis/Urticaria — āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ/āϚāĻžāĻ•āĻž āĻ“āĻ āĻž
2Cetirizine — āϏ⧇āϟāĻŋāϰāĻŋāϜāĻŋāύSecond-Generation Antihistamine — āĻĻā§āĻŦāĻŋāĻ¤ā§€ā§Ÿ āĻĒā§āϰāϜāĻ¨ā§āĻŽā§‡āϰ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻšāĻŋāĻ¸ā§āϟāĻžāĻŽāĻŋāύAllergic Symptoms — āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āωāĻĒāϏāĻ°ā§āĻ—
3Levocetirizine — āϞ⧇āĻ­ā§‹āϏ⧇āϟāĻŋāϰāĻŋāϜāĻŋāύSecond-Generation Antihistamine — āĻĻā§āĻŦāĻŋāĻ¤ā§€ā§Ÿ āĻĒā§āϰāϜāĻ¨ā§āĻŽā§‡āϰ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻšāĻŋāĻ¸ā§āϟāĻžāĻŽāĻŋāύAllergy Relief — āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āωāĻĒāϏāĻ°ā§āĻ— āύāĻŋ⧟āĻ¨ā§āĻ¤ā§āϰāĻŖ
4Fluticasone Furoate Nasal — āĻĢā§āϞ⧁āϟāĻŋāĻ•āĻžāϏāύ āĻĢāĻŋāωāĻ°ā§‹ā§Ÿā§‡āϟIntranasal Corticosteroid — āύāĻžāϕ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ•āĻ°ā§āϟāĻŋāϕ⧋āĻ¸ā§āĻŸā§‡āĻ°ā§Ÿā§‡āĻĄAllergic Rhinitis — āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ
5Mometasone Furoate Nasal — āĻŽā§‹āĻŽā§‡āϟāĻžāϏāύ āĻĢāĻŋāωāĻ°ā§‹ā§Ÿā§‡āϟIntranasal Corticosteroid — āύāĻžāϕ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ•āĻ°ā§āϟāĻŋāϕ⧋āĻ¸ā§āĻŸā§‡āĻ°ā§Ÿā§‡āĻĄAllergic Rhinitis — āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ
6Azelastine Nasal — āĻ…ā§āϝāĻžāĻœā§‡āϞāĻžāĻ¸ā§āϟāĻŋāύIntranasal Antihistamine — āύāĻžāϕ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻšāĻŋāĻ¸ā§āϟāĻžāĻŽāĻŋāύNasal Allergy Symptoms — āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āωāĻĒāϏāĻ°ā§āĻ—

Confidence: 0.95āĨ¤

Important — āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ: Choice of medicine depends on symptoms, comorbidities, contraindications and treatment response.

āĻŦāĻžāĻ‚āϞāĻž: āϕ⧋āύ āĻ“āώ⧁āϧ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āĻšāĻŦ⧇ āϤāĻž āϰ⧋āĻ—ā§€āϰ āωāĻĒāϏāĻ°ā§āĻ—, āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āϰ⧋āĻ—, āĻ“āώ⧁āϧ⧇āϰ āύāĻŋāώ⧇āϧāĻžāĻœā§āĻžāĻž āĻāĻŦāĻ‚ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžā§Ÿ āϏāĻžā§œāĻžāϰ āĻ“āĻĒāϰ āύāĻŋāĻ°ā§āĻ­āϰ āĻ•āϰ⧇āĨ¤


🟧 14. DOCTOR’S DIAGNOSIS VS INDEPENDENT DIAGNOSIS

āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟ āĻŦāύāĻžāĻŽ āĻ¸ā§āĻŦāĻžāϧ⧀āύ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟

Doctor’s Documented Dx — āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϞ⧇āĻ–āĻž āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟

Not documented — āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

Independent Provisional Dx — āĻ¸ā§āĻŦāĻžāϧ⧀āύ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟

Dx 1: Suspected Superficial Dermatophytosis (Tinea Infection; Site Unspecified).

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ¤ā§āĻŦāϕ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻŦāĻž āĻĻāĻžāĻĻ; āφāĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻ¸ā§āĻĨāĻžāύ āĻ…āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟāĨ¤

Confidence: 0.70āĨ¤

Dx 2: Possible Coexisting Allergic Rhinitis.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻšāĻžāĻŦāĻ¸ā§āĻĨāĻžāύāĻ•āĻžāϰ⧀ āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϜāύāĻŋāϤ āĻĒā§āϰāĻĻāĻžāĻšā§‡āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻžāĨ¤

Confidence: 0.75āĨ¤

🟩 Similarities — āĻŽāĻŋāϞ

  • English: Itraconazole and luliconazole are consistent with treatment of certain fungal skin infections. āĻŦāĻžāĻ‚āϞāĻž: Itraconazole āĻ“ Luliconazole āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āĻ¤ā§āĻŦāϕ⧇āϰ āϰ⧋āϗ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āϏāĻ™ā§āϗ⧇ āϏāĻžāĻŽāĻžā§āϜāĻ¸ā§āϝāĻĒā§‚āĻ°ā§āĻŖāĨ¤
  • English: The printed advice about transmission and clothing hygiene is consistent with concern about a contagious skin condition. āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ— āϛ⧋āρ⧟āĻžāĻšā§‡ āĻšāĻ“ā§ŸāĻž āĻ“ āĻ•āĻžāĻĒ⧜ āĻĒāϰāĻŋāĻˇā§āĻ•āĻžāϰ āϰāĻžāĻ–āĻžāϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āϏāĻ‚āĻ•ā§āϰāĻžāĻŽāĻ• āϚāĻ°ā§āĻŽāϰ⧋āϗ⧇āϰ āϏāĻ¨ā§āĻĻ⧇āĻšāϕ⧇ āϏāĻŽāĻ°ā§āĻĨāύ āĻ•āϰ⧇āĨ¤
  • English: Fexofenadine and fluticasone nasal spray are consistent with management of possible allergic rhinitis. āĻŦāĻžāĻ‚āϞāĻž: Fexofenadine āĻ“ Fluticasone Nasal Spray āύāĻžāϕ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āϏāĻ™ā§āϗ⧇ āϏāĻžāĻŽāĻžā§āϜāĻ¸ā§āϝāĻĒā§‚āĻ°ā§āĻŖāĨ¤

Similarity Assessment Confidence — āĻŽāĻŋāϞ⧇āϰ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ: 0.85āĨ¤

🟧 Differences — āĻ…āĻŽāĻŋāϞ

  • English: The physician did not document a diagnosis. āĻŦāĻžāĻ‚āϞāĻž: āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āϕ⧋āύ⧋ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟ āϞ⧇āϖ⧇āύāύāĻŋāĨ¤
  • English: The independent diagnosis is based mainly on medication selection. āĻŦāĻžāĻ‚āϞāĻž: āĻ¸ā§āĻŦāĻžāϧ⧀āύ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟ āĻĒā§āϰāϧāĻžāύāϤ āĻ“āώ⧁āϧ⧇āϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻĻ⧇āϖ⧇ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤
  • English: The anatomical site and appearance of the skin lesion are unknown. āĻŦāĻžāĻ‚āϞāĻž: āĻ¤ā§āĻŦāϕ⧇āϰ āĻ•ā§āώāϤ⧇āϰ āĻ…āĻŦāĻ¸ā§āĻĨāĻžāύ āĻ“ āĻĒā§āϰāĻ•ā§ƒāϤ āĻšā§‡āĻšāĻžāϰāĻž āϜāĻžāύāĻž āύ⧇āχāĨ¤
  • English: A bacterial infection cannot be established from the uncertain azithromycin entry. āĻŦāĻžāĻ‚āϞāĻž: Azithromycin-āĻāϰ āĻ…āĻ¸ā§āĻĒāĻˇā§āϟ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻĨ⧇āϕ⧇ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžā§Ÿ āύāĻžāĨ¤

Final Comparison — āĻšā§‚ā§œāĻžāĻ¨ā§āϤ āϤ⧁āϞāύāĻž

English: Direct diagnostic agreement cannot be measured because the physician did not record a diagnosis. The independent assessment is broadly consistent with the apparent treatment pattern.

āĻŦāĻžāĻ‚āϞāĻž: āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āϰ⧋āϗ⧇āϰ āύāĻžāĻŽ āύāĻž āϞ⧇āĻ–āĻžā§Ÿ āĻĻ⧁āϟāĻŋ āϰ⧋āĻ—āύāĻŋāĻ°ā§āĻŖā§Ÿā§‡āϰ āϏāϰāĻžāϏāϰāĻŋ āĻŽāĻŋāϞ āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖ āϏāĻŽā§āĻ­āĻŦ āύ⧟āĨ¤ āϤāĻŦ⧇ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āĻ“āώ⧁āϧ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇āϰ āϏāĻ™ā§āϗ⧇ āĻ¸ā§āĻŦāĻžāϧ⧀āύ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ⧇āϰ āĻŽā§‹āϟāĻžāĻŽā§āϟāĻŋ āϏāĻžāĻŽāĻžā§āϜāĻ¸ā§āϝ āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

Confidence: 0.90 for comparison methodologyāĨ¤


🟩 15. DOCTOR’S ORIGINAL ADVICE

āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻŽā§‚āϞ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻž

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āĻŽā§āĻĻā§āϰāĻŋāϤ āĻŦāĻžāĻ‚āϞāĻžā§Ÿ āϚāĻžāϰāϟāĻŋ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

1. āφāĻĒāύāĻžāϰ āϰ⧋āĻ—āϟāĻŋ āϛ⧋āρ⧟āĻžāĻšā§‡āĨ¤

English Meaning: Your condition is contagious.

āĻŦāĻžāĻ‚āϞāĻž āĻŦā§āϝāĻžāĻ–ā§āϝāĻž: āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āϏāĻ‚āĻ•ā§āϰāĻžāĻŽāĻ• āĻ¤ā§āĻŦāϕ⧇āϰ āϰ⧋āϗ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰ⧇ āĻāχ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻž āĻĻāĻŋā§Ÿā§‡āϛ⧇āύ āĻŦāϞ⧇ āĻŦā§‹āĻāĻž āϝāĻžā§ŸāĨ¤

2. āĻĒā§āϰāϤāĻŋāĻĻāĻŋāύ āĻĒāϰāύ⧇āϰ āĻ•āĻžāĻĒ⧜, āĻ—āĻžāĻŽāĻ›āĻž āϧ⧁āĻŦ⧇āύāĨ¤

English Meaning: Wash your clothes and towels regularly.

āĻŦāĻžāĻ‚āϞāĻž āĻŦā§āϝāĻžāĻ–ā§āϝāĻž: āĻ•āĻžāĻĒ⧜ āĻ“ āĻ—āĻžāĻŽāĻ›āĻžāϰ āĻŽāĻžāĻ§ā§āϝāĻŽā§‡ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻ›ā§œāĻžāύ⧋āϰ āĻā§āρāĻ•āĻŋ āĻ•āĻŽāĻžāϤ⧇ āĻĒāϰāĻŋāĻˇā§āĻ•āĻžāϰ-āĻĒāϰāĻŋāĻšā§āĻ›āĻ¨ā§āύāϤāĻž āĻŦāϜāĻžā§Ÿ āϰāĻžāĻ–āϤ⧇ āĻŦāϞāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤

3. āĻāĻ•āϜāύ āφāϰ⧇āĻ•āϜāύ⧇āϰ āĻ•āĻžāĻĒ⧜ āĻĒāϰāĻŦ⧇āύ āύāĻžāĨ¤

English Meaning: Do not share clothing with other people.

āĻŦāĻžāĻ‚āϞāĻž āĻŦā§āϝāĻžāĻ–ā§āϝāĻž: āĻĒāϰāĻŋāĻŦāĻžāϰ⧇āϰ āϏāĻĻāĻ¸ā§āϝāĻĻ⧇āϰ āĻŽāĻ§ā§āϝ⧇ āĻŦā§āϝāĻ•ā§āϤāĻŋāĻ—āϤ āĻ•āĻžāĻĒ⧜ āĻŦāĻŋāύāĻŋāĻŽā§Ÿ āĻā§œāĻžāϤ⧇ āĻŦāϞāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤

4. āĻĒāϰāĻŋāĻŦāĻžāϰ⧇āϰ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āϏāĻŦāĻžāχ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āύāĻŋāĻŦ⧇āύāĨ¤

English Meaning: Other family members should receive medical attention.

āĻŦāĻžāĻ‚āϞāĻž āĻŦā§āϝāĻžāĻ–ā§āϝāĻž: āĻĒāϰāĻŋāĻŦāĻžāϰ⧇āϰ āĻ…āĻ¨ā§āϝ āϏāĻĻāĻ¸ā§āϝāĻĻ⧇āϰ āĻāĻ•āχ āϧāϰāύ⧇āϰ āϰ⧋āĻ— āφāϛ⧇ āĻ•āĻŋ āύāĻž āϤāĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤ āϤāĻŦ⧇ āωāĻĒāϏāĻ°ā§āĻ—āĻšā§€āύ āϏāĻŦāĻžāχāϕ⧇ āĻ¸ā§āĻŦ⧟āĻ‚āĻ•ā§āϰāĻŋ⧟āĻ­āĻžāĻŦ⧇ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āĻĻ⧇āĻ“ā§ŸāĻžāϰ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āύ⧇āχāĨ¤

Confidence for printed advice transcription — āĻŽā§āĻĻā§āϰāĻŋāϤ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻž āĻļāύāĻžāĻ•ā§āϤāĻ•āϰāĻŖ: 0.95āĨ¤


🟧 16. GUIDELINE-BASED MANAGEMENT

āĻ—āĻžāχāĻĄāϞāĻžāχāύ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻĒāϰāĻŋāĻ•āĻ˛ā§āĻĒāύāĻž

Step 1 — Confirm the Diagnosis

āĻĒā§āϰāĻĨāĻŽ āϧāĻžāĻĒ â€” āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž

English: Examine the skin and perform KOH microscopy when clinically indicated.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€āϰ āĻ¤ā§āĻŦāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇ āĻāĻŦāĻ‚ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϞ⧇ KOH āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.95āĨ¤

Step 2 — Evaluate Disease Extent

āĻĻā§āĻŦāĻŋāĻ¤ā§€ā§Ÿ āϧāĻžāĻĒ â€” āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āĻŦāĻŋāĻ¸ā§āϤāĻžāϰ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ

English: Determine whether the infection is localized, extensive, recurrent or treatment resistant.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āϏ⧀āĻŽāĻŋāϤ, āĻŦā§āϝāĻžāĻĒāĻ•, āĻŦāĻžāϰāĻŦāĻžāϰ āĻšāĻ“ā§ŸāĻž āĻ…āĻĨāĻŦāĻž āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻĒā§āϰāϤāĻŋāϰ⧋āϧ⧀ āĻ•āĻŋ āύāĻž āϤāĻž āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.95āĨ¤

Step 3 — Select Antifungal Therapy

āϤ⧃āĻ¤ā§€ā§Ÿ āϧāĻžāĻĒ â€” āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āύāĻŋāĻ°ā§āĻŦāĻžāϚāύ

English: Localized uncomplicated dermatophytosis often responds to topical antifungal treatment.

āĻŦāĻžāĻ‚āϞāĻž: āϏ⧀āĻŽāĻŋāϤ āĻ“ āϏāĻžāϧāĻžāϰāĻŖ āĻĻāĻžāĻĻ⧇āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻ…āύ⧇āĻ• āϏāĻŽā§Ÿ āĻļ⧁āϧ⧁ āĻ¤ā§āĻŦāϕ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āϝāĻĨ⧇āĻˇā§āϟāĨ¤

English: Systemic treatment may be appropriate for selected extensive, refractory or complicated infections.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻŦā§āϝāĻžāĻĒāĻ•, āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžā§Ÿ āύāĻž āϏāĻžāϰāĻž āĻ…āĻĨāĻŦāĻž āϜāϟāĻŋāϞ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇ āĻŽā§āϖ⧇ āĻ–āĻžāĻ“ā§ŸāĻžāϰ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.95āĨ¤

Step 4 — Review Systemic Antifungal Safety

āϚāϤ⧁āĻ°ā§āĻĨ āϧāĻžāĻĒ â€” āĻŽā§āϖ⧇ āĻ–āĻžāĻ“ā§ŸāĻžāϰ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ⧇āϰ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž

English: Review liver disease, heart failure, pregnancy and relevant drug interactions before systemic itraconazole treatment.

āĻŦāĻžāĻ‚āϞāĻž: āĻŽā§āϖ⧇ āĻ–āĻžāĻ“ā§ŸāĻžāϰ Itraconazole āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āφāϗ⧇ āϞāĻŋāĻ­āĻžāϰ⧇āϰ āϰ⧋āĻ—, āĻšā§ƒāĻĻā§â€Œāϰ⧋āĻ—, āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ“āώ⧁āϧ⧇āϰ āϏāĻ™ā§āϗ⧇ āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.98āĨ¤

Step 5 — Assess Possible Allergic Rhinitis

āĻĒāĻžā§āϚāĻŽ āϧāĻžāĻĒ â€” āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ

English: Confirm nasal symptoms and select appropriate treatment according to severity and clinical findings.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āωāĻĒāϏāĻ°ā§āĻ— āϝāĻžāϚāĻžāχ āĻ•āϰ⧇ āϰ⧋āϗ⧇āϰ āϤ⧀āĻŦā§āϰāϤāĻž āĻ…āύ⧁āϝāĻžā§Ÿā§€ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.95āĨ¤

Step 6 — Review Antibiotic Requirement

āώāĻˇā§āĻ  āϧāĻžāĻĒ â€” āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻŦāĻžā§Ÿā§‹āϟāĻŋāϕ⧇āϰ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§ŸāϤāĻž āϝāĻžāϚāĻžāχ

English: Avoid azithromycin unless there is a supported bacterial indication.

āĻŦāĻžāĻ‚āϞāĻž: āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āωāĻĒāϝ⧁āĻ•ā§āϤ āĻ•āĻžāϰāĻŖ āύāĻž āĻĨāĻžāĻ•āϞ⧇ Azithromycin āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āωāϚāĻŋāϤ āύ⧟āĨ¤

Confidence: 0.98āĨ¤


🟩 17. PRESCRIPTION SAFETY ASSESSMENT

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ

Medicine — āĻ“āώ⧁āϧMain Concern — āĻĒā§āϰāϧāĻžāύ āϏāĻŽāĻ¸ā§āϝāĻžRequired Review — āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύConfidence
Itracon SUBAUnclear dose, hepatic and cardiac risks — āĻ…āĻ¸ā§āĻĒāĻˇā§āϟ āĻĄā§‹āϜ, āϞāĻŋāĻ­āĻžāϰ āĻ“ āĻšā§ƒāĻĻā§â€Œāϰ⧋āϗ⧇āϰ āĻā§āρāĻ•āĻŋVerify dose and safety — āĻĄā§‹āϜ āĻ“ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āϝāĻžāϚāĻžāχ0.98
TinacureDiagnosis unconfirmed — āϰ⧋āĻ— āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟Examine skin lesion — āĻ¤ā§āĻŦāϕ⧇āϰ āĻ•ā§āώāϤ āĻĒāϰ⧀āĻ•ā§āώāĻž0.95
ZimaxPossible cancellation; no documented bacterial indication — āĻŦāĻžāϤāĻŋāϞ āĻšā§Ÿā§‡ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇; āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻž āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āĻĒā§āϰāĻŽāĻžāĻŖ āύ⧇āχConfirm actual prescription status — āĻ“āώ⧁āϧāϟāĻŋ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡āϛ⧇ āĻ•āĻŋ āύāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž0.98
FastelIndication not documented — āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ•āĻžāϰāĻŖ āϞ⧇āĻ–āĻž āύ⧇āχReview allergy symptoms — āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āωāĻĒāϏāĻ°ā§āĻ— āϝāĻžāϚāĻžāχ0.90
ABC BarExact composition uncertain — āĻĒā§āϰāĻ•ā§ƒāϤ āĻ—āĻ āύ āĻ…āύāĻŋāĻļā§āϚāĻŋāϤCheck product label — āĻĒāĻŖā§āϝ⧇āϰ āĻŽā§‹ā§œāĻ• āϝāĻžāϚāĻžāχ0.95
SnofasPotential interaction with itraconazole — āχāĻŸā§āϰāĻžāϕ⧋āύāĻžāϜāϞ⧇āϰ āϏāĻ™ā§āϗ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻžReview interaction risk — āĻĒāĻžāϰāĻ¸ā§āĻĒāϰāĻŋāĻ• āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻžāϰ āĻā§āρāĻ•āĻŋ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ0.95

🟧 18. TEN CLINICAL DECISION-MAKING MODULES

ā§§ā§ĻāϟāĻŋ āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ āĻ—ā§āϰāĻšāϪ⧇āϰ āĻŽāĻĄāĻŋāωāϞ

🟧 MODULE 01 — CLINICAL DECISION-MAKING ALGORITHM

āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ āĻ—ā§āϰāĻšāϪ⧇āϰ āϧāĻžāĻĒāĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻĒāĻĻā§āϧāϤāĻŋ

English Meaning — āχāĻ‚āϰ⧇āϜāĻŋ āĻŦā§āϝāĻžāĻ–ā§āϝāĻž: A structured approach to diagnosis, investigation and treatment.

āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ: āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟, āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ“ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āύāĻŋāĻ°ā§āϧāĻžāϰāϪ⧇āϰ āĻāĻ•āϟāĻŋ āϧāĻžāĻĒāĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻĒāĻĻā§āϧāϤāĻŋāĨ¤

Clinical Application — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻĒā§āĻ°ā§Ÿā§‹āĻ—

Assess symptoms → Examine lesions → Consider differential diagnoses → Perform relevant tests → Select treatment → Review response.

āĻŦāĻžāĻ‚āϞāĻž: āωāĻĒāϏāĻ°ā§āĻ— āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ → āĻ¤ā§āĻŦāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻž → āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āϰ⧋āĻ— āĻŦāĻŋāĻŦ⧇āϚāύāĻž → āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āĻĒāϰ⧀āĻ•ā§āώāĻž → āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āύāĻŋāĻ°ā§āĻŦāĻžāϚāύ → āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžā§Ÿ āϏāĻžā§œāĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύāĨ¤

āϏāĻšāϜ āĻŦāĻžāĻ‚āϞāĻž āĻŦā§āϝāĻžāĻ–ā§āϝāĻž

āĻĒā§āϰāĻĨāĻŽā§‡ āϰ⧋āĻ—āϟāĻŋ āϕ⧀ āϤāĻž āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤ āĻāϰāĻĒāϰ āϏ⧇āχ āϰ⧋āϗ⧇āϰ āϜāĻ¨ā§āϝ āωāĻĒāϝ⧁āĻ•ā§āϤ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻĻāĻŋāϤ⧇ āĻšāĻŦ⧇āĨ¤ āĻļ⧁āϧ⧁ āĻ“āώ⧁āϧ āĻĻ⧇āϖ⧇ āύāĻŋāĻļā§āϚāĻŋāϤ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟ āĻ•āϰāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

Patient-Specific Assessment — āϰ⧋āĻ—ā§€āĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ

English: Suspected dermatophytosis requires clinical verification before treatment adequacy can be determined.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻĻāĻžāĻĻ āϏāϰāĻžāϏāϰāĻŋ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰ⧇ āϝāĻžāϚāĻžāχ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤ āϤāĻžāϰāĻĒāϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āϝāĻĨāĻžāϝāĻĨ āĻ•āĻŋ āύāĻž āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖ āĻ•āϰāĻž āϝāĻžāĻŦ⧇āĨ¤

Evidence — āĻĒā§āϰāĻŽāĻžāĻŖ

English: Clinical examination and KOH testing improve diagnostic assessment when tinea is uncertain.

āĻŦāĻžāĻ‚āϞāĻž: āĻĻāĻžāĻĻ āϏāĻŽā§āĻĒāĻ°ā§āϕ⧇ āϏāĻ¨ā§āĻĻ⧇āĻš āĻĨāĻžāĻ•āϞ⧇ āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ“ KOH āĻĒāϰ⧀āĻ•ā§āώāĻž āϰ⧋āĻ—āύāĻŋāĻ°ā§āĻŖā§Ÿā§‡ āϏāĻžāĻšāĻžāĻ¯ā§āϝ āĻ•āϰ⧇āĨ¤

Confidence: 0.96āĨ¤


🟩 MODULE 02 — DIAGNOSTIC EVIDENCE AND UNCERTAINTY

āϰ⧋āĻ—āύāĻŋāĻ°ā§āĻŖā§Ÿā§‡āϰ āĻĒā§āϰāĻŽāĻžāĻŖ āĻ“ āĻ…āύāĻŋāĻļā§āϚ⧟āϤāĻž

English Meaning: Evaluation of supporting evidence and the limits of diagnostic certainty.

āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ: āϰ⧋āĻ—āύāĻŋāĻ°ā§āĻŖā§Ÿā§‡āϰ āĻĒāĻ•ā§āώ⧇ āĻĨāĻžāĻ•āĻž āĻĒā§āϰāĻŽāĻžāĻŖ āĻ“ āĻ…āύāĻŋāĻļā§āϚ⧟āϤāĻžāϰ āϏ⧀āĻŽāĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύāĨ¤

Clinical Application — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻĒā§āĻ°ā§Ÿā§‹āĻ—

English: Separate documented findings from inferred possibilities.

āĻŦāĻžāĻ‚āϞāĻž: āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϞāĻŋāĻ–āĻŋāϤ āϤāĻĨā§āϝ āĻāĻŦāĻ‚ āĻ…āύ⧁āĻŽāĻžāύāĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āϏāĻŽā§āĻ­āĻžāĻŦāύāĻžāϕ⧇ āφāϞāĻžāĻĻāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

āϏāĻšāϜ āĻŦāĻžāĻ‚āϞāĻž āĻŦā§āϝāĻžāĻ–ā§āϝāĻž

Itraconazole āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡āϛ⧇ āĻŽāĻžāύ⧇āχ āϰ⧋āĻ—ā§€āϰ āĻĻāĻžāĻĻ āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟āĨ¤ āĻāĻ•āχ āĻ“āώ⧁āϧ āĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϰ⧋āϗ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Patient-Specific Assessment — āϰ⧋āĻ—ā§€āĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ

English: No lesion examination or fungal test result is available.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€āϰ āĻ¤ā§āĻŦāϕ⧇āϰ āĻ•ā§āώāϤ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āϤāĻĨā§āϝ āĻŦāĻž āĻ›āĻ¤ā§āϰāĻžāĻ• āĻļāύāĻžāĻ•ā§āϤāĻ•āϰāϪ⧇āϰ āϰāĻŋāĻĒā§‹āĻ°ā§āϟ āύ⧇āχāĨ¤

Evidence — āĻĒā§āϰāĻŽāĻžāĻŖ

English: Dermatophytosis may clinically resemble eczema and other inflammatory skin disorders.

āĻŦāĻžāĻ‚āϞāĻž: āĻĻāĻžāĻĻ āĻ…āύ⧇āĻ• āϏāĻŽā§Ÿ āĻāĻ•āϜāĻŋāĻŽāĻž āĻŦāĻž āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ¤ā§āĻŦāϕ⧇āϰ āĻĒā§āϰāĻĻāĻžāĻšāϜāύāĻŋāϤ āϰ⧋āϗ⧇āϰ āĻŽāϤ⧋ āĻĻ⧇āĻ–āϤ⧇ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.98 for uncertainty assessmentāĨ¤


🟧 MODULE 03 — PRESCRIPTION SAFETY AUDIT

āĻ“āώ⧁āϧ⧇āϰ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āύāĻŋāϰ⧀āĻ•ā§āώāĻž

English Meaning: Assessment of indications, doses, interactions, contraindications and possible prescribing errors.

āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ: āĻ“āώ⧁āϧ⧇āϰ āĻ•āĻžāϰāĻŖ, āĻĄā§‹āϜ, āĻĒāĻžāϰāĻ¸ā§āĻĒāϰāĻŋāĻ• āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž, āύāĻŋāώ⧇āϧāĻžāĻœā§āĻžāĻž āĻ“ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ-āϭ⧁āϞ āϝāĻžāϚāĻžāχāĨ¤

Clinical Application — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻĒā§āĻ°ā§Ÿā§‹āĻ—

English: Review systemic itraconazole dosing, possible azithromycin cancellation and itraconazole–fluticasone interaction.

āĻŦāĻžāĻ‚āϞāĻž: Itraconazole-āĻāϰ āĻĄā§‹āϜ, Azithromycin āĻŦāĻžāϤāĻŋāϞ āĻšā§Ÿā§‡āϛ⧇ āĻ•āĻŋ āύāĻž āĻāĻŦāĻ‚ Itraconazole–Fluticasone interaction āϝāĻžāϚāĻžāχ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

āϏāĻšāϜ āĻŦāĻžāĻ‚āϞāĻž āĻŦā§āϝāĻžāĻ–ā§āϝāĻž

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āϏāĻŦ āĻ“āώ⧁āϧ āϏāϰāĻžāϏāϰāĻŋ āϚāĻžāϞāĻŋā§Ÿā§‡ āϝāĻžāĻ“ā§ŸāĻžāϰ āφāϗ⧇ āĻ…āĻ¸ā§āĻĒāĻˇā§āϟ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻžāϗ⧁āϞ⧋ āĻĒāϰāĻŋāĻˇā§āĻ•āĻžāϰ āĻ•āϰāĻž āϜāϰ⧁āϰāĻŋāĨ¤

Patient-Specific Assessment — āϰ⧋āĻ—ā§€āĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ

English: The handwritten dose and antibiotic status are not sufficiently clear for safe dispensing decisions.

āĻŦāĻžāĻ‚āϞāĻž: āĻšāĻžāϤ⧇āϰ āϞ⧇āĻ–āĻž āĻĄā§‹āϜ āĻ“ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻŦāĻžā§Ÿā§‹āϟāĻŋāĻ• āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āύāĻŋāϰāĻžāĻĒāĻĻ⧇ āĻ“āώ⧁āϧ āĻĻ⧇āĻ“ā§ŸāĻžāϰ āĻŽāϤ⧋ āϝāĻĨ⧇āĻˇā§āϟ āĻ¸ā§āĻĒāĻˇā§āϟ āύ⧟āĨ¤

Evidence — āĻĒā§āϰāĻŽāĻžāĻŖ

English: Itraconazole has clinically important CYP3A4 interactions and hepatic/cardiac warnings.

āĻŦāĻžāĻ‚āϞāĻž: Itraconazole-āĻāϰ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ CYP3A4 interaction āĻāĻŦāĻ‚ āϞāĻŋāĻ­āĻžāϰ āĻ“ āĻšā§ƒāĻĻā§â€ŒāϝāĻ¨ā§āĻ¤ā§āϰāϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āϏāϤāĻ°ā§āĻ•āϤāĻž āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

Confidence: 0.98āĨ¤


🟩 MODULE 04 — RED FLAGS AND EMERGENCY REFERRAL

āĻŦāĻŋāĻĒāĻĻāϏāĻ‚āϕ⧇āϤ āĻ“ āϜāϰ⧁āϰāĻŋ āϰ⧇āĻĢāĻžāϰ⧇āϞ

English Meaning: Identification of symptoms requiring urgent medical evaluation.

āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ: āϝ⧇āϏāĻŦ āωāĻĒāϏāĻ°ā§āĻ— āĻĻ⧇āĻ–āĻž āĻĻāĻŋāϞ⧇ āϜāϰ⧁āϰāĻŋ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύ, āϏ⧇āϗ⧁āϞ⧋ āĻļāύāĻžāĻ•ā§āϤ āĻ•āϰāĻžāĨ¤

Clinical Application — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻĒā§āĻ°ā§Ÿā§‹āĻ—

English: Assess breathing difficulty, severe allergic reactions, jaundice, rapidly spreading painful lesions and new signs of heart failure.

āĻŦāĻžāĻ‚āϞāĻž: āĻļā§āĻŦāĻžāϏāĻ•āĻˇā§āϟ, āϗ⧁āϰ⧁āϤāϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ, āϜāĻ¨ā§āĻĄāĻŋāϏ, āĻĻā§āϰ⧁āϤ āĻ›ā§œāĻŋā§Ÿā§‡ āĻĒ⧜āĻž āĻŦā§āϝāĻĨāĻžāϝ⧁āĻ•ā§āϤ āĻ•ā§āώāϤ āĻāĻŦāĻ‚ āύāϤ⧁āύ āĻšā§ƒāĻĻā§â€ŒāϝāĻ¨ā§āĻ¤ā§āϰ⧇āϰ āϏāĻŽāĻ¸ā§āϝāĻžāϰ āϞāĻ•ā§āώāĻŖ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

āϏāĻšāϜ āĻŦāĻžāĻ‚āϞāĻž āĻŦā§āϝāĻžāĻ–ā§āϝāĻž

āϏāĻžāϧāĻžāϰāĻŖ āĻĻāĻžāĻĻ āϜāϰ⧁āϰāĻŋ āϰ⧋āĻ— āύ⧟āĨ¤ āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻļā§āĻŦāĻžāϏāĻ•āĻˇā§āϟ, āĻšā§‹āĻ– āĻšāϞ⧁āĻĻ āĻšā§Ÿā§‡ āϝāĻžāĻ“ā§ŸāĻž, āĻĒāĻž āĻĢ⧁āϞ⧇ āϝāĻžāĻ“ā§ŸāĻž āĻ…āĻĨāĻŦāĻž āϗ⧁āϰ⧁āϤāϰ āĻ“āώ⧁āϧ-āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž āĻšāϞ⧇ āĻĻā§āϰ⧁āϤ āĻšāĻžāϏāĻĒāĻžāϤāĻžāϞ⧇ āϝ⧇āϤ⧇ āĻšāĻŦ⧇āĨ¤

Patient-Specific Assessment — āϰ⧋āĻ—ā§€āĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ

English: No red flags were recorded, but their absence cannot be assumed.

āĻŦāĻžāĻ‚āϞāĻž: āϕ⧋āύ⧋ āĻŦāĻŋāĻĒāĻĻāϏāĻ‚āϕ⧇āϤ āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤ āϤāĻŦ⧇ āĻāϰ āĻ…āĻ°ā§āĻĨ āϰ⧋āĻ—ā§€āϰ āĻŦāĻŋāĻĒāĻĻāϏāĻ‚āϕ⧇āϤ āύ⧇āĻ‡â€”āĻāĻŽāύ āύ⧟āĨ¤

Evidence — āĻĒā§āϰāĻŽāĻžāĻŖ

English: Itraconazole product labeling includes warnings about serious liver injury and heart failure.

āĻŦāĻžāĻ‚āϞāĻž: Itraconazole-āĻāϰ āĻ“āώ⧁āϧ-āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻžā§Ÿ āϗ⧁āϰ⧁āϤāϰ āϞāĻŋāĻ­āĻžāϰ-āĻ•ā§āώāϤāĻŋ āĻāĻŦāĻ‚ āĻšā§ƒāĻĻā§â€ŒāϝāĻ¨ā§āĻ¤ā§āϰ⧇āϰ āĻ•āĻžāĻ°ā§āϝāĻ•ā§āώāĻŽāϤāĻž āĻ•āĻŽā§‡ āϝāĻžāĻ“ā§ŸāĻžāϰ āĻā§āρāĻ•āĻŋ āωāĻ˛ā§āϞ⧇āĻ– āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

Confidence: 0.98āĨ¤


🟧 MODULE 05 — EVIDENCE-BASED TREATMENT COMPARISON

āĻĒā§āϰāĻŽāĻžāĻŖāĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āϤ⧁āϞāύāĻž

English Meaning: Comparison of prescribed therapy with established guidelines and clinical evidence.

āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ: āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻĻ⧇āĻ“ā§ŸāĻž āĻ“āώ⧁āϧ⧇āϰ āϏāĻ™ā§āϗ⧇ āĻ¸ā§āĻŦā§€āĻ•ā§ƒāϤ āĻ—āĻžāχāĻĄāϞāĻžāχāύ āĻ“ āĻŦ⧈āĻœā§āĻžāĻžāύāĻŋāĻ• āĻĒā§āϰāĻŽāĻžāϪ⧇āϰ āϤ⧁āϞāύāĻžāĨ¤

Clinical Application — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻĒā§āĻ°ā§Ÿā§‹āĻ—

English: Compare topical antifungal therapy, systemic antifungal treatment, allergy treatment and the need for antibiotics.

āĻŦāĻžāĻ‚āϞāĻž: āĻŦāĻžāĻšā§āϝāĻŋāĻ• āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ, āĻŽā§āϖ⧇ āĻ–āĻžāĻ“ā§ŸāĻžāϰ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ, āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻāĻŦāĻ‚ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻŦāĻžā§Ÿā§‹āϟāĻŋāϕ⧇āϰ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§ŸāϤāĻž āϤ⧁āϞāύāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

āϏāĻšāϜ āĻŦāĻžāĻ‚āϞāĻž āĻŦā§āϝāĻžāĻ–ā§āϝāĻž

āϏ⧀āĻŽāĻŋāϤ āĻĻāĻžāĻĻ⧇ āĻ…āύ⧇āĻ• āϏāĻŽā§Ÿ āĻ•ā§āϰāĻŋāĻŽ āϝāĻĨ⧇āĻˇā§āϟ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ āĻŦā§āϝāĻžāĻĒāĻ• āĻŦāĻž āϜāϟāĻŋāϞ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇ āĻŽā§āϖ⧇ āĻ–āĻžāĻ“ā§ŸāĻžāϰ āĻ“āώ⧁āϧ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻ›āĻžā§œāĻž āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻŦāĻžā§Ÿā§‹āϟāĻŋāĻ• āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšā§Ÿ āύāĻžāĨ¤

Patient-Specific Assessment — āϰ⧋āĻ—ā§€āĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ

English: The extent of disease is unknown, so the need for systemic antifungal treatment cannot be confirmed.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—āϟāĻŋ āĻ•āϤāϟāĻž āĻ›ā§œāĻŋā§Ÿā§‡āϛ⧇ āϤāĻž āϜāĻžāύāĻž āύ⧇āχāĨ¤ āϤāĻžāχ āĻŽā§āϖ⧇ āĻ–āĻžāĻ“ā§ŸāĻžāϰ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āĻ…āĻĒāϰāĻŋāĻšāĻžāĻ°ā§āϝ āĻ›āĻŋāϞ āĻ•āĻŋ āύāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžāĻšā§āϛ⧇ āύāĻžāĨ¤

Evidence — āĻĒā§āϰāĻŽāĻžāĻŖ

English: Current evidence supports topical treatment for many localized infections and systemic therapy for selected extensive or refractory cases.

āĻŦāĻžāĻ‚āϞāĻž: āĻŦāĻ°ā§āϤāĻŽāĻžāύ āĻĒā§āϰāĻŽāĻžāĻŖ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻ…āύ⧇āĻ• āϏ⧀āĻŽāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇ āĻŦāĻžāĻšā§āϝāĻŋāĻ• āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āϝāĻĨ⧇āĻˇā§āϟ āĻāĻŦāĻ‚ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻŦā§āϝāĻžāĻĒāĻ• āĻŦāĻž āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻĒā§āϰāϤāĻŋāϰ⧋āϧ⧀ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇ āĻŽā§āϖ⧇ āĻ–āĻžāĻ“ā§ŸāĻžāϰ āĻ“āώ⧁āϧ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.95āĨ¤


🟩 MODULE 06 — FOLLOW-UP AND CLINICAL OUTCOMES

āĻĢāϞ⧋āφāĻĒ āĻ“ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āĻĢāϞāĻžāĻĢāϞ

English Meaning: Evaluation of treatment response, adverse effects, recurrence and clinical recovery.

āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ: āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āĻ•āĻžāĻ°ā§āϝāĻ•āĻžāϰāĻŋāϤāĻž, āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž, āϰ⧋āĻ— āĻĢāĻŋāϰ⧇ āφāϏāĻž āĻāĻŦāĻ‚ āϏ⧁āĻ¸ā§āĻĨāϤāĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύāĨ¤

Clinical Application — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻĒā§āĻ°ā§Ÿā§‹āĻ—

English: Assess improvement in itching, scaling, lesion size and nasal symptoms.

āĻŦāĻžāĻ‚āϞāĻž: āϚ⧁āϞāĻ•āĻžāύāĻŋ, āĻ–ā§‹āϏāĻž āĻ“āĻ āĻž, āĻ•ā§āώāϤ⧇āϰ āφāĻ•āĻžāϰ āĻāĻŦāĻ‚ āύāĻžāϕ⧇āϰ āωāĻĒāϏāĻ°ā§āĻ— āĻ•āĻŽāϛ⧇ āĻ•āĻŋ āύāĻž āĻĻ⧇āĻ–āϤ⧇ āĻšāĻŦ⧇āĨ¤

āϏāĻšāϜ āĻŦāĻžāĻ‚āϞāĻž āĻŦā§āϝāĻžāĻ–ā§āϝāĻž

āĻ“āώ⧁āϧ āĻĻ⧇āĻ“ā§ŸāĻžāϰ āĻĒāϰ⧇ āϰ⧋āĻ—ā§€ āĻ­āĻžāϞ⧋ āĻšāĻšā§āϛ⧇āύ āĻ•āĻŋ āύāĻž āϤāĻž āĻĻ⧇āĻ–āĻž āϜāϰ⧁āϰāĻŋāĨ¤ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ⧇ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟ āĻ“ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻĒ⧁āύāĻ°ā§āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Patient-Specific Assessment — āϰ⧋āĻ—ā§€āĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ

English: No follow-up findings or treatment outcomes are available.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€āϰ āĻĢāϞ⧋āφāĻĒ⧇āϰ āĻĢāϞāĻžāĻĢāϞ āĻŦāĻž āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āĻĒāϰ⧇ āωāĻ¨ā§āύāϤāĻŋāϰ āϤāĻĨā§āϝ āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāύāĻŋāĨ¤

Evidence — āĻĒā§āϰāĻŽāĻžāĻŖ

English: Lack of response should prompt reassessment of diagnosis, adherence and possible antifungal resistance.

āĻŦāĻžāĻ‚āϞāĻž: āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžā§Ÿ āωāĻ¨ā§āύāϤāĻŋ āύāĻž āĻšāϞ⧇ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟, āϏāĻ āĻŋāĻ•āĻ­āĻžāĻŦ⧇ āĻ“āώ⧁āϧ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāĻŦāĻ‚ āĻ›āĻ¤ā§āϰāĻžāϕ⧇āϰ āĻ“āώ⧁āϧāĻĒā§āϰāϤāĻŋāϰ⧋āϧ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āĻĒ⧁āύāĻ°ā§āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.95āĨ¤


🟧 MODULE 07 — INVESTIGATION INTERPRETATION

āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ āĻŦāĻŋāĻļā§āϞ⧇āώāĻŖ

English Meaning: Interpretation of laboratory results in relation to clinical findings.

āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ: āϰ⧋āĻ—ā§€āϰ āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻ…āĻŦāĻ¸ā§āĻĨāĻž āĻ“ āωāĻĒāϏāĻ°ā§āϗ⧇āϰ āϏāĻ™ā§āϗ⧇ āĻ˛ā§āϝāĻžāĻŦāϰ⧇āϟāϰāĻŋ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ āĻŽāĻŋāϞāĻŋā§Ÿā§‡ āĻĻ⧇āĻ–āĻžāĨ¤

Clinical Application — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻĒā§āĻ°ā§Ÿā§‹āĻ—

English: Interpret KOH results, fungal culture and relevant safety investigations according to clinical findings.

āĻŦāĻžāĻ‚āϞāĻž: KOH āĻĒāϰ⧀āĻ•ā§āώāĻž, āĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āĻ•āĻžāϞāϚāĻžāϰ āĻāĻŦāĻ‚ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻžāϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻĒāϰ⧀āĻ•ā§āώāĻžāϗ⧁āϞ⧋ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻ…āĻŦāĻ¸ā§āĻĨāĻžāϰ āϏāĻ™ā§āϗ⧇ āĻŽāĻŋāϞāĻŋā§Ÿā§‡ āĻŦā§āϝāĻžāĻ–ā§āϝāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

āϏāĻšāϜ āĻŦāĻžāĻ‚āϞāĻž āĻŦā§āϝāĻžāĻ–ā§āϝāĻž

KOH āĻĒāϰ⧀āĻ•ā§āώāĻžā§Ÿ āĻ›āĻ¤ā§āϰāĻžāϕ⧇āϰ āĻšāĻžāχāĻĢāĻž āĻĒāĻžāĻ“ā§ŸāĻž āϗ⧇āϞ⧇ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϰ⧋āϗ⧇āϰ āĻĒāĻ•ā§āώ⧇ āĻĒā§āϰāĻŽāĻžāĻŖ āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāĨ¤ āϤāĻŦ⧇ āύ⧇āϤāĻŋāĻŦāĻžāϚāĻ• āĻĢāϞāĻžāĻĢāϞ āϏāĻŦ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻ›āĻ¤ā§āϰāĻžāĻ• āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻĒ⧁āϰ⧋āĻĒ⧁āϰāĻŋ āĻŦāĻžāϤāĻŋāϞ āĻ•āϰ⧇ āύāĻžāĨ¤

Patient-Specific Assessment — āϰ⧋āĻ—ā§€āĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ

English: No investigation result is available for interpretation.

āĻŦāĻžāĻ‚āϞāĻž: āĻŦāĻŋāĻļā§āϞ⧇āώāĻŖ āĻ•āϰāĻžāϰ āĻŽāϤ⧋ āϕ⧋āύ⧋ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ āύ⧇āχāĨ¤

Evidence — āĻĒā§āϰāĻŽāĻžāĻŖ

English: KOH microscopy is commonly used in the diagnostic assessment of suspected tinea.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻĻāĻžāĻĻ⧇āϰ āϰ⧋āĻ—āύāĻŋāĻ°ā§āĻŖā§Ÿā§‡ KOH āĻĒāϰ⧀āĻ•ā§āώāĻž āĻāĻ•āϟāĻŋ āĻĒā§āϰāϚāϞāĻŋāϤ āĻĒāĻĻā§āϧāϤāĻŋāĨ¤

Confidence: 0.95āĨ¤


🟩 MODULE 08 — PATIENT EDUCATION

āϰ⧋āĻ—ā§€āϕ⧇ āĻ¸ā§āĻŦāĻžāĻ¸ā§āĻĨā§āϝāĻļāĻŋāĻ•ā§āώāĻž

English Meaning: Providing understandable guidance about disease, treatment, hygiene and prevention.

āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ: āϰ⧋āĻ—, āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž, āĻĒāϰāĻŋāĻˇā§āĻ•āĻžāϰ-āĻĒāϰāĻŋāĻšā§āĻ›āĻ¨ā§āύāϤāĻž āĻāĻŦāĻ‚ āĻĒā§āϰāϤāĻŋāϰ⧋āϧ āϏāĻŽā§āĻĒāĻ°ā§āϕ⧇ āϰ⧋āĻ—ā§€āϕ⧇ āϏāĻšāϜ āĻ­āĻžāώāĻžā§Ÿ āĻŦā§‹āĻāĻžāύ⧋āĨ¤

Clinical Application — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻĒā§āĻ°ā§Ÿā§‹āĻ—

English: Encourage correct medication use, clean clothing, personal hygiene and avoidance of unnecessary steroid creams.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻ āĻŋāĻ•āĻ­āĻžāĻŦ⧇ āĻ“āώ⧁āϧ āĻŦā§āϝāĻŦāĻšāĻžāϰ, āĻ•āĻžāĻĒ⧜ āĻĒāϰāĻŋāĻˇā§āĻ•āĻžāϰ āϰāĻžāĻ–āĻž, āĻŦā§āϝāĻ•ā§āϤāĻŋāĻ—āϤ āĻĒāϰāĻŋāĻšā§āĻ›āĻ¨ā§āύāϤāĻž āĻāĻŦāĻ‚ āĻ…āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āĻ¸ā§āĻŸā§‡āĻ°ā§Ÿā§‡āĻĄ āĻ•ā§āϰāĻŋāĻŽ āĻĒāϰāĻŋāĻšāĻžāϰ⧇āϰ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļ āĻĻāĻŋāϤ⧇ āĻšāĻŦ⧇āĨ¤

āϏāĻšāϜ āĻŦāĻžāĻ‚āϞāĻž āĻŦā§āϝāĻžāĻ–ā§āϝāĻž

āĻĻāĻžāĻĻ āϏāĻ¨ā§āĻĻ⧇āĻš āĻšāϞ⧇ āφāĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻ¸ā§āĻĨāĻžāύ āĻĒāϰāĻŋāĻˇā§āĻ•āĻžāϰ āĻ“ āĻļ⧁āĻ•āύāĻž āϰāĻžāĻ–āĻŦ⧇āύāĨ¤ āĻ…āĻ¨ā§āϝ⧇āϰ āĻ•āĻžāĻĒ⧜ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻŦ⧇āύ āύāĻžāĨ¤ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻž āĻ›āĻžā§œāĻž āύāϤ⧁āύ āĻ•ā§āϰāĻŋāĻŽ āϝ⧋āĻ— āĻ•āϰāĻŦ⧇āύ āύāĻžāĨ¤

Patient-Specific Assessment — āϰ⧋āĻ—ā§€āĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ

English: The patient should receive clear instructions about itraconazole dosing and whether azithromycin was cancelled.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€āϕ⧇ Itraconazole-āĻāϰ āϏāĻ āĻŋāĻ• āĻĄā§‹āϜ āĻāĻŦāĻ‚ Azithromycin āĻŦāĻžāϤāĻŋāϞ āĻšā§Ÿā§‡āϛ⧇ āĻ•āĻŋ āύāĻž āϤāĻž āĻĒāϰāĻŋāĻˇā§āĻ•āĻžāϰāĻ­āĻžāĻŦ⧇ āϜāĻžāύāĻžāύ⧋ āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

Evidence — āĻĒā§āϰāĻŽāĻžāĻŖ

English: CDC advises avoiding steroid-containing creams for suspected ringworm unless appropriately directed.

āĻŦāĻžāĻ‚āϞāĻž: CDC āĻĻāĻžāĻĻ āϏāĻ¨ā§āĻĻ⧇āĻš āĻšāϞ⧇ āĻ…āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āĻ¸ā§āĻŸā§‡āĻ°ā§Ÿā§‡āĻĄāϝ⧁āĻ•ā§āϤ āĻ•ā§āϰāĻŋāĻŽ āĻŦā§āϝāĻŦāĻšāĻžāϰ āύāĻž āĻ•āϰāĻžāϰ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļ āĻĻā§‡ā§ŸāĨ¤

Confidence: 0.98āĨ¤


🟧 MODULE 09 — GUIDELINE UPDATE AND EVIDENCE QUALITY

āĻ—āĻžāχāĻĄāϞāĻžāχāύ āφāĻĒāĻĄā§‡āϟ āĻ“ āĻŦ⧈āĻœā§āĻžāĻžāύāĻŋāĻ• āĻĒā§āϰāĻŽāĻžāϪ⧇āϰ āĻŽāĻžāύ

English Meaning: Reviewing recent guidelines and evaluating the reliability of supporting evidence.

āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ: āϏāĻžāĻŽā§āĻĒā§āϰāϤāĻŋāĻ• āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻ—āĻžāχāĻĄāϞāĻžāχāύ āĻ“ āϏāĻ‚āĻļā§āϞāĻŋāĻˇā§āϟ āĻ—āĻŦ⧇āώāĻŖāĻžāϰ āύāĻŋāĻ°ā§āĻ­āϰāϝ⧋āĻ—ā§āϝāϤāĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύāĨ¤

Clinical Application — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻĒā§āĻ°ā§Ÿā§‹āĻ—

English: Use dermatophytosis guidance, CDC recommendations on resistant ringworm and ARIA–EAACI allergic rhinitis guidelines.

āĻŦāĻžāĻ‚āϞāĻž: āĻĻāĻžāĻĻ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻž, CDC-āĻāϰ āĻĒā§āϰāϤāĻŋāϰ⧋āϧ⧀ āĻĻāĻžāĻĻāϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āϤāĻĨā§āϝ āĻāĻŦāĻ‚ ARIA–EAACI-āĻāϰ āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āĻ—āĻžāχāĻĄāϞāĻžāχāύ āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

āϏāĻšāϜ āĻŦāĻžāĻ‚āϞāĻž āĻŦā§āϝāĻžāĻ–ā§āϝāĻž

āĻ—āĻžāχāĻĄāϞāĻžāχāύ āĻĨ⧇āϕ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āύāĻŋ⧟āĻŽ āϜāĻžāύāĻž āϝāĻžā§ŸāĨ¤ āĻ•āĻŋāĻ¨ā§āϤ⧁ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻ—āĻžāχāĻĄāϞāĻžāχāύ āĻĒā§āĻ°ā§Ÿā§‹āϗ⧇āϰ āφāϗ⧇ āϰ⧋āϗ⧇āϰ āϧāϰāύ āĻ“ āϤ⧀āĻŦā§āϰāϤāĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰāϤ⧇ āĻšā§ŸāĨ¤

Patient-Specific Assessment — āϰ⧋āĻ—ā§€āĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ

English: Evidence supports the general therapeutic roles of the prescribed medicines but does not establish that every medicine was necessary in this patient.

āĻŦāĻžāĻ‚āϞāĻž: āĻŦ⧈āĻœā§āĻžāĻžāύāĻŋāĻ• āĻĒā§āϰāĻŽāĻžāĻŖ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻ“āώ⧁āϧāϗ⧁āϞ⧋āϰ āϏāĻžāϧāĻžāϰāĻŖ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻ—āϤ āĻ­ā§‚āĻŽāĻŋāĻ•āĻž āĻ°ā§Ÿā§‡āϛ⧇āĨ¤ āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻāχ āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āĻĒā§āϰāϤāĻŋāϟāĻŋ āĻ“āώ⧁āϧ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āĻ›āĻŋāĻ˛â€”āĻāĻŽāύ āύāĻŋāĻļā§āϚ⧟āϤāĻž āύ⧇āχāĨ¤

Evidence — āĻĒā§āϰāĻŽāĻžāĻŖ

English: AAFP 2025, CDC 2026 and ARIA–EAACI recommendations provide relevant guidance.

āĻŦāĻžāĻ‚āϞāĻž: AAFP ⧍ā§Ļ⧍ā§Ģ, CDC ⧍ā§Ļ⧍ā§Ŧ āĻāĻŦāĻ‚ ARIA–EAACI-āĻāϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻž āĻāχ āϰ⧋āĻ—āϗ⧁āϞ⧋āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžā§Ÿ āĻĒā§āϰāĻžāϏāĻ™ā§āĻ—āĻŋāĻ•āĨ¤

Confidence: 0.98 for source relevanceāĨ¤


🟩 MODULE 10 — MEDICAL SEO AND ARTICLE TRANSPARENCY

āĻŽā§‡āĻĄāĻŋāĻ•ā§āϝāĻžāϞ SEO āĻ“ āϤāĻĨā§āϝ āĻĒā§āϰāĻ•āĻžāĻļ⧇āϰ āĻ¸ā§āĻŦāĻšā§āĻ›āϤāĻž

English Meaning: Optimizing evidence-based medical content for discoverability while clearly communicating uncertainty and limitations.

āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ: āϏāĻ āĻŋāĻ• āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻŦāĻŋāώ⧟āĻ• āϤāĻĨā§āϝ āϏāĻžāĻ°ā§āϚ āχāĻžā§āϜāĻŋāύ⧇āϰ āϜāĻ¨ā§āϝ āωāĻĒāϝ⧋āĻ—ā§€āĻ­āĻžāĻŦ⧇ āϏāĻžāϜāĻžāύ⧋ āĻāĻŦāĻ‚ āϰ⧋āĻ—āύāĻŋāĻ°ā§āĻŖā§Ÿā§‡āϰ āĻ…āύāĻŋāĻļā§āϚ⧟āϤāĻž āĻ“ āϏ⧀āĻŽāĻžāĻŦāĻĻā§āϧāϤāĻž āĻ¸ā§āĻĒāĻˇā§āϟāĻ­āĻžāĻŦ⧇ āĻĒā§āϰāĻ•āĻžāĻļ āĻ•āϰāĻžāĨ¤

Clinical Application — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻĒā§āĻ°ā§Ÿā§‹āĻ—

SEO Title — āϏāĻžāĻ°ā§āϚ āĻļāĻŋāϰ⧋āύāĻžāĻŽ:

Suspected Dermatophytosis with Allergic Rhinitis — Clinical Case Review.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻĻāĻžāĻĻ āĻ“ āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āϕ⧇āϏ āϰāĻŋāĻ­āĻŋāωāĨ¤

Focus Keyword — āĻĒā§āϰāϧāĻžāύ āϕ⧀āĻ“ā§ŸāĻžāĻ°ā§āĻĄ:

Superficial Dermatophytosis — āĻ¤ā§āĻŦāϕ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĨ¤

Secondary Keywords — āϏāĻšāĻžā§ŸāĻ• āϕ⧀āĻ“ā§ŸāĻžāĻ°ā§āĻĄ:

Tinea, Itraconazole, Luliconazole, Allergic Rhinitis, Prescription Review.

āĻŦāĻžāĻ‚āϞāĻž: āĻĻāĻžāĻĻ, āχāĻŸā§āϰāĻžāϕ⧋āύāĻžāϜāϞ, āϞ⧁āϞāĻŋāϕ⧋āύāĻžāϜāϞ, āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻāĻŦāĻ‚ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āĻŦāĻŋāĻļā§āϞ⧇āώāĻŖāĨ¤

āϏāĻšāϜ āĻŦāĻžāĻ‚āϞāĻž āĻŦā§āϝāĻžāĻ–ā§āϝāĻž

āϝ⧇āĻšā§‡āϤ⧁ āϰ⧋āĻ—āϟāĻŋ āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟, āϤāĻžāχ āφāĻ°ā§āϟāĻŋāϕ⧇āϞ⧇āϰ āĻļāĻŋāϰ⧋āύāĻžāĻŽā§‡ Suspected — āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻļāĻŦā§āĻĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

Patient-Specific Assessment — āϰ⧋āĻ—ā§€āĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ

English: The patient’s identity is retained in this private review as supplied, but public publication requires appropriate consent and privacy review.

āĻŦāĻžāĻ‚āϞāĻž: āĻŦā§āϝāĻ•ā§āϤāĻŋāĻ—āϤ āĻŦāĻŋāĻļā§āϞ⧇āώāϪ⧇ āĻĻ⧇āĻ“ā§ŸāĻž āϰ⧋āĻ—ā§€āϰ āĻĒāϰāĻŋāϚ⧟ āϰāĻžāĻ–āĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤ āϤāĻŦ⧇ āĻĒā§āϰāĻ•āĻžāĻļā§āϝ āĻ“ā§Ÿā§‡āĻŦāϏāĻžāχāĻŸā§‡ āĻĒā§āϰāĻ•āĻžāĻļ⧇āϰ āφāϗ⧇ āϰ⧋āĻ—ā§€āϰ āωāĻĒāϝ⧁āĻ•ā§āϤ āϏāĻŽā§āĻŽāϤāĻŋ āĻāĻŦāĻ‚ āĻŦā§āϝāĻ•ā§āϤāĻŋāĻ—āϤ āϤāĻĨā§āϝ⧇āϰ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Evidence — āĻĒā§āϰāĻŽāĻžāĻŖ

English: Transparent reporting distinguishes documented medical findings from clinical inference.

āĻŦāĻžāĻ‚āϞāĻž: āĻ¸ā§āĻŦāĻšā§āĻ›āĻ­āĻžāĻŦ⧇ āϤāĻĨā§āϝ āĻĒā§āϰāĻ•āĻžāĻļ āĻ•āϰāϞ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϞāĻŋāĻ–āĻŋāϤ āϤāĻĨā§āϝ āĻāĻŦāĻ‚ āĻ¸ā§āĻŦāĻžāϧ⧀āύāĻ­āĻžāĻŦ⧇ āĻ•āϰāĻž āϧāĻžāϰāĻŖāĻžāϰ āĻĒāĻžāĻ°ā§āĻĨāĻ•ā§āϝ āĻĒāĻžāĻ āĻ• āĻŦ⧁āĻāϤ⧇ āĻĒāĻžāϰ⧇āύāĨ¤

Confidence: 0.98āĨ¤


🟧 19. REFERRAL RECOMMENDATION

āϕ⧋āύ āĻŦāĻŋāĻļ⧇āώāĻœā§āĻžā§‡āϰ āĻ•āĻžāϛ⧇ āϰ⧋āĻ—ā§€āϕ⧇ āĻĒāĻžāĻ āĻžāĻŦ⧇āύ?

Primary Referral — āĻĒā§āϰāϧāĻžāύ āϰ⧇āĻĢāĻžāϰ⧇āϞ

Dermatologist — āϚāĻ°ā§āĻŽāϰ⧋āĻ— āĻŦāĻŋāĻļ⧇āώāĻœā§āĻžāĨ¤

Reason — āĻ•āĻžāϰāĻŖ: Evaluation of suspected dermatophytosis, particularly if extensive, recurrent or treatment resistant.

āĻŦāĻžāĻ‚āϞāĻž: āĻĻāĻžāĻĻ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āĻāĻŦāĻ‚ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻŦā§āϝāĻžāĻĒāĻ•, āĻĒ⧁āύāϰāĻžāĻŦ⧃āĻ¤ā§āϤ āĻ…āĻĨāĻŦāĻž āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻĒā§āϰāϤāĻŋāϰ⧋āϧ⧀ āĻšāϞ⧇ āωāĻĒāϝ⧁āĻ•ā§āϤ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āύāĻŋāĻ°ā§āϧāĻžāϰāϪ⧇āϰ āϜāĻ¨ā§āϝāĨ¤

Confidence: 0.95āĨ¤

Secondary Referral — āĻĻā§āĻŦāĻŋāĻ¤ā§€ā§Ÿ āϰ⧇āĻĢāĻžāϰ⧇āϞ

ENT Specialist / Allergist — āύāĻžāĻ•-āĻ•āĻžāύ-āĻ—āϞāĻž āĻŦāĻž āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻŦāĻŋāĻļ⧇āώāĻœā§āĻžāĨ¤

Reason — āĻ•āĻžāϰāĻŖ: Persistent or inadequately controlled nasal allergy symptoms.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžā§Ÿā§€ āĻšāϞ⧇ āĻ…āĻĨāĻŦāĻž āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžā§Ÿ āύāĻŋ⧟āĻ¨ā§āĻ¤ā§āϰāĻŖ āύāĻž āĻšāϞ⧇āĨ¤

Confidence: 0.90āĨ¤


🟩 20. EDUCATIONAL CLINICAL PRESCRIPTION DEMO

āĻļāĻŋāĻ•ā§āώāĻž āĻ“ āĻĄāϕ⧁āĻŽā§‡āĻ¨ā§āĻŸā§‡āĻļāύ⧇āϰ āϜāĻ¨ā§āϝ āύāĻŽā§āύāĻž āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ

Patient — āϰ⧋āĻ—ā§€: Nasima Begum — āύāĻžāϏāĻŋāĻŽāĻž āĻŦ⧇āĻ—āĻŽāĨ¤

Age — āĻŦ⧟āϏ: 35 years — ā§Šā§Ģ āĻŦāĻ›āϰāĨ¤

Original Consultation Date — āĻŽā§‚āϞ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āϤāĻžāϰāĻŋāĻ–: 20 October 2026 — ⧍ā§Ļ āĻ…āĻ•ā§āĻŸā§‹āĻŦāϰ ⧍ā§Ļ⧍ā§ŦāĨ¤

C/C — Chief Complaints — āĻĒā§āϰāϧāĻžāύ āĻ…āĻ­āĻŋāϝ⧋āĻ—

Not documented in original prescription — āĻŽā§‚āϞ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

HPI — History of Present Illness — āĻŦāĻ°ā§āϤāĻŽāĻžāύ āϰ⧋āϗ⧇āϰ āχāϤāĻŋāĻšāĻžāϏ

Not documented — āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

O/E — On Examination — āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ

Not documented — āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

Investigation — āϰ⧋āĻ—āύāĻŋāĻ°ā§āĻŖā§Ÿā§‡āϰ āĻĒāϰ⧀āĻ•ā§āώāĻž

No physician-documented investigation — āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϞ⧇āĻ–āĻž āϕ⧋āύ⧋ āĻĒāϰ⧀āĻ•ā§āώāĻž āύ⧇āχāĨ¤

Provisional Diagnosis — āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟

Dx 1: Suspected Superficial Dermatophytosis (Site Unspecified).

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻĻāĻžāĻĻ āĻŦāĻž āĻ¤ā§āĻŦāϕ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ; āφāĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻ¸ā§āĻĨāĻžāύ āĻ…āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟāĨ¤

Dx 2: Possible Allergic Rhinitis.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϜāύāĻŋāϤ āĻĒā§āϰāĻĻāĻžāĻšā§‡āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻžāĨ¤

D/D — Differential Diagnosis — āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϰ⧋āĻ—

Eczema — āĻāĻ•āϜāĻŋāĻŽāĻžāĨ¤

Pityriasis Versicolor — āϛ⧁āϞāĻŋāĨ¤

Cutaneous Candidiasis — āĻ¤ā§āĻŦāϕ⧇āϰ āĻ•ā§āϝāĻžāύāĻĄāĻŋāĻĄāĻž āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĨ¤

Other inflammatory skin disorders — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻĒā§āϰāĻĻāĻžāĻšāϜāύāĻŋāϤ āϚāĻ°ā§āĻŽāϰ⧋āĻ—āĨ¤

Medication Reconciliation — āĻ“āώ⧁āϧ āϝāĻžāϚāĻžāχ

Original medicines requiring review — āĻŽā§‚āϞ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āϝ⧇āϏāĻŦ āĻ“āώ⧁āϧ āϝāĻžāϚāĻžāχ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ:

  1. Itracon SUBA 65 mg — āĻĄā§‹āϜ āĻ“ āϏāĻŽā§ŸāĻ•āĻžāϞ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤
  2. Tinacure Cream — āφāĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻ¸ā§āĻĨāĻžāύ āĻ“ āĻŦā§āϝāĻŦāĻšāĻžāϰāĻŦāĻŋāϧāĻŋ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤
  3. Zimax 500 mg — āĻ“āώ⧁āϧāϟāĻŋ āĻŦāĻžāϤāĻŋāϞ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇ āĻ•āĻŋ āύāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤
  4. Fastel 180 mg — āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ•āĻžāϰāĻŖ āĻ“ āĻĄā§‹āϜ āϝāĻžāϚāĻžāχ āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤
  5. ABC Antifungal Bar — āĻĒāĻŖā§āϝ⧇āϰ āĻĒā§āϰāĻ•ā§ƒāϤ āωāĻĒāĻžāĻĻāĻžāύ āĻ“ āĻŦā§āϝāĻŦāĻšāĻžāϰāĻŦāĻŋāϧāĻŋ āϝāĻžāϚāĻžāχ āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤
  6. Snofas Nasal Spray — āĻ¸ā§āĻĒā§āϰ⧇āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻž āĻ“ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ interaction āϝāĻžāϚāĻžāχ āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

Clinical Plan — āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻĒāϰāĻŋāĻ•āĻ˛ā§āĻĒāύāĻž

English: Confirm the diagnosis, reconcile medication instructions, assess safety and select treatment based on clinical findings.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇, āĻ“āώ⧁āϧ⧇āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻž āϝāĻžāϚāĻžāχ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇, āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇ āĻāĻŦāĻ‚ āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ⧇āϰ āĻ­āĻŋāĻ¤ā§āϤāĻŋāϤ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Follow-up — āĻĒ⧁āύāϰāĻžā§Ÿ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ

English: Review according to symptoms, treatment response and medication safety.

āĻŦāĻžāĻ‚āϞāĻž: āωāĻĒāϏāĻ°ā§āĻ—, āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžā§Ÿ āωāĻ¨ā§āύāϤāĻŋ āĻāĻŦāĻ‚ āĻ“āώ⧁āϧ⧇āϰ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻĒ⧁āύāϰāĻžā§Ÿ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Referral — āϰ⧇āĻĢāĻžāϰ⧇āϞ

Dermatology — āϚāĻ°ā§āĻŽāϰ⧋āĻ— āĻŦāĻŋāĻ­āĻžāĻ—āĨ¤

ENT/Allergy if indicated — āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϞ⧇ āύāĻžāĻ•-āĻ•āĻžāύ-āĻ—āϞāĻž āĻŦāĻž āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻŦāĻŋāĻ­āĻžāĻ—āĨ¤

Important — āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ: This is an educational clinical documentation example, not a new prescription authorizing medication dispensing.

āĻŦāĻžāĻ‚āϞāĻž: āĻāϟāĻŋ āĻļāĻŋāĻ•ā§āώāĻžāĻŽā§‚āϞāĻ• āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻĄāϕ⧁āĻŽā§‡āĻ¨ā§āĻŸā§‡āĻļāύ⧇āϰ āύāĻŽā§āύāĻžāĨ¤ āĻāϟāĻŋ āύāϤ⧁āύ āĻ“āώ⧁āϧ āĻĻ⧇āĻ“ā§ŸāĻžāϰ āĻ…āύ⧁āĻŽā§‹āĻĻāĻŋāϤ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āύ⧟āĨ¤

Confidence: 0.95 for documentation accuracy; diagnosis remains provisionalāĨ¤


🟧 21. FINAL CLINICAL ASSESSMENT

āĻšā§‚ā§œāĻžāĻ¨ā§āϤ āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ

Doctor’s Documented Diagnosis — āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϞāĻŋāĻ–āĻŋāϤ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟

Not documented — āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

Independent Provisional Diagnosis — āĻ¸ā§āĻŦāĻžāϧ⧀āύ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟

Dx: Suspected Superficial Dermatophytosis (Tinea Infection; Site Unspecified) with Possible Coexisting Allergic Rhinitis.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ¤ā§āĻŦāϕ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻŦāĻž āĻĻāĻžāĻĻ (āφāĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻ¸ā§āĻĨāĻžāύ āĻ…āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ), āϏāĻ™ā§āϗ⧇ āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϜāύāĻŋāϤ āĻĒā§āϰāĻĻāĻžāĻšā§‡āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻžāĨ¤

Diagnostic Confidence — āϰ⧋āĻ—āύāĻŋāĻ°ā§āĻŖā§Ÿā§‡āϰ āĻŦāĻŋāĻļā§āĻŦāĻžāϏāϝ⧋āĻ—ā§āϝāϤāĻž: 0.65/1.00āĨ¤

Clinical Justification — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āϝ⧁āĻ•ā§āϤāĻŋ

English: The combination of itraconazole, luliconazole and antifungal cleansing advice supports suspicion of a fungal skin disorder.

āĻŦāĻžāĻ‚āϞāĻž: Itraconazole, Luliconazole āĻāĻŦāĻ‚ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āĻĒāϰāĻŋāĻˇā§āĻ•āĻžāϰ-āĻĒāϰāĻŋāĻšā§āĻ›āĻ¨ā§āύāϤāĻžāϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻž āĻ¤ā§āĻŦāϕ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϰ⧋āϗ⧇āϰ āϏāĻ¨ā§āĻĻ⧇āĻšāϕ⧇ āϏāĻŽāĻ°ā§āĻĨāύ āĻ•āϰ⧇āĨ¤

English: The presence of fexofenadine and intranasal fluticasone suggests possible treatment for allergic rhinitis.

āĻŦāĻžāĻ‚āϞāĻž: Fexofenadine āĻāĻŦāĻ‚ āύāĻžāϕ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ Fluticasone āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻ•āϰ⧇āĨ¤

English: Neither diagnosis is confirmed by documented examination findings or laboratory testing.

āĻŦāĻžāĻ‚āϞāĻž: āϕ⧋āύ⧋ āϰ⧋āĻ—āχ āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āϞāĻŋāĻ–āĻŋāϤ āĻĢāϞāĻžāĻĢāϞ āĻŦāĻž āĻ˛ā§āϝāĻžāĻŦāϰ⧇āϟāϰāĻŋ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻŽāĻžāĻ§ā§āϝāĻŽā§‡ āύāĻŋāĻļā§āϚāĻŋāϤ āĻšā§ŸāύāĻŋāĨ¤


🟩 22. OVERVIEW / SUMMARY

āϏāĻžāϰāϏāĻ‚āĻ•ā§āώ⧇āĻĒ

This case involves a 35-year-old patient whose prescription contains oral and topical antifungal medicines, an antihistamine, an intranasal corticosteroid, an antifungal cleansing product and a possibly cancelled antibiotic.

āĻŦāĻžāĻ‚āϞāĻž: āĻāχ āϕ⧇āϏ⧇ ā§Šā§Ģ āĻŦāĻ›āϰ āĻŦ⧟āϏ⧀ āϰ⧋āĻ—ā§€āϰ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āĻŽā§āϖ⧇ āĻ–āĻžāĻ“ā§ŸāĻžāϰ āĻ“ āĻ¤ā§āĻŦāϕ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ, āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻšāĻŋāĻ¸ā§āϟāĻžāĻŽāĻŋāύ, āĻ¨ā§āϝāĻžāϜāĻžāϞ āĻ¸ā§āĻŸā§‡āĻ°ā§Ÿā§‡āĻĄ, āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āϏāĻžāĻŦāĻžāύ āĻāĻŦāĻ‚ āϏāĻŽā§āĻ­āĻŦāϤ āĻŦāĻžāϤāĻŋāϞ āĻ•āϰāĻž āĻāĻ•āϟāĻŋ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻŦāĻžā§Ÿā§‹āϟāĻŋāĻ• āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

The leading working diagnosis is suspected superficial dermatophytosis with possible allergic rhinitis.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒā§āϰāϧāĻžāύ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟ āĻšāϞ⧋ āĻ¤ā§āĻŦāϕ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻŦāĻž āĻĻāĻžāĻĻ, āϏāĻ™ā§āϗ⧇ āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻžāĨ¤

The absence of documented symptoms, examination findings and investigation results is the most important limitation.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€āϰ āωāĻĒāϏāĻ°ā§āĻ—, āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ āĻāĻŦāĻ‚ āĻ˛ā§āϝāĻžāĻŦāϰ⧇āϟāϰāĻŋ āϰāĻŋāĻĒā§‹āĻ°ā§āϟ āύāĻž āĻĨāĻžāĻ•āĻžāχ āĻāχ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ⧇āϰ āϏāĻŦāĻšā§‡ā§Ÿā§‡ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āϏ⧀āĻŽāĻžāĻŦāĻĻā§āϧāϤāĻžāĨ¤

Overall Confidence: 0.65āĨ¤


🟧 23. ACTIONABLE CLINICAL PLAN

āĻ•āϰāĻŖā§€ā§Ÿ āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻĒāϰāĻŋāĻ•āĻ˛ā§āĻĒāύāĻž

1. Confirm Dermatological Diagnosis — āϚāĻ°ā§āĻŽāϰ⧋āĻ— āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻžāĨ¤

Examine the lesion and consider KOH testing when indicated.

āĻŦāĻžāĻ‚āϞāĻž: āĻ¤ā§āĻŦāϕ⧇āϰ āĻ•ā§āώāϤ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰ⧇ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ…āύ⧁āϝāĻžā§Ÿā§€ KOH āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

2. Verify Itraconazole Dose — āχāĻŸā§āϰāĻžāϕ⧋āύāĻžāϜāϞ⧇āϰ āĻĄā§‹āϜ āϝāĻžāϚāĻžāχāĨ¤

Confirm the handwritten regimen with the prescriber.

āĻŦāĻžāĻ‚āϞāĻž: āĻšāĻžāϤ⧇āϰ āϞ⧇āĻ–āĻž āĻĄā§‹āϜ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻ•āĻžāĻ› āĻĨ⧇āϕ⧇ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

3. Clarify Zimax Status — āϜāĻŋāĻŽā§āϝāĻžāĻ•ā§āϏ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ…āĻŦāĻ¸ā§āĻĨāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻžāĨ¤

Determine whether azithromycin was prescribed or cancelled.

āĻŦāĻžāĻ‚āϞāĻž: Azithromycin āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡āϛ⧇, āύāĻžāĻ•āĻŋ āϕ⧇āĻŸā§‡ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡āϛ⧇ āϤāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

4. Assess Medication Safety — āĻ“āώ⧁āϧ⧇āϰ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύāĨ¤

Review liver disease, heart failure, pregnancy and drug interactions.

āĻŦāĻžāĻ‚āϞāĻž: āϞāĻŋāĻ­āĻžāϰ, āĻšā§ƒāĻĻā§â€ŒāϝāĻ¨ā§āĻ¤ā§āϰ, āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ“āώ⧁āϧ⧇āϰ āϏāĻ™ā§āϗ⧇ āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

5. Evaluate Nasal Symptoms — āύāĻžāϕ⧇āϰ āωāĻĒāϏāĻ°ā§āĻ— āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύāĨ¤

Confirm whether the patient has allergic rhinitis.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€āϰ āϏāĻ¤ā§āϝāĻŋāχ āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻ°ā§Ÿā§‡āϛ⧇ āĻ•āĻŋ āύāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

6. Plan Clinical Follow-up — āĻĢāϞ⧋āφāĻĒ āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖāĨ¤

Review treatment response and any adverse effects.

āĻŦāĻžāĻ‚āϞāĻž: āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āωāĻ¨ā§āύāϤāĻŋ āĻ“ āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.95āĨ¤


🟩 24. REFERENCE LIST

āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻŦāĻŋāĻœā§āĻžāĻžāύ⧇āϰ āϤāĻĨā§āϝāϏ⧂āĻ¤ā§āϰ

A. Standard Medical Textbooks — āĻŽāĻžāύāϏāĻŽā§āĻŽāϤ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻŦāĻŋāĻœā§āĻžāĻžāύ⧇āϰ āĻĒāĻžāĻ ā§āϝāĻĒ⧁āĻ¸ā§āϤāĻ•

1. Harrison’s Principles of Internal Medicine. 22nd Edition.

Relevant topics: Fungal Infections, Infectious Diseases and Allergic Disorders.

āĻŦāĻžāĻ‚āϞāĻž: āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ, āϏāĻ‚āĻ•ā§āϰāĻžāĻŽāĻ• āϰ⧋āĻ— āĻāĻŦāĻ‚ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϜāύāĻŋāϤ āϰ⧋āϗ⧇āϰ āĻĒā§āϰāĻžāϏāĻ™ā§āĻ—āĻŋāĻ• āĻ…āĻ§ā§āϝāĻžā§ŸāĨ¤

2. Andrews’ Diseases of the Skin: Clinical Dermatology. 14th Edition.

Relevant topics: Superficial Fungal Infections and Dermatophytosis.

āĻŦāĻžāĻ‚āϞāĻž: āĻ¤ā§āĻŦāϕ⧇āϰ āωāĻĒāϰāĻŋāĻ­āĻžāϗ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻ“ āĻĻāĻžāĻĻ āϏāĻŽā§āĻĒāĻ°ā§āĻ•āĻŋāϤ āĻ…āĻ§ā§āϝāĻžā§ŸāĨ¤

3. Katzung’s Basic & Clinical Pharmacology.

Relevant topics: Antifungal Drugs, Macrolide Antibiotics, Antihistamines and Corticosteroids.

āĻŦāĻžāĻ‚āϞāĻž: āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ, āĻŽā§āϝāĻžāĻ•ā§āϰ⧋āϞāĻžāχāĻĄ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻŦāĻžā§Ÿā§‹āϟāĻŋāĻ•, āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻšāĻŋāĻ¸ā§āϟāĻžāĻŽāĻŋāύ āĻ“ āĻ•āĻ°ā§āϟāĻŋāϕ⧋āĻ¸ā§āĻŸā§‡āĻ°ā§Ÿā§‡āĻĄā§‡āϰ āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĨ¤

4. Goodman & Gilman’s The Pharmacological Basis of Therapeutics.

Relevant topics: Antimicrobial Pharmacology, Drug Interactions and Corticosteroids.

āĻŦāĻžāĻ‚āϞāĻž: āĻœā§€āĻŦāĻžāϪ⧁āĻŦāĻŋāϰ⧋āϧ⧀ āĻ“āώ⧁āϧ, āĻ“āώ⧁āϧ⧇āϰ āĻĒāĻžāϰāĻ¸ā§āĻĒāϰāĻŋāĻ• āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž āĻāĻŦāĻ‚ āĻ•āĻ°ā§āϟāĻŋāϕ⧋āĻ¸ā§āĻŸā§‡āĻ°ā§Ÿā§‡āĻĄā§‡āϰ āĻ•āĻžāĻ°ā§āϝāĻĒā§āϰāĻ•ā§āϰāĻŋ⧟āĻžāĨ¤

B. Clinical Guidelines — āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻ—āĻžāχāĻĄāϞāĻžāχāύ

5. American Family Physician. Diagnosis and Management of Tinea Infections. 2025.

āĻŦāĻžāĻ‚āϞāĻž: āĻĻāĻžāĻĻ āĻ“ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ Tinea āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟ āĻāĻŦāĻ‚ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āϏāĻŽā§āĻĒāĻ°ā§āĻ•āĻŋāϤ āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻžāĨ¤

6. CDC. Clinician Brief: Emerging Ringworm. Updated 13 October 2026.

āĻŦāĻžāĻ‚āϞāĻž: āύāϤ⧁āύ āĻāĻŦāĻ‚ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ-āĻĒā§āϰāϤāĻŋāϰ⧋āϧ⧀ āĻĻāĻžāĻĻ āϏāĻŽā§āĻĒāĻ°ā§āϕ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ•āĻĻ⧇āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻžāĨ¤

7. CDC. Treatment of Ringworm. Updated 21 October 2026.

āĻŦāĻžāĻ‚āϞāĻž: āĻĻāĻžāĻĻ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž, āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāĻŦāĻ‚ āĻ¸ā§āĻŸā§‡āĻ°ā§Ÿā§‡āĻĄ āĻ•ā§āϰāĻŋāĻŽ āĻā§œāĻŋā§Ÿā§‡ āϚāϞāĻžāϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻžāĨ¤

8. ARIA–EAACI Guidelines, 2024–2025 Revision, Part I.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϤ⧇ āύāĻžāϕ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ“āώ⧁āϧ āϏāĻŽā§āĻĒāĻ°ā§āĻ•āĻŋāϤ āĻ—āĻžāχāĻĄāϞāĻžāχāύāĨ¤

DOI: 10.1111/all.70131.

9. ARIA–EAACI Guidelines, 2024–2025 Revision, Part II.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϤ⧇ āĻŽā§āϖ⧇ āĻ–āĻžāĻ“ā§ŸāĻžāϰ āĻ“ āĻšā§‹āϖ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ“āώ⧁āϧ āϏāĻŽā§āĻĒāĻ°ā§āĻ•āĻŋāϤ āĻ—āĻžāχāĻĄāϞāĻžāχāύāĨ¤

DOI: 10.1111/all.70305.

C. Peer-Reviewed Journals with Verified DOI — DOI-āϝāĻžāϚāĻžāχāĻ•ā§ƒāϤ āĻ—āĻŦ⧇āώāĻŖāĻž

10. Caplan AS, et al. Clinical Course, Antifungal Susceptibility, and Genomic Sequencing of Trichophyton indotineae. JAMA Dermatology. 2024;160(7):701–709.

DOI: 10.1001/jamadermatol.2024.1126.

āĻŦāĻžāĻ‚āϞāĻž: Trichophyton indotineae āĻ›āĻ¤ā§āϰāĻžāϕ⧇āϰ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ, āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āϏāĻ‚āĻŦ⧇āĻĻāύāĻļā§€āϞāϤāĻž āĻāĻŦāĻ‚ āϜāĻŋāύāĻ—āϤ āĻŦāĻŋāĻļā§āϞ⧇āώāĻŖ āύāĻŋā§Ÿā§‡ āĻ—āĻŦ⧇āώāĻŖāĻžāĨ¤

11. Gupta AK, et al. Trichophyton indotineae: Epidemiology, Antifungal Resistance and Antifungal Stewardship Strategies. Journal of the European Academy of Dermatology and Venereology. 2026;40(1):29–45.

DOI: 10.1111/jdv.20810.

āĻŦāĻžāĻ‚āϞāĻž: Trichophyton indotineae-āĻāϰ āĻŦāĻŋāĻ¸ā§āϤāĻžāϰ, āĻ“āώ⧁āϧāĻĒā§āϰāϤāĻŋāϰ⧋āϧ āĻāĻŦāĻ‚ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻĢāĻžāĻ™ā§āĻ—āĻžāϞ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āϝāĻĨāĻžāĻ°ā§āĻĨāϤāĻž āύāĻŋā§Ÿā§‡ āĻŦ⧈āĻœā§āĻžāĻžāύāĻŋāĻ• āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻžāĨ¤

12. ARIA–EAACI Guidelines—Part I: Intranasal Treatments. Allergy. 2026;81(4):954–976.

DOI: 10.1111/all.70131.

āĻŦāĻžāĻ‚āϞāĻž: āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāĻ• āϰāĻžāχāύāĻžāχāϟāĻŋāϏ⧇ āύāĻžāϕ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ“āώ⧁āϧ āύāĻŋā§Ÿā§‡ āĻĒā§āϰāĻŽāĻžāĻŖāĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āϏ⧁āĻĒāĻžāϰāĻŋāĻļāĨ¤

D. Bangladesh Drug Information — āĻŦāĻžāĻ‚āϞāĻžāĻĻ⧇āĻļ⧇āϰ āĻ“āώ⧁āϧāϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āϤāĻĨā§āϝāϏ⧂āĻ¤ā§āϰ

13. MedEx Bangladesh — Itracon SUBA 65 mg.

āĻŦāĻžāĻ‚āϞāĻž: Itraconazole-āĻāϰ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ, āĻĄā§‹āϜ, āĻŽā§‚āĻ˛ā§āϝ, āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ“ āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻžāĨ¤

14. MedEx Bangladesh — Tinacure 1% Cream.

āĻŦāĻžāĻ‚āϞāĻž: Luliconazole āĻ•ā§āϰāĻŋāĻŽā§‡āϰ āϤāĻĨā§āϝāĨ¤

15. MedEx Bangladesh — Zimax 500 mg.

āĻŦāĻžāĻ‚āϞāĻž: Azithromycin-āĻāϰ āϤāĻĨā§āϝāĨ¤

16. MedEx Bangladesh — Fastel 180 mg.

āĻŦāĻžāĻ‚āϞāĻž: Fexofenadine-āĻāϰ āϤāĻĨā§āϝāĨ¤

17. MedEx Bangladesh — Snofas Nasal Spray.

āĻŦāĻžāĻ‚āϞāĻž: Fluticasone Furoate-āĻāϰ āϤāĻĨā§āϝāĨ¤

18. Arogga Bangladesh — ABC Anti-Fungal Bar.

āĻŦāĻžāĻ‚āϞāĻž: ABC Anti-Fungal Bar-āĻāϰ āωāĻĒāĻžāĻĻāĻžāύ āĻ“ āĻŦāĻžāϜāĻžāϰāĻŽā§‚āĻ˛ā§āϝ⧇āϰ āϤāĻĨā§āϝāĨ¤


🟧 25. ARTICLE TRANSPARENCY AND PUBLICATION INFORMATION

āφāĻ°ā§āϟāĻŋāϕ⧇āϞ⧇āϰ āĻ¸ā§āĻŦāĻšā§āĻ›āϤāĻž āĻ“ āĻĒā§āϰāĻ•āĻžāĻļāύāĻžāϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āϤāĻĨā§āϝ

Article Type — āφāĻ°ā§āϟāĻŋāϕ⧇āϞ⧇āϰ āϧāϰāύ: Educational Clinical Case Review — āĻļāĻŋāĻ•ā§āώāĻžāĻŽā§‚āϞāĻ• āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āϕ⧇āϏ āĻŦāĻŋāĻļā§āϞ⧇āώāĻŖāĨ¤

Original Prescription — āĻŽā§‚āϞ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ: 1 — āĻāĻ•āϟāĻŋāĨ¤

Investigation Reports — āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āϰāĻŋāĻĒā§‹āĻ°ā§āϟ: 0 — āĻļā§‚āĻ¨ā§āϝāĨ¤

Additional Clinical Images — āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻ›āĻŦāĻŋ: 0 — āĻļā§‚āĻ¨ā§āϝāĨ¤

Diagnostic Status — āϰ⧋āĻ—āύāĻŋāĻ°ā§āĻŖā§Ÿā§‡āϰ āĻ…āĻŦāĻ¸ā§āĻĨāĻž: Provisional — āϏāĻŽā§āĻ­āĻžāĻŦā§āϝāĨ¤

Evidence Limitation — āĻĒā§āϰāĻŽāĻžāϪ⧇āϰ āϏ⧀āĻŽāĻžāĻŦāĻĻā§āϧāϤāĻž: No documented symptoms, examination or confirmatory investigation — āϞāĻŋāĻ–āĻŋāϤ āωāĻĒāϏāĻ°ā§āĻ—, āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻž āĻŦāĻž āϰ⧋āĻ— āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻžāϰ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āϤāĻĨā§āϝ āύ⧇āχāĨ¤

Confidence Interpretation — āĻ¸ā§āϕ⧋āϰ⧇āϰ āĻ…āĻ°ā§āĻĨ: Scores represent qualitative confidence in the available evidence, not validated probabilities that the patient has a particular disease.

āĻŦāĻžāĻ‚āϞāĻž: āĻāĻ–āĻžāύ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻ¸ā§āϕ⧋āϰāϗ⧁āϞ⧋ āωāĻĒāϞāĻŦā§āϧ āϤāĻĨā§āϝ⧇āϰ āĻ­āĻŋāĻ¤ā§āϤāĻŋāϤ⧇ āĻŦāĻŋāĻļā§āĻŦāĻžāϏāϝ⧋āĻ—ā§āϝāϤāĻžāϰ āϗ⧁āĻŖāĻ—āϤ āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύāĨ¤ āĻāϗ⧁āϞ⧋ āϰ⧋āĻ— āĻšāĻ“ā§ŸāĻžāϰ āĻŦ⧈āĻœā§āĻžāĻžāύāĻŋāĻ•āĻ­āĻžāĻŦ⧇ āϝāĻžāϚāĻžāχāĻ•ā§ƒāϤ āĻļāϤāĻ•āϰāĻž āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āύ⧟āĨ¤

Publication Privacy — āĻĒā§āϰāĻ•āĻžāĻļāύāĻžāϰ āĻ—ā§‹āĻĒāĻ¨ā§€ā§ŸāϤāĻž: Appropriate patient consent is required before publicly disclosing identifying medical information.

āĻŦāĻžāĻ‚āϞāĻž: āϰ⧋āĻ—ā§€āϰ āĻĒāϰāĻŋāϚ⧟ āĻļāύāĻžāĻ•ā§āϤ āĻ•āϰāĻž āϝāĻžā§Ÿ āĻāĻŽāύ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϤāĻĨā§āϝ āĻĒā§āϰāĻ•āĻžāĻļ⧇āϰ āφāϗ⧇ āωāĻĒāϝ⧁āĻ•ā§āϤ āϏāĻŽā§āĻŽāϤāĻŋ āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤


🟩 FINAL ARTICLE AUTHORSHIP

āϞ⧇āĻ–āϕ⧇āϰ āϤāĻĨā§āϝ

Author Name — āϞ⧇āĻ–āϕ⧇āϰ āύāĻžāĻŽ: Md. Rafiqul Islam Lipu.

Md.Rafiqul Islam Lipu

Website — āĻ“ā§Ÿā§‡āĻŦāϏāĻžāχāϟ: LIPU MED — raiyyantahsan.comāĨ¤

Date — āϤāĻžāϰāĻŋāĻ–: Monday, 2 November 2026 — āϏ⧋āĻŽāĻŦāĻžāϰ, ⧍ āύāϭ⧇āĻŽā§āĻŦāϰ ⧍ā§Ļ⧍ā§ŦāĨ¤

Preparation Time — āĻĒā§āϰāĻ¸ā§āϤ⧁āϤāĻŋāϰ āϏāĻŽā§Ÿ: Bangladesh Standard Time — āĻŦāĻžāĻ‚āϞāĻžāĻĻ⧇āĻļ āϏāĻŽā§ŸāĨ¤

Case Number — āϕ⧇āϏ āύāĻŽā§āĻŦāϰ: TC(1486).

Department Code — āĻŦāĻŋāĻ­āĻžāĻ—ā§€ā§Ÿ āϕ⧋āĻĄ: 02.

Dermatology Case Number — āϚāĻ°ā§āĻŽāϰ⧋āĻ— āĻŦāĻŋāĻ­āĻžāϗ⧇āϰ āϕ⧇āϏ āύāĻŽā§āĻŦāϰ: 107.

Clinical Assessment Status — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ⧇āϰ āĻ…āĻŦāĻ¸ā§āĻĨāĻž: Provisional, Evidence-Based and Pending Clinical Confirmation — āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ, āĻĒā§āϰāĻŽāĻžāĻŖāĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻāĻŦāĻ‚ āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āύāĻŋāĻļā§āϚāĻŋāϤāĻ•āϰāϪ⧇āϰ āĻ…āĻĒ⧇āĻ•ā§āώāĻžā§ŸāĨ¤

FINAL Dx: Suspected Superficial Dermatophytosis (Tinea Infection; Site Unspecified) with Possible Coexisting Allergic Rhinitis.

āĻšā§‚ā§œāĻžāĻ¨ā§āϤ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ Dx: āĻ¤ā§āĻŦāϕ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻŦāĻž āĻĻāĻžāĻĻ (āφāĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻ¸ā§āĻĨāĻžāύ āĻ…āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ), āϏāĻ™ā§āϗ⧇ āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϜāύāĻŋāϤ āĻĒā§āϰāĻĻāĻžāĻšā§‡āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻžāĨ¤

Final Diagnostic Confidence: 0.65/1.00āĨ¤

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top